



National Health (Listing of Pharmaceutical Benefits) Instrument 2012

PB 71 of 2012

made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the

National Health Act 1953

Compilation No. 136

Compilation date: 1 November 2023

Includes amendments up to: F2023L01452

Registered: 23 November 2023

This compilation is in 7 volumes

Volume 1: sections 1–26 and Schedule 1 (Part 1: A–C)

Volume 2: Schedule 1 (Part 1: D–K)

Volume 3: Schedule 1 (Part 1: L–P)

Volume 4: Schedule 1 (Part 1: Q–Z, Part 2), Schedules 2 and 3

Volume 5: Schedule 4 (Part 1: A–E)

Volume 6: Schedule 4 (Part 1: F–R)

Volume 7: Schedule 4 (Part 1: S–Z, Part 3), Schedule 5 and
Endnotes

Each volume has its own contents

Prepared by the Office of Parliamentary Counsel, Canberra

About this compilation

This compilation

This is a compilation of the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012* that shows the text of the law as amended and in force on 1 November 2023 (the *compilation date*).

The notes at the end of this compilation (the *endnotes*) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Schedule 1—Ready-prepared pharmaceutical benefits	1
Part 1—Ready-prepared pharmaceutical benefits for prescription and supply	1

Schedule 1—Ready-prepared pharmaceutical benefits

Note: See sections 5 to 10, 16 to 18, 20, 21 and 23 to 26.

Part 1—Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Labetalol	Tablet containing labetalol hydrochloride 100 mg	Oral		Presolol 100	AF	MP NP			100	5	100		
Lacosamide	Oral solution 10 mg per mL, 200 mL	Oral		Vimpat	UC	MP NP	C8770 C8815 C12092	P12092	2	5	1		
									6	5	1		
	Tablet 50 mg	Oral	a	Lacoress	LR	MP NP	C8813		14	1	14		
				Lacosam	AF	MP NP	C8813 C8815 C12092	P8813	14	1	14		
				Lacosamide ARX	XT	MP NP	C8813 C8815 C12092	P8813	14	1	14		
			a	Lacosamide Lupin	GQ	MP NP	C8813 C8815 C12092	P8813	14	1	14		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 100 mg	Oral	a	Lacosamide Sandoz	SZ	MP NP	C8813 C8815 C12092	P8813	14	1	14		
			a	Vimcosa	CR	MP NP	C8813 C8815 C12092	P8813	14	1	14		
			a	Vimpat	UC	MP NP	C8813 C8815 C12092	P8813	14	1	14		
			a	Lacosam	AF	MP NP	C8813 C8815 C12092	P8815 P12092	56	5	14		
			a	Lacosamide ARX	XT	MP NP	C8813 C8815 C12092	P8815 P12092	56	5	14		
			a	Lacosamide Lupin	GQ	MP NP	C8813 C8815 C12092	P8815 P12092	56	5	14		
			a	Lacosamide Sandoz	SZ	MP NP	C8813 C8815 C12092	P8815 P12092	56	5	14		
			a	Vimcosa	CR	MP NP	C8813 C8815 C12092	P8815 P12092	56	5	14		
			a	Vimpat	UC	MP NP	C8813 C8815 C12092	P8815 P12092	56	5	14		
			a	Lacoress	LR	MP NP	C8770 C8813 C8815	P8813	14	1	14		
			a	Lacosamide Sandoz	SZ	MP	C8770 C8813 C8815 C12092 C12225	P8813 P12225	14	1	14		
						NP	C8770 C8813	P8813	14	1	14		

Ready-prepared pharmaceutical benefits **Schedule 1**
Ready-prepared pharmaceutical benefits for prescription and supply **Part 1**

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Vimcosa	CR	MP	C8815 C12092 C8770 C8813 C8815 C12092 C12225	P8813 P12225	14	1	14		
						NP	C8770 C8813 C8815 C12092	P8813	14	1	14		
			a	Vimpat	UC	MP	C8770 C8813 C8815 C12092 C12225	P8813 P12225	14	1	14		
						NP	C8770 C8813 C8815 C12092	P8813	14	1	14		
			a	Lacoress	LR	MP NP	C8770 C8813 C8815	P8770 P8815	56	5	56		
			a	Lacosam	AF	MP NP	C8770 C8815 C12092		56	5	56		
			a	Lacosamide ARX	XT	MP NP	C8770 C8815 C12092		56	5	56		
			a	Lacosamide Lupin	GQ	MP NP	C8770 C8815 C12092		56	5	56		
			a	Lacosamide Sandoz	SZ	MP	C8770 C8813 C8815 C12092 C12225	P8770 P8815 P12092	56	5	56		
						NP	C8770 C8813 C8815 C12092	P8770 P8815 P12092	56	5	56		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Vimcosa	CR	MP	C8770 C8813 C8815 C12092 C12225	P8770 P8815 P12092	56	5	56		
						NP	C8770 C8813 C8815 C12092	P8770 P8815 P12092	56	5	56		
			a	Vimpat	UC	MP	C8770 C8813 C8815 C12092 C12225	P8770 P8815 P12092	56	5	56		
						NP	C8770 C8813 C8815 C12092	P8770 P8815 P12092	56	5	56		
	Tablet 150 mg	Oral	a	Lacoress	LR	MP NP	C8770 C8813 C8815	P8813	14	1	14		
			a	Vimcosa	CR	MP	C8770 C8813 C8815 C12092 C12225	P8813 P12225	14	1	14		
						NP	C8770 C8813 C8815 C12092	P8813	14	1	14		
			a	Vimpat	UC	MP	C8770 C8813 C8815 C12092 C12225	P8813 P12225	14	1	14		
						NP	C8770 C8813 C8815 C12092	P8813	14	1	14		
			a	Lacoress	LR	MP NP	C8770 C8813 C8815	P8770 P8815	56	5	56		

Ready-prepared pharmaceutical benefits **Schedule 1**
Ready-prepared pharmaceutical benefits for prescription and supply **Part 1**

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Lacosam	AF	MP NP	C8770 C8815 C12092		56	5	56		
			a	Lacosamide ARX	XT	MP NP	C8770 C8815 C12092		56	5	56		
			a	Lacosamide Lupin	GQ	MP NP	C8770 C8815 C12092		56	5	56		
			a	Lacosamide Sandoz	SZ	MP NP	C8770 C8815 C12092		56	5	56		
			a	Vimcosa	CR	MP	C8770 C8813 C8815 C12092 C12225	P8770 P8815 P12092	56	5	56		
						NP	C8770 C8813 C8815 C12092	P8770 P8815 P12092	56	5	56		
			a	Vimpat	UC	MP	C8770 C8813 C8815 C12092 C12225	P8770 P8815 P12092	56	5	56		
						NP	C8770 C8813 C8815 C12092	P8770 P8815 P12092	56	5	56		
	Tablet 200 mg	Oral	a	Lacoress	LR	MP NP	C8770 C8815		56	5	56		
			a	Lacosam	AF	MP NP	C8770 C8815 C12092		56	5	56		
			a	Lacosamide ARX	XT	MP NP	C8770 C8815 C12092		56	5	56		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lamivudine	Oral solution 10 mg per mL, 240 mL Tablet 100 mg Tablet 150 mg Tablet 300 mg	Oral	a	Lacosamide Lupin	GQ	MP NP	C8770 C8815 C12092		56	5	56		
			a	Lacosamide Sandoz	SZ	MP NP	C8770 C8815 C12092		56	5	56		
			a	Vimcosa	CR	MP NP	C8770 C8815 C12092		56	5	56		
			a	Vimpat	UC	MP NP	C8770 C8815 C12092		56	5	56		
				3TC	VI	MP NP	C4454 C4512		8	5	1		D(100)
			a	Zeffix	RW	MP NP	C4993 C5036		56	5	28		D(100)
			a	Zetlam	AF	MP NP	C4993 C5036		56	5	28		D(100)
			a	3TC	VI	MP NP	C4454 C4512		120	5	60		D(100)
			a	Lamivudine Alphapharm	AF	MP NP	C4454 C4512		120	5	60		D(100)
			a	3TC	VI	MP NP	C4454 C4512		60	5	30		D(100)
Lamivudine with zidovudine	Tablet 150 mg-300 mg	Oral	a	Lamivudine Alphapharm	AF	MP NP	C4454 C4512		60	5	30		D(100)
			a	Combivir	VI	MP NP	C4454 C4512		120	5	60		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lamotrigine	Tablet 5 mg	Oral	a	Lamivudine 150 mg + Zidovudine 300 mg Alphapharm	AF	MP NP	C4454 C4512		120	5	60		D(100)
			a	Lamivudine/Zidovudine Viatris 150/300	AL	MP NP	C4454 C4512		120	5	60		D(100)
				Lamictal	AS	MP NP	C11081		56	5	56		
	Tablet 25 mg	Oral	a	APO-Lamotrigine	TX	MP NP	C11081		56	5	56		
			a	APX-Lamotrigine	TY	MP NP	C11081		56	5	56		
			a	Lamictal	AS	MP NP	C11081		56	5	56		
			a	LAMITAN	RF	MP NP	C11081		56	5	56		
			a	Lamotrigine GH	GQ	MP NP	C11081		56	5	56		
			a	Logem	AL	MP NP	C11081		56	5	56		
			a	NOUMED LAMOTRIGINE	VO	MP NP	C11081		56	5	56		
			a	Reedos 25	ZS	MP NP	C11081		56	5	56		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 50 mg	Oral	a	Sandoz Lamotrigine	HX	MP NP	C11081		56	5	56		
			a	APO-Lamotrigine	TX	MP NP	C11081		56	5	56		
			a	APX-Lamotrigine	TY	MP NP	C11081		56	5	56		
			a	Lamictal	AS	MP NP	C11081		56	5	56		
			a	LAMITAN	RF	MP NP	C11081		56	5	56		
			a	Lamotrigine GH	GQ	MP NP	C11081		56	5	56		
			a	Logem	AL	MP NP	C11081		56	5	56		
			a	NOUMED LAMOTRIGINE	VO	MP NP	C11081		56	5	56		
	Tablet 100 mg	Oral	a	Reedos 50	ZS	MP NP	C11081		56	5	56		
			a	Sandoz Lamotrigine	HX	MP NP	C11081		56	5	56		
			a	APO-Lamotrigine	TX	MP NP	C11081		56	5	56		
			a	APX-Lamotrigine	TY	MP	C11081		56	5	56		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Lamictal	AS	MP NP	C11081		56	5	56		
			a	LAMITAN	RF	MP NP	C11081		56	5	56		
			a	Lamotrigine GH	GQ	MP NP	C11081		56	5	56		
			a	Logem	AL	MP NP	C11081		56	5	56		
			a	NOUMED LAMOTRIGINE	VO	MP NP	C11081		56	5	56		
			a	Reedos 100	ZS	MP NP	C11081		56	5	56		
			a	Sandoz Lamotrigine	HX	MP NP	C11081		56	5	56		
	Tablet 200 mg	Oral	a	APO-Lamotrigine	TX	MP NP	C11081		56	5	56		
			a	APX-Lamotrigine	TY	MP NP	C11081		56	5	56		
			a	Lamictal	AS	MP NP	C11081		56	5	56		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	LAMITAN	RF	MP NP	C11081		56	5	56		
			a	Lamotrigine GH	GQ	MP NP	C11081		56	5	56		
			a	Logem	AL	MP NP	C11081		56	5	56		
			a	NOUMED LAMOTRIGINE	VO	MP NP	C11081		56	5	56		
			a	Reedos 200	ZS	MP NP	C11081		56	5	56		
			a	Sandoz Lamotrigine	HX	MP NP	C11081		56	5	56		
Lanadelumab	Injection 300 mg in 2 mL single use pre-filled syringe	Injection		Takhzyro	TK	MP	C12435 C12464 C12467		1	5	1		
Lanreotide	Injection 60 mg (as acetate) in single dose pre-filled syringe	Injection	a	Mytolac	GH	MP	C4575 C7025 C7509 C7532 C9260 C9261		2	5	1		D(100)
			a	Somatuline Autogel	IS	MP	C4575 C7025 C7509 C7532 C9260 C9261		2	5	1		D(100)
	Injection 90 mg (as acetate) in single dose pre-filled syringe	Injection	a	Mytolac	GH	MP	C4575 C7025 C7509 C7532 C9260 C9261		2	5	1		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lansoprazole	Injection 120 mg (as acetate) in single dose pre-filled syringe	Injection	a	Somatuline Autogel	IS	MP	C4575 C7025 C7509 C7532 C9260 C9261		2	5	1		D(100)
			a	Mytolac	GH	MP	C4575 C7025 C7509 C7532 C9260 C9261 C10061 C10075 C10077		2	5	1		D(100)
			a	Somatuline Autogel	IS	MP	C4575 C7025 C7509 C7532 C9260 C9261 C10061 C10075 C10077		2	5	1		D(100)
	Capsule 15 mg	Oral		Zopral	AF	MP NP	C5444 C5512		30	5	30		
	Capsule 30 mg	Oral		APO-Lansoprazole	TX	MP	C8774 C8775 C8776 C8780 C11310	P8774 P8775	28	1	28		
							C8774 C8775 C8776 C8780	P8774 P8775	28	1	28		
				Lanzopran	RA	MP	C8774 C8775 C8776 C8780 C11310	P8774 P8775	28	1	28		
							C8774 C8775 C8776 C8780	P8774 P8775	28	1	28		
							C8774 C8775	P8774 P8775	28	1	28		
				NOUMED LANSOPRAZOLE	VO	MP	C8774 C8775	P8774 P8775	28	1	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
							C8776 C8780 C11310						
				Zopral	NP	MP	C8774 C8775 C8776 C8780	P8774 P8775	28	1	28		
					AF	MP	C8774 C8775 C8776 C8780 C11310	P8774 P8775	28	1	28		
				APO-Lansoprazole	NP	MP	C8774 C8775 C8776 C8780	P8774 P8775	28	1	28		
					TX	MP	C8774 C8775 C8776 C8780 C11310	P8776 P8780	28	5	28		
				Lanzopran	NP	MP	C8774 C8775 C8776 C8780	P8776 P8780	28	5	28		
					RA	MP	C8774 C8775 C8776 C8780 C11310	P8776 P8780	28	5	28		
				NOUMED LANSOPRAZOLE	NP	MP	C8774 C8775 C8776 C8780	P8776 P8780	28	5	28		
					VO	MP	C8774 C8775 C8776 C8780 C11310	P8776 P8780	28	5	28		
					NP	MP	C8774 C8775 C8776 C8780	P8776 P8780	28	5	28		
				Zopral	AF	MP	C8774 C8775	P8776 P8780	28	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP	C8776 C8780 C11310						
				APO-Lansoprazole	TX	MP	C8774 C8775 C8776 C8780	P8776 P8780	28	5	28		
				Lanzopran	RA	MP	C8774 C8775 C8776 C8780 C11310	P11310	56	5	28		
				NOUMED LANSOPRAZOLE	VO	MP	C8774 C8775 C8776 C8780 C11310	P11310	56	5	28		
				Zopral	AF	MP	C8774 C8775 C8776 C8780 C11310	P11310	56	5	28		
	Tablet 15 mg (orally disintegrating)	Oral	a	APO-Lansoprazole ODT	TX	MP NP	C5444 C5512		28	5	28		
			a	Lansoprazole ODT GH	GQ	MP NP	C5444 C5512		28	5	28		
			a	Zopral ODT	AF	MP NP	C5444 C5512		28	5	28		
			a	Zoton FasTabs	PF	MP NP	C5444 C5512		28	5	28		
	Tablet 30 mg (orally	Oral		APO-Lansoprazole ODT	TX	MP	C8774 C8775	P8774 P8775	28	1	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	disintegrating)						C8776 C8780 C11310						
					NP		C8774 C8775 C8776 C8780	P8774 P8775	28	1	28		
				Lansoprazole ODT GH	GQ	MP	C8774 C8775 C8776 C8780 C11310	P8774 P8775	28	1	28		
					NP		C8774 C8775 C8776 C8780	P8774 P8775	28	1	28		
				Zopral ODT	AF	MP	C8774 C8775 C8776 C8780 C11310	P8774 P8775	28	1	28		
					NP		C8774 C8775 C8776 C8780	P8774 P8775	28	1	28		
				Zoton FasTabs	PF	MP	C8774 C8775 C8776 C8780 C11310	P8774 P8775	28	1	28		
					NP		C8774 C8775 C8776 C8780	P8774 P8775	28	1	28		
				APO-Lansoprazole ODT	TX	MP	C8774 C8775 C8776 C8780 C11310	P8776 P8780	28	5	28		
					NP		C8774 C8775 C8776 C8780	P8776 P8780	28	5	28		
				Lansoprazole ODT GH	GQ	MP	C8774 C8775	P8776 P8780	28	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP	C8776 C8780 C11310						
				Zopral ODT	AF	MP	C8774 C8775 C8776 C8780	P8776 P8780	28	5	28		
						NP	C8774 C8775 C8776 C8780 C11310	P8776 P8780	28	5	28		
				Zoton FasTabs	PF	MP	C8774 C8775 C8776 C8780 C11310	P8776 P8780	28	5	28		
						NP	C8774 C8775 C8776 C8780	P8776 P8780	28	5	28		
				APO-Lansoprazole ODT	TX	MP	C8774 C8775 C8776 C8780 C11310	P11310	56	5	28		
				Lansoprazole ODT GH	GQ	MP	C8774 C8775 C8776 C8780 C11310	P11310	56	5	28		
				Zopral ODT	AF	MP	C8774 C8775 C8776 C8780 C11310	P11310	56	5	28		
				Zoton FasTabs	PF	MP	C8774 C8775 C8776 C8780	P11310	56	5	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lanthanum	Tablet, chewable, 500 mg (as carbonate hydrate)	Oral		Fosrenol	TK	MP	C11310 C5491		90	5	90		
						NP	C5530 C9762		180	5	90		C(100)
	Tablet, chewable, 750 mg (as carbonate hydrate)	Oral		Fosrenol	TK	MP	C5491		90	5	90		
						NP	C5530 C9762		180	5	90		C(100)
	Tablet, chewable, 1000 mg (as carbonate hydrate)	Oral		Fosrenol	TK	MP	C5491		90	5	90		
						NP	C5530 C9762		180	5	90		C(100)
Lapatinib	Tablet 250 mg (as ditosilate monohydrate)	Oral		Tykerb	NV	MP	C9360 C13007		140	2	70		
Larotrectinib	Capsule 25 mg (as sulfate)	Oral		Vitrakvi	BN	MP	C12980 C12981 C12982	P12981 P12982	56	2	56		
						MP	C12980 C12981 C12982	P12980	56	5	56		
	Capsule 100 mg (as sulfate)	Oral		Vitrakvi	BN	MP	C12980 C12981 C12982	P12981 P12982	56	2	56		
						MP	C12980 C12981 C12982	P12980	56	5	56		
	Oral solution 20 mg per mL (as sulfate), 50 mL, 2	Oral		VITRAKVI	BN	MP	C12980 C12981 C12982	P12981 P12982	1	2	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						MP	C12980 C12981 C12982	P12980	1	5	1		
Latanoprost	Eye drops 50 micrograms per mL, 2.5 mL	Application to the eye	a	APO-Latanoprost	TX	AO MP			1	5	1		
			a	Latanoprost Sandoz	SZ	AO MP			1	5	1		
			a	Xalaprost	AF	AO MP			1	5	1		
			a	Xalatan	AS	AO MP			1	5	1		
Latanoprost with timolol	Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL	Application to the eye	a	APO-Latanoprost/Timolol 0.05/5	TX	AO	C5038		1	5	1		
						MP	C4343		1	5	1		
			a	Xalacom	AS	AO	C5038		1	5	1		
						MP	C4343		1	5	1		
			a	Xalamol 50/5	AF	AO	C5038		1	5	1		
						MP	C4343		1	5	1		
Leflunomide	Tablet 10 mg	Oral	a	Arabloc	AV	MP	C13753 C13771		30	5	30		
			a	Arava	SW	MP	C13753 C13771		30	5	30		
			a	Ataris 10	AF	MP	C13753 C13771		30	5	30		
			a	Leflunomide APOTEX	GX	MP	C13753 C13771		30	5	30		
			a	Leflunomide generichealth	HQ	MP	C13753 C13771		30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lenalidomide	Tablet 20 mg	Oral	a	Leflunomide Sandoz	SZ	MP	C13753 C13771		30	5	30		
			a	Lunava 10	RW	MP	C13753		30	5	30		
			a	Arava	SW	MP	C13753 C13771		30	5	30		
			a	Ataris 20	AF	MP	C13753 C13771		30	5	30		
			a	Leflunomide APOTEX	GX	MP	C13753 C13771		30	5	30		
			a	Leflunomide generichealth	HQ	MP	C13753 C13771		30	5	30		
			a	Leflunomide Sandoz	SZ	MP	C13753 C13771		30	5	30		
	Capsule 5 mg	Oral	a	Lunava 20	RW	MP	C13753		30	5	30		
				Cipla Lenalidomide	LR	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
						MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
						MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
				Lenalide	JU	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
						MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
						MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
				Lenalidomide Dr.Reddy's	RI	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide Sandoz	SZ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide-Teva	TB	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide Viatris	AF	MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Revlimid	CJ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Capsule 10 mg	Oral	Cipla Lenalidomide	LR	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalide	JU	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide Dr.Reddy's	RI	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide Sandoz	SZ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)

Ready-prepared pharmaceutical benefits **Schedule 1**
Ready-prepared pharmaceutical benefits for prescription and supply **Part 1**

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Capsule 15 mg	Oral	Lenalidomide-Teva	TB	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide Viatris	AF	MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Revlimid	CJ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Cipla Lenalidomide	LR	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalide	JU	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide Dr.Reddy's	RI	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide Sandoz	SZ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide-Teva	TB	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
			Lenalidomide Viatris	AF	MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Revlimid	CJ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	28		D(100)
	Capsule 25 mg	Oral	Cipla Lenalidomide	LR	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Lenalide	JU	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Lenalidomide Dr.Reddy's	RI	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Lenalidomide Sandoz	SZ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Lenalidomide-Teva	TB	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lenvatinib	Capsule 4 mg (as mesilate)	Oral		Lenalidomide Viatris	AF	MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
				Revlimid	CJ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
				Lenvima		MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
					EI	MP	C6578 C6604 C8584 C11168 C13921 C13972 C14007 C14041 C14042 C14043	P6578 P6604	30	2	30		
						MP	C6578 C6604 C8584 C11168 C13921 C13972 C14007 C14041 C14042 C14043	P13921 P13972 P14007 P14041 P14042 P14043	60	2	30		
						MP	C6578 C6604 C8584 C11168 C13921 C13972 C14007 C14041 C14042 C14043	P8584 P11168	90	2	30		
	Capsule 10 mg (as mesilate)	Oral		Lenvima	EI	MP	C6578 C6604 C13921 C13972 C14007 C14041 C14042 C14043		60	2	30		
Lercanidipine	Tablet containing lercanidipine	Oral	a	BTC Lercanidipine	JB	MP			28	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	hydrochloride 10 mg	Oral	a	Lercanidipine APOTEX	GX	MP NP			28	5	28		
	a		Zanidip	GO	MP NP			28	5	28			
	a		Zircol 10	AL	MP NP			28	5	28			
	a		BTC Lercanidipine	JB	MP NP		P14238	56	5	28			
	a		Lercanidipine APOTEX	GX	MP NP		P14238	56	5	28			
	a		Zanidip	GO	MP NP		P14238	56	5	28			
	a		Zircol 10	AL	MP NP		P14238	56	5	28			
	a		BTC Lercanidipine	JB	MP NP			28	5	28			
	a		Lercanidipine APOTEX	GX	MP NP			28	5	28			
	a		Zanidip	GO	MP NP			28	5	28			
	a		Zircol 20	AL	MP NP			28	5	28			

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lercanidipine with enalapril	Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg	Oral	a	BTC Lercanidipine	JB	MP NP		P14238	56	5	28		
			a	Lercanidipine APOTEX	GX	MP NP		P14238	56	5	28		
			a	Zanidip	GO	MP NP		P14238	56	5	28		
			a	Zircol 20	AL	MP NP		P14238	56	5	28		
				Zan-Extra 10/10	GO	MP NP	C4398 C14245	P4398	28	5	28		
						MP NP	C4398 C14245	P14245	56	5	28		
				Zan-Extra 10/20	GO	MP NP	C4398 C14245	P4398	28	5	28		
						MP NP	C4398 C14245	P14245	56	5	28		
Letrozole	Tablet 2.5 mg	Oral	a	Femara 2.5 mg	NV	MP NP	C5464		30	5	30		
			a	Femolet	AF	MP NP	C5464		30	5	30		
			a	Gynotril	ZS	MP NP	C5464		30	5	30		
			a	Letrozole APOTEX	GX	MP	C5464		30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Leuporelin	I.M. injection (3 month modified release), powder for injection containing leuporelin acetate 30 mg with diluent in pre-filled dual-chamber syringe	Injection				NP							
			a	Letrozole GH	HQ	MP NP	C5464		30	5	30		
			a	Letrozole Sandoz	SZ	MP NP	C5464		30	5	30		
			a	Pharmacor Letrozole 2.5	CR	MP NP	C5464		30	5	30		
				Lucrin Depot Paediatric 30 mg PDS	VE	MP	C12351 C13624		1	1	1		
				Lucrin Depot 7.5mg PDS	VE	MP	C6409		1	5	1		
	I.M. injection (modified release), powder for injection containing leuporelin acetate 7.5 mg with diluent in pre-filled dual-chamber syringe	Injection		Lucrin Depot 3 Month PDS	VE	MP	C6409		1	1	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	syringe											
	I.M. injection (modified release), powder for injection containing leuprorelin acetate 30 mg with diluent in pre-filled dual-chamber syringe	Injection	Lucrin Depot 4 Month PDS	VE	MP	C6409		1	1	1		
	I.M. injection (modified release), powder for injection containing leuprorelin acetate 45 mg with diluent in pre-filled dual-chamber syringe	Injection	Lucrin Depot 6-Month	VE	MP	C6409		1	0	1		
	Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 7.5 mg, injection set	Injection	Eligard 1 month	MF	MP	C6409		1	5	1		
	Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 22.5 mg, injection set	Injection	Eligard 3 month	MF	MP	C6409		1	1	1		
	Suspension for	Injection	Eligard 4 month	MF	MP	C6409		1	1	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Leuprorelin and bicalutamide	subcutaneous injection (modified release) containing leuprorelin acetate 30 mg, injection set												
	Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 45 mg, injection set	Injection		Eligard 6 month	MF	MP	C6409 C12351 C13624		1	0	1		
	Pack containing 1 syringe containing leuprorelin 7.5 mg (as acetate) and 28 tablets bicalutamide 50 mg	Injection/oral		Bi ELIGARD CP	MF	MP	C4895		1	5	1		
	Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 28 tablets bicalutamide 50 mg	Injection/oral		Bi ELIGARD CP	MF	MP	C4895		1	0	1		
	Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 84 tablets bicalutamide 50 mg	Injection/oral		Bi ELIGARD CP	MF	MP	C4895		1	1	1		
Levetiracetam	Oral solution 100 mg per mL, 300 mL	Oral	a	APO-Levetiracetam	TX	MP NP	C11077		1	5	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 250 mg	Oral	a	Keppra	UC	MP NP	C11077		1	5	1		
			a	Kerron	ZS	MP NP	C11077		1	5	1		
			a	Levetiracetam-AFT	AE	MP NP	C11077		1	5	1		
			a	Levetiracetam GH	GQ	MP NP	C11077		1	5	1		
			a	APO-Levetiracetam	TX	MP NP	C11116		60	5	60		
			a	Keppra	UC	MP NP	C11116		60	5	60		
			a	Kevtam 250	AF	MP NP	C11116		60	5	60		
			a	Levactam	ZS	MP NP	C11116		60	5	60		
			a	Levecetam 250	RZ	MP NP	C11116		60	5	60		
			a	Levetiracetam GH	GQ	MP NP	C11116		60	5	60		
			a	Levetiracetam Mylan	AL	MP NP	C11116		60	5	60		
			a	Levetiracetam SZ	SZ	MP NP	C11116		60	5	60		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 500 mg	Oral	a	Levi 250	RW	MP NP	C11116		60	5	60		
			a	NOUMED LEVETIRACETAM	VO	MP NP	C11116		60	5	60		
			a	APO-Levetiracetam	TX	MP NP	C11116		60	5	60		
			a	Keppra	UC	MP NP	C11116		60	5	60		
			a	Kevtam 500	AF	MP NP	C11116		60	5	60		
			a	Levactam	ZS	MP NP	C11116		60	5	60		
			a	Levecetam 500	RZ	MP NP	C11116		60	5	60		
			a	Levetiracetam GH	GQ	MP NP	C11116		60	5	60		
			a	Levetiracetam Mylan	AL	MP NP	C11116		60	5	60		
			a	Levetiracetam SZ	SZ	MP NP	C11116		60	5	60		
			a	Levi 500	RW	MP NP	C11116		60	5	60		
			a	NOUMED LEVETIRACETAM	VO	MP NP	C11116		60	5	60		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 1 g	Oral	a	APO-Levetiracetam	TX	MP NP	C11116		60	5	60		
			a	Keppra	UC	MP NP	C11116		60	5	60		
			a	Kevtam 1000	AF	MP NP	C11116		60	5	60		
			a	Levactam	ZS	MP NP	C11116		60	5	60		
			a	Levecetam 1000	RZ	MP NP	C11116		60	5	60		
			a	Levetiracetam GH	GQ	MP NP	C11116		60	5	60		
			a	Levetiracetam Mylan	AL	MP NP	C11116		60	5	60		
			a	Levetiracetam SZ	SZ	MP NP	C11116		60	5	60		
			a	Levi 1000	RW	MP NP	C11116		60	5	60		
			a	NOUMED LEVETIRACETAM	VO	MP NP	C11116		60	5	60		
Levodopa with benserazide	Capsule containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride)	Oral		Madopar 62.5	RO	MP NP			100	5	100		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride)	Oral		Madopar 125	RO	MP NP			100	5	100		
	Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) (sustained release)	Oral		Madopar HBS	RO	MP NP			100	5	100		
	Capsule containing levodopa 200 mg with 50 mg benserazide (as hydrochloride)	Oral		Madopar	RO	MP NP			100	5	100		
	Dispersible tablet containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride)	Oral		Madopar Rapid 62.5	RO	MP NP			100	5	100		
	Dispersible tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride)	Oral		Madopar Rapid 125	RO	MP NP			100	5	100		
	Tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride)	Oral		Madopar 125	RO	MP NP			100	5	100		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Levodopa with carbidopa	Tablet containing levodopa 200 mg with 50 mg benserazide (as hydrochloride)	Oral		Madopar	RO	MP NP			100	5	100		
	Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg per mL, 100 mL	Intra-intestinal		Duodopa	VE	MP NP	C10197 C10386	P10197	28	5	7		
						MP	C10138 C10161 C10363 C10375	P10138 P10161	28	5	7		C(100)
						MP NP	C10197 C10386	P10386	56	5	7		
						MP	C10138 C10161 C10363 C10375	P10363 P10375	56	5	7		C(100)
	Tablet 100 mg-25 mg (as monohydrate)	Oral	a	APO-Levodopa/Carbidopa	TX	MP NP			100	5	100		
			a	Kinson	AF	MP NP			100	5	100		
			a	SINADOPA 100/25	RW	MP NP			100	5	100		
			a	Sinemet 100/25	AL	MP NP			100	5	100		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Levodopa with carbidopa and entacapone	Tablet (modified release) 200 mg-50 mg (as monohydrate)	Oral		Sinemet CR	AL	MP NP	C5253		100	5	100		
	Tablet 250 mg-25 mg (as monohydrate)	Oral	a	APO-Levodopa/Carbidopa	TX	MP NP			100	5	100		
			a	SINADOPA 250/25	RW	MP NP			100	5	100		
			a	Sinemet	AL	MP NP			100	5	100		
	Tablet 50 mg-12.5 mg (as monohydrate)-200 mg	Oral	a	Carlevent	TX	MP NP	C5212 C5288		200	4	100		
			a	L.C.E. Sandoz	HX	MP NP	C5212 C5288		200	4	100		
			a	Lecteva	TB	MP NP	C5212 C5288		200	4	100		
			a	Stalevo 50/12.5/200mg	SZ	MP NP	C5212 C5288		200	4	100		
	Tablet 75 mg-18.75 mg (as monohydrate)-200 mg	Oral	a	Carlevent	TX	MP NP	C5212 C5288		200	4	100		
			a	L.C.E. Sandoz	HX	MP NP	C5212 C5288		200	4	100		
			a	Lecteva	TB	MP	C5212 C5288		200	4	100		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
	Tablet 100 mg-25 mg (as monohydrate)-200 mg	Oral	a	Stalevo 75/18.75/200mg	SZ	MP NP	C5212 C5288		200	4	100		
			a	Carlevent	TX	MP NP	C5212 C5288		200	4	100		
			a	L.C.E. Sandoz	HX	MP NP	C5212 C5288		200	4	100		
			a	Lecteva	TB	MP NP	C5212 C5288		200	4	100		
			a	Stalevo 100/25/200mg	SZ	MP NP	C5212 C5288		200	4	100		
	Tablet 125 mg-31.25 mg (as monohydrate)-200 mg	Oral	a	Carlevent	TX	MP NP	C5212 C5288		200	4	100		
			a	L.C.E. Sandoz	HX	MP NP	C5212 C5288		200	4	100		
			a	Lecteva	TB	MP NP	C5212 C5288		200	4	100		
			a	Stalevo 125/31.25/200mg	SZ	MP NP	C5212 C5288		200	4	100		
	Tablet 150 mg-37.5 mg (as monohydrate)-200 mg	Oral	a	Carlevent	TX	MP NP	C5212 C5288		200	4	100		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Levonorgestrel	Tablet 200 mg-50 mg (as monohydrate)-200 mg	Oral	a	L.C.E. Sandoz	HX	MP NP	C5212 C5288		200	4	100		
			a	Lecteva	TB	MP NP	C5212 C5288		200	4	100		
			a	Stalevo 150/37.5/200mg	SZ	MP NP	C5212 C5288		200	4	100		
			a	Carlevent	TX	MP NP	C5212 C5288		200	4	100		
			a	L.C.E. Sandoz	HX	MP NP	C5212 C5288		200	4	100		
			a	Lecteva	TB	MP NP	C5212 C5288		200	4	100		
			a	Stalevo 200/50/200mg	SZ	MP NP	C5212 C5288		200	4	100		
	Intrauterine drug delivery system 19.5 mg	Intrauterine		Kyleena	SY	MP NP	C5214		1	0	1		
	Intrauterine drug delivery system 52 mg	intrauterine		Mirena	BN	MP NP	C5135 C5214 C5289		1	0	1		
	Tablets 30 micrograms, 28	Oral		Microlut 28	BN	MP NP MW			4	2	4		
Levonorgestrel with	Pack containing 6	Oral	a	Logynon ED	SY	MP			4	2	4		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
ethinylestradiol	tablets 50 micrograms-30 micrograms, 5			Trifeme 28	FZ	MP			4	2	4		
	tablets 75 micrograms-40 micrograms, 10					NP							
	tablets 125 micrograms-30 micrograms and 7 inert tablets		a	Triquilar ED	BN	MP			4	2	4		
	Pack containing 21 tablets 100 micrograms-20 micrograms and 7 inert tablets	Oral		Femme-Tab ED 20/100	AE	MP			4	2	4		
	Pack containing 21 tablets 125 micrograms-50 micrograms and 7 inert tablets	Oral		Microgynon 50 ED	BN	MP			4	2	4		
	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	Oral	a	Eleanor 150/30 ED	XT	MP			4	2	4		
			a	Evelyn 150/30 ED	GQ	MP			4	2	4		
			a	Femme-Tab ED 30/150	AE	MP			4	2	4		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Levothyroxine	Tablet containing 50 micrograms anhydrous levothyroxine sodium	Oral	a	Lenest 30 ED	AF	MP NP			4	2	4		
			a	Levlen ED	SY	MP NP			4	2	4		
			a	Micronelle 30 ED	TX	MP NP			4	2	4		
				Monofeme 28	FZ	MP NP			4	2	4		
			a	APO-Levothyroxine	XT	MP NP			200	1	200		
			b	Eltroxin	LT	MP NP			200	1	200		
			a	Eutroxsig	LN	MP NP			200	1	200		
			b	Levothox	AF	MP NP			200	1	200		
			a	Levothyroxine Lup	GQ	MP NP			200	1	200		
			a	Levothyroxine Sandoz	SZ	MP NP			200	1	200		
			a	LEVOXINE	RA	MP NP			200	1	200		
			a	Oroxine	AS	MP			200	1	200		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
			a	Thyrox	IX	MP NP			200	1	200		
	Tablet containing 75 micrograms anhydrous levothyroxine sodium	Oral	a	APO-Levothyroxine	XT	MP NP			200	1	200		
			b	Eltroxin	LT	MP NP			200	1	200		
			a	Eutroxsig	LN	MP NP			200	1	200		
			b	Levothox	AF	MP NP			200	1	200		
			a	Levothyroxine Lup	GQ	MP NP			200	1	200		
			a	Levothyroxine Sandoz	SZ	MP NP			200	1	200		
			a	LEVOXINE	RA	MP NP			200	1	200		
			a	Oroxine	AS	MP NP			200	1	200		
			a	Thyrox	IX	MP NP			200	1	200		
	Tablet containing 100 micrograms	Oral	a	APO-Levothyroxine	XT	MP NP			200	1	200		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	anhydrous levothyroxine sodium		b	Eltroxin	LT	MP NP			200	1	200		
			a	Eutroxsig	LN	MP NP			200	1	200		
			b	Levothox	AF	MP NP			200	1	200		
			a	Levothyroxine Lup	GQ	MP NP			200	1	200		
			a	Levothyroxine Sandoz	SZ	MP NP			200	1	200		
			a	LEVOXINE	RA	MP NP			200	1	200		
			a	Oroxine	AS	MP NP			200	1	200		
			a	Thyrox	IX	MP NP			200	1	200		
	Tablet containing 125 micrograms anhydrous levothyroxine sodium	Oral		Eltroxin	LT	MP NP			200	1	200		
	Tablet containing 200 micrograms anhydrous	Oral	a	APO-Levothyroxine	XT	MP NP			200	1	200		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	levothyroxine sodium		b	Eltroxin	LT	MP NP			200	1	200		
			a	Eutroxsig	LN	MP NP			200	1	200		
			b	Levothox	AF	MP NP			200	1	200		
			a	Levothyroxine Lup	GQ	MP NP			200	1	200		
			a	Levothyroxine Sandoz	SZ	MP NP			200	1	200		
			a	LEVOXINE	RA	MP NP			200	1	200		
			a	Oroxine	AS	MP NP			200	1	200		
			a	Thyrox	IX	MP NP			200	1	200		
Lidocaine	Infusion containing lidocaine hydrochloride 500 mg in 5 mL	Injection		Xylocard 500	AS	MP NP			10	0	10		
	Injection containing lidocaine hydrochloride monohydrate 50 mg in 5 mL	Injection		Lignocaine Injection (Pfizer)	WZ	See Note 4	See Note 4	See Note 4	See Note 4	See Note 4	5	5	PB(MP) PB(NP)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Linagliptin	Tablet 5 mg	Oral		Trajenta	BY	MP	C6346 C6363 C6376 C7505 C7541		30	5	30		
						NP	C6346 C6363 C6376 C7505		30	5	30		
Linagliptin with metformin	Tablet containing 2.5 mg linagliptin with 500 mg metformin hydrochloride	Oral		Trajentamet	BY	MP	C6333 C6336 C6344 C6443 C7507 C7530		60	5	60		
						NP	C6333 C6336 C6344 C6443 C7530		60	5	60		
	Tablet containing 2.5 mg linagliptin with 850 mg metformin hydrochloride	Oral		Trajentamet	BY	MP	C6333 C6336 C6344 C6443 C7507 C7530		60	5	60		
						NP	C6333 C6336 C6344 C6443 C7530		60	5	60		
	Tablet containing 2.5 mg linagliptin with 1000 mg metformin hydrochloride	Oral		Trajentamet	BY	MP	C6333 C6336 C6344 C6443 C7507 C7530		60	5	60		
						NP	C6333 C6336 C6344 C6443 C7530		60	5	60		
Lincomycin	Injection 600 mg (as hydrochloride)	Injection	a	Lincocin	PF	MP NP MW			5	0	5		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	monohydrate) in 2 mL		a	LINCOMYCIN SXP	XN	PDP MP NP MW			5	0	5		
Liothyronine	Tablet containing liothyronine sodium 20 micrograms	Oral		Tertroxin	AS	MP NP	C6382 C6410 C6475		100	2	100		
Lipegfilgrastim	Injection 6 mg in 0.6 mL single use pre-filled syringe	Injection		Lonquex	TB	MP	C7822 C7843 C9224 C9322		1	11	1		D(100)
Lisdexamfetamine	Capsule containing lisdexamfetamine dimesilate 20 mg	Oral		Vyvanse	TK	MP NP	C10792		30	5	30		
	Capsule containing lisdexamfetamine dimesilate 30 mg	Oral		Vyvanse	TK	MP NP	C10792		30	5	30		
	Capsule containing lisdexamfetamine dimesilate 40 mg	Oral		Vyvanse	TK	MP NP	C10792		30	5	30		
	Capsule containing lisdexamfetamine dimesilate 50 mg	Oral		Vyvanse	TK	MP NP	C10792		30	5	30		
	Capsule containing	Oral		Vyvanse	TK	MP	C10792		30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lisinopril	lisdexamfetamine dimesilate 60 mg	Oral		Vyvanse	NP		C10792		30	5	30		
	Capsule containing lisdexamfetamine dimesilate 70 mg				TK	MP NP							
	Tablet 5 mg	Oral	a	APO-Lisinopril	TX	MP NP			30	5	30		
			a	Fibsol 5	RW	MP NP							
			a	Lisinopril Sandoz	SZ	MP NP							
			a	Zestril	IX	MP NP							
			a	Zinopril 5	AL	MP NP							
			a	APO-Lisinopril	TX	MP NP		P14238					
			a	Fibsol 5	RW	MP NP		P14238					
			a	Lisinopril Sandoz	SZ	MP NP		P14238					
			a	Zestril	IX	MP NP		P14238					

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 10 mg	Oral	a	Zinopril 5	AL	MP NP		P14238	60	5	30		
			a	APO-Lisinopril	TX	MP NP			30	5	30		
			a	Fibsol 10	RW	MP NP			30	5	30		
			a	Lisinopril Sandoz	SZ	MP NP			30	5	30		
			a	Zestril	IX	MP NP			30	5	30		
			a	Zinopril 10	AL	MP NP			30	5	30		
	Tablet 20 mg	Oral	a	APO-Lisinopril	TX	MP NP		P14238	60	5	30		
			a	Fibsol 10	RW	MP NP		P14238	60	5	30		
			a	Lisinopril Sandoz	SZ	MP NP		P14238	60	5	30		
			a	Zestril	IX	MP NP		P14238	60	5	30		
			a	Zinopril 10	AL	MP NP		P14238	60	5	30		
			a	APO-Lisinopril	TX	MP NP			30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lithium	Tablet containing lithium carbonate 250	Oral	a	Fibsol 20	RW	MP NP			30	5	30		
			a	Lisinopril generichealth	GQ	MP NP			30	5	30		
			a	Lisinopril Sandoz	SZ	MP NP			30	5	30		
			a	Zestril	IX	MP NP			30	5	30		
			a	Zinopril 20	AL	MP NP			30	5	30		
			a	APO-Lisinopril	TX	MP NP		P14238	60	5	30		
			a	Fibsol 20	RW	MP NP		P14238	60	5	30		
			a	Lisinopril generichealth	GQ	MP NP		P14238	60	5	30		
			a	Lisinopril Sandoz	SZ	MP NP		P14238	60	5	30		
			a	Zestril	IX	MP NP		P14238	60	5	30		
			a	Zinopril 20	AL	MP NP		P14238	60	5	30		
Lithium	Tablet containing lithium carbonate 250	Oral		Lithicarb	AS	MP NP			200	2	200		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	mg												
Loperamide	Tablet containing lithium carbonate 450 mg (slow release)	Oral		Quilonum SR	AS	MP NP			200	2	100		
	Capsule containing loperamide hydrochloride 2 mg	Oral	a	Gastrex	CR	MP NP	C6343 C6364	P6364	12	0	12		
			a	Gastro-Stop	AS	MP NP	C6343 C6364	P6364	12	0	12		
			a	Gastrex	CR	MP NP	C6343 C6364	P6343	60	0	12		
			a	Gastro-Stop	AS	MP NP	C6343 C6364	P6343	60	0	12		
Lopinavir with ritonavir	Oral liquid 400 mg-100 mg per 5 mL, 60 mL	Oral		Kaletra	VE	MP NP	C4454 C4512		10	5	1		D(100)
	Tablet 100 mg-25 mg	Oral		Kaletra	VE	MP NP	C4454 C4512		120	5	60		D(100)
	Tablet 200 mg-50 mg	Oral		Kaletra	VE	MP NP	C4454 C4512		240	5	120		D(100)
Lorlatinib	Tablet 25 mg	Oral		Lorviqua	PF	MP	C13558 C13716		90	3	90		
	Tablet 100 mg	Oral		Lorviqua	PF	MP	C13558 C13716		30	3	30		
Lumacaftor with ivacaftor	Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg	Oral		Orkambi	VR	MP	See Note 3	See Note 3	See Note 3	See Note 3	56		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Lurasidone	Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg	Oral		Orkambi	VR	MP	See Note 3	See Note 3	See Note 3	See Note 3	56		D(100)
	Tablet containing lumacaftor 100 mg with ivacaftor 125 mg	Oral		Orkambi	VR	MP	See Note 3		See Note 3	See Note 3	112		D(100)
	Tablet containing lumacaftor 200 mg with ivacaftor 125 mg	Oral		Orkambi	VR	MP	See Note 3		See Note 3	See Note 3	112		D(100)
	Tablet containing lurasidone hydrochloride 40 mg	Oral	a	APO-Lurasidone	TX	MP NP	C4246		30	5	30		
			a	Ardix Lurasidone	RX	MP NP	C4246		30	5	30		
			a	Latuda	SE	MP NP	C4246		30	5	30		
			a	Lavione	AF	MP NP	C4246		30	5	30		
			a	Lurasidone Lupin	GQ	MP NP	C4246		30	5	30		
			a	Lurasidone Sandoz	SZ	MP NP	C4246		30	5	30		
			a	LURASIDONE SUN	RA	MP NP	C4246		30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing lurasidone hydrochloride 80 mg	Oral	a	Pharmacor Lurasidone	CR	MP NP	C4246		30	5	30		
			a	APO-Lurasidone	TX	MP NP	C4246		30	5	30		
			a	Ardix Lurasidone	RX	MP NP	C4246		30	5	30		
			a	Latuda	SE	MP NP	C4246		30	5	30		
			a	Lavione	AF	MP NP	C4246		30	5	30		
			a	Lurasidone Lupin	GQ	MP NP	C4246		30	5	30		
			a	Lurasidone Sandoz	SZ	MP NP	C4246		30	5	30		
			a	LURASIDONE SUN	RA	MP NP	C4246		30	5	30		
			a	Pharmacor Lurasidone	CR	MP NP	C4246		30	5	30		
Lutropin alfa	Powder for injection 75 I.U. with solvent	Injection		Luveris	SG	MP	C5251		14	0	1		D(100)
Macitentan	Tablet 10 mg	Oral		Opsumit	JC	MP	See Note 3	See Note 3	See Note 3	See Note 3	30		D(100)
Macrogol 3350	Oral liquid 13.125 g in 25 mL with	Oral		Movicol Liquid	NE	MP NP	C4576 C4577 C4580 C4596	P6171	2	3	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	electrolytes, 500 mL						C4601 C6171						
					MP		C4576 C4577	P4576 P4577	2	5	1		
					NP		C4580 C4596	P4580 P4596					
							C4601 C6171	P4601					
	Sachets containing powder for oral solution 13.125 g with electrolytes, 30	Oral	a	APOHEALTH Macrogol with Electrolytes	GX	MP	See Note 2	See Note 2	See Note 2	See Note 2	1		C(100)
			a	APO-MACROGOL plus ELECTROLYTES	TX	MP	See Note 2	See Note 2	See Note 2	See Note 2	1		C(100)
			a	Chemists' Own Macrogol with Electrolytes	RW	MP	See Note 2	See Note 2	See Note 2	See Note 2	1		C(100)
			a	Macrovic	RF	MP	See Note 2	See Note 2	See Note 2	See Note 2	1		C(100)
			a	Molaxole	GO	MP	See Note 2	See Note 2	See Note 2	See Note 2	1		C(100)
			a	Movicol	NE	MP	See Note 2	See Note 2	See Note 2	See Note 2	1		C(100)
			a	APOHEALTH Macrogol with Electrolytes	GX	MP	C4576 C4577	P4576 P4577	1	5	1		
					NP		C4580 C4596	P4580 P4596					
							C4601 C6171	P4601					
			a	APO-MACROGOL plus ELECTROLYTES	TX	MP	C4576 C4577	P4576 P4577	1	5	1		
					NP		C4580 C4596	P4580 P4596					
							C4601 C6171	P4601					
			a	Chemists' Own Macrogol with	RW	MP	C4576 C4577	P4576 P4577	1	5	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
				Electrolytes		NP	C4580 C4596 C4601 C6171	P4580 P4596 P4601					
	a			Macrovic	RF	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1		
	a			Molaxole	GO	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1		
	a			Movicol	NE	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1		
	a			APOHEALTH Macrogol with Electrolytes	GX	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1		
	a			APO-MACROGOL plus ELECTROLYTES	TX	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1		
	a			Chemists' Own Macrogol with Electrolytes	RW	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1		
	a			Macrovic	RF	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1		
	a			Molaxole	GO	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Movicol	NE	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1		
	Powder for oral solution 510 g	Oral		OsmoLax	KY	MP	See Note 2	See Note 2	See Note 2	See Note 2	1		C(100)
						MP NP	C4171 C4173 C4177 C4179 C4180 C6170	P4171 P4173 P4177 P4179 P4180	1	5	1		
						MP NP	C4171 C4173 C4177 C4179 C4180 C6170	P6170	2	3	1		
Magnesium	Tablet 37.4 mg (as aspartate dihydrate)	Oral		Mag-Sup	PP	MP NP	C5466 C5506		50	5	50		
				MagMin (PBS)	BB	MP NP	C5466 C5506		50	5	50		
Mannitol	Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers	Inhalation by mouth		Bronchitol	HT	MP	C7362 C7367 C9527 C9593		4	5	1		D(100)
Maraviroc	Tablet 150 mg	Oral		Celsentri	VI	MP NP	C5008		120	5	60		D(100)
	Tablet 300 mg	Oral		Celsentri	VI	MP NP	C5008		120	5	60		D(100)
Mecasermin	Solution for injection 40 mg in 4 mL (10 mg per	Injection		Increlex	IS	MP	C13293 C13317 C13320		See Note 3	See Note 3	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Medroxyprogesterone	mL)												
	Injection containing medroxyprogesterone acetate 150 mg in 1 mL	Injection	a	Depo-Provera	PF	MP NP			1	1	1		
			a	Depo-Ralovera	FZ	MP NP			1	1	1		
	Tablet containing medroxyprogesterone acetate 5 mg	Oral	a	Provera	PF	MP NP			56	2	56		
			a	Ralovera	FZ	MP NP			56	2	56		
	Tablet containing medroxyprogesterone acetate 10 mg	Oral	a	Provera	PF	MP NP			30	2	30		
			a	Ralovera	FZ	MP NP			30	2	30		
			a	Provera	PF	MP		P6244	100	2	100		
			a	Ralovera	FZ	MP		P6244	100	2	100		
	Tablet containing medroxyprogesterone acetate 100 mg	Oral		Provera	PF	MP	C5649 C5791		100	2	100		
	Tablet containing medroxyprogesterone acetate 200 mg	Oral		Provera	PF	MP	C5649 C5791		60	2	60		
	Tablet containing medroxyprogesterone acetate 250 mg	Oral		Provera	PF	MP	C5649 C5791		60	2	60		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing medroxyprogesterone acetate 500 mg	Oral		Provera	PF	MP	C5731		30	2	30		
Mefenamic acid	Capsule 250 mg	Oral	a	FEMIN	LI	MP NP	C6213 C6229		50	2	50		
			a	Ponstan	PF	MP NP	C6213 C6229		50	2	50		
Meloxicam	Capsule 7.5 mg	Oral		APO-Meloxicam	TX	MP NP	C4907 C4962		30	3	30		
				Chem mart Meloxicam	CH	MP NP	C4907 C4962		30	3	30		
				MELOBIC	RF	MP NP	C4907 C4962		30	3	30		
				Meloxicam Sandoz	SZ	MP NP	C4907 C4962		30	3	30		
				Mobic	BY	MP NP	C4907 C4962		30	3	30		
				Movalis 7.5	RW	MP NP	C4907 C4962		30	3	30		
				Moxicam	AF	MP NP	C4907 C4962		30	3	30		
				Terry White Chemists Meloxicam	TW	MP NP	C4907 C4962		30	3	30		
	Capsule 15 mg	Oral		APO-Meloxicam	TX	MP	C4907 C4962		30	3	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
					NP							
			Chem mart Meloxicam	CH	MP NP	C4907 C4962		30	3	30		
			MELOBIC	RF	MP NP	C4907 C4962		30	3	30		
			Meloxicam Sandoz	SZ	MP NP	C4907 C4962		30	3	30		
			Mobic	BY	MP NP	C4907 C4962		30	3	30		
			Movalis 15	RW	MP NP	C4907 C4962		30	3	30		
			Moxicam	AF	MP NP	C4907 C4962		30	3	30		
			Terry White Chemists Meloxicam	TW	MP NP	C4907 C4962		30	3	30		
	Tablet 7.5 mg	Oral	APX-Meloxicam	TY	MP NP	C4907 C4962		30	3	30		
			CIPLA MELOXICAM 7.5	LR	MP NP	C4907 C4962		30	3	30		
			MELOBIC	RF	MP NP	C4907 C4962		30	3	30		
			Meloxibell	GQ	MP NP	C4907 C4962		30	3	30		
			Meloxicam Sandoz	SZ	MP	C4907 C4962		30	3	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
				Mobic	BY	MP NP	C4907 C4962		30	3	30		
				Movalis 7.5	RW	MP NP	C4907 C4962		30	3	30		
				Moxicam 7.5	AF	MP NP	C4907 C4962		30	3	30		
				Pharmacor Meloxicam 7.5	CR	MP NP	C4907 C4962		30	3	30		
	Tablet 15 mg	Oral		APX-Meloxicam	TY	MP NP	C4907 C4962		30	3	30		
				CIPLA MELOXICAM 15	LR	MP NP	C4907 C4962		30	3	30		
				MELOBIC	RF	MP NP	C4907 C4962		30	3	30		
				Meloxibell	GQ	MP NP	C4907 C4962		30	3	30		
				Meloxicam Sandoz	SZ	MP NP	C4907 C4962		30	3	30		
				Meloxicam Viatris	AL	MP NP	C4907 C4962		30	3	30		
				Mobic	BY	MP NP	C4907 C4962		30	3	30		
				Movalis 15	RW	MP	C4907 C4962		30	3	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Melpalalan	Tablet 2 mg	Oral	a	Moxicam 15	AF	MP	C4907 C4962		30	3	30		
				Pharmacor Meloxicam 15	CR	MP	C4907 C4962		30	3	30		
				Alkeran	AS	MP			25	1	25		
				APO-Memantine	TX	MP	C13936 C13966 C14000		56	5	56		
						NP	C13966		56	5	56		
				Ebixa	LU	MP	C13936 C13966 C14000		56	5	56		
						NP	C13966		56	5	56		
				Memantine generichealth	GQ	MP	C13936 C13966 C14000		56	5	56		
						NP	C13966		56	5	56		
				Memanza	RW	MP	C13936 C13966 C14000		56	5	56		
Memantine	Tablet containing memantine hydrochloride 10 mg	Oral	a	APO-Memantine	TX	MP	C13936 C13966 C14000		28	5	28		
						NP	C13966		28	5	28		
						NP	C13966		28	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Mepolizumab	Injection 100 mg in 1 mL single dose pre-filled pen	Injection	a	Ebixa	LU	MP	C13936 C13966 C14000		28	5	28		
						NP	C13966		28	5	28		
			a	Memantine generichealth	GQ	MP	C13936 C13966 C14000		28	5	28		
						NP	C13966		28	5	28		
Mepolizumab	Injection 100 mg in 1 mL single dose pre-filled pen	Injection		Nucala	GK	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
Mercaptopurine	Powder for injection 100 mg	Injection		Nucala	GK	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Oral suspension containing mercaptopurine monohydrate 20 mg per mL, 100 mL	Oral		Allmercap	LM	MP			1	2	1		
Mesalazine	Tablet containing mercaptopurine monohydrate 50 mg	Oral	a	MERCAPTOPURINE-LINK	LM	MP			100	2	25		
			a	Purinethol	AS	MP			100	2	25		
	Enemas 1 g in 100 mL, 7	Rectal		Pentasa	FP	MP NP	C4888		4	1	1		
	Enemas 2 g in 60 mL, 7	Rectal		Salofalk	FD	MP NP	C4888		4	1	1		
	Enemas 4 g in 60 mL,	Rectal		Salofalk	FD	MP	C4888		4	1	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	7					NP							
	Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g	Rectal		Salofalk	FD	MP NP	C4888		4	1	1		
	Sachet containing granules, 500 mg per sachet	Oral		Salofalk	FD	MP NP	C9444 C14260	P9444	200	5	100		
						MP NP	C9444 C14260	P14260	400	5	100		
	Sachet containing granules, 1 g per sachet	Oral		Salofalk	FD	MP NP	C9444 C14260	P9444	100	5	100		
						MP NP	C9444 C14260	P14260	200	5	100		
	Sachet containing prolonged release granules, 1 g per sachet	Oral		Pentasa	FP	MP NP	C9443 C9444 C14229 C14260	P9443 P9444	100	5	100		
						MP NP	C9443 C9444 C14229 C14260	P14229 P14260	200	5	100		
	Sachet containing granules, 1.5 g per sachet	Oral		Salofalk	FD	MP NP	C9444 C14260	P9444	60	5	60		
						MP NP	C9444 C14260	P14260	120	5	60		
	Sachet containing prolonged release granules, 2 g per sachet	Oral		Pentasa	FP	MP NP	C9443 C9444 C14229 C14260	P9443 P9444	60	5	60		
						MP	C9443 C9444	P14229 P14260	120	5	60		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Sachet containing granules, 3 g per sachet	Oral		Salofalk	FD	MP NP	C14229 C14260 C9444 C14260	P9444	30	5	30		
						MP NP	C9444 C14260	P14260	60	5	30		
	Sachet containing prolonged release granules, 4 g per sachet	Oral		Pentasa	FP	MP NP	C9444 C14260	P9444	30	5	30		
						MP NP	C9444 C14260	P14260	60	5	30		
	Suppository (moulded) 1 g	Rectal		Salofalk	FD	MP NP	C4878		30	1	30		
	Suppository 1 g	Rectal		Pentasa	FP	MP NP	C4878		28	1	28		
	Tablet 250 mg (enteric coated)	Oral		Mesasal	GO	MP NP	C9443 C9444 C14229 C14260	P9443 P9444	100	5	100		
						MP NP	C9443 C9444 C14229 C14260	P14229 P14260	200	5	100		
	Tablet 500 mg (enteric coated)	Oral		Salofalk	FD	MP NP	C9443 C9444 C14229 C14260	P9443 P9444	200	5	100		
						MP NP	C9443 C9444 C14229 C14260	P14229 P14260	400	5	100		
	Tablet 500 mg (prolonged release)	Oral		Pentasa	FP	MP NP	C9443 C9444 C14229 C14260	P9443 P9444	200	5	100		
						MP	C9443 C9444	P14229 P14260	400	5	100		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 800 mg (enteric coated)	Oral		Asacol	EU	MP NP	NP C14229 C14260 C9444 C14260	P9444	90	5	90		
						MP NP	C9444 C14260	P14260	180	5	90		
	Tablet 1 g (enteric coated)	Oral		Salofalk	FD	MP NP	C9443 C9444 C14229 C14260	P9443 P9444	120	5	60		
						MP NP	C9443 C9444 C14229 C14260	P14229 P14260	240	5	60		
	Tablet 1 g (prolonged release)	Oral		Pentasa	FP	MP NP	C9443 C9444 C14229 C14260	P9443 P9444	120	5	60		
						MP NP	C9443 C9444 C14229 C14260	P14229 P14260	240	5	60		
	Tablet 1.2 g (prolonged release)	Oral	a	Mesalazine 1.2 TAKEDA	NQ	MP NP	C9444 C14260	P9444	120	5	60		
			a	Mezavant	TK	MP NP	C9444 C14260	P9444	120	5	60		
			a	MESALZ	RA	MP NP	C9444 C14260	P9444	120	5	120		
			a	Mesalazine 1.2 TAKEDA	NQ	MP NP	C9444 C14260	P14260	240	5	60		
			a	Mezavant	TK	MP NP	C9444 C14260	P14260	240	5	60		
				MESALZ	RA	MP	C9444 C14260	P14260	240	5	120		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Mesna	Tablet 1.6 g (enteric coated)	Oral		Asacol	EU	MP NP	C9444 C14260	P9444	120	4	60		
						MP NP	C9444 C14260	P14260	240	4	60		
	Solution for I.V. injection 400 mg in 4 mL ampoule	Injection		Uromitexan	BX	MP	C5106		15	5	15		
						MP	C5130		15	5	15		C(100)
Metformin	Solution for I.V. injection 1 g in 10 mL ampoule	Injection		Uromitexan	BX	MP	C5106		15	5	15		
						MP	C5130		15	5	15		C(100)
	Tablet (extended release) containing metformin hydrochloride 500 mg	Oral	a	APO-Metformin XR 500	TX	MP NP			120	5	120		
			a	Blooms the Chemist Metformin XR 500	IB	MP NP			120	5	120		
			a	Diabex XR 500	AL	MP NP			120	5	120		
			a	Metex XR	RW	MP NP			120	5	120		
			a	Metformin XR 500 APOTEX	GX	MP NP			120	5	120		
			a	Pharmacor Metformin XR	CR	MP NP			120	5	120		
	Tablet containing	Oral	a	APO-Metformin 500	TX	MP			100	5	100		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	metformin hydrochloride 500 mg		a	APX-Metformin	TY	MP NP			100	5	100		
			a	Diabex	AL	MP NP			100	5	100		
			a	Diaformin	AF	MP NP			100	5	100		
			a	FORMET 500	RF	MP NP			100	5	100		
			a	Glucobete 500	ZS	MP NP			100	5	100		
			a	Metformin AN	EA	MP NP			100	5	100		
			a	Metformin GH	HQ	MP NP			100	5	100		
			a	Metformin Sandoz	SZ	MP NP			100	5	100		
	Tablet containing metformin hydrochloride 850 mg	Oral	a	APO-Metformin 850	TX	MP NP			60	5	60		
			a	APX-Metformin	TY	MP NP			60	5	60		
			a	Chem mart Metformin	CH	MP NP			60	5	60		
			a	Diabex 850	AL	MP			60	5	60		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
			a	Diaformin 850	AF	MP			60	5	60		
			a	FORMET 850	RF	MP			60	5	60		
			a	Glucobete 850	ZS	MP			60	5	60		
			a	Metformin AN	EA	MP			60	5	60		
			a	Metformin Sandoz	SZ	MP			60	5	60		
			a	Terry White Chemists Metformin	TW	MP			60	5	60		
	Tablet (extended release) containing metformin hydrochloride 1 g	Oral	a	APO-Metformin XR 1000	TX	MP			60	5	60		
			a	Blooms the Chemist Metformin XR 1000	IB	MP			60	5	60		
			a	Diabex XR 1000	AL	MP			60	5	60		
			a	Diaformin XR 1000	AF	MP			60	5	60		
			a	METEX XR	RF	MP			60	5	60		
			a	Pharmacor Metformin XR	CR	MP			60	5	60		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing metformin hydrochloride 1 g	Oral	a	APO-Metformin 1000	TX	MP NP			90	5	90		
			a	APX-Metformin	TY	MP NP			90	5	90		
			a	Diabex 1000	AL	MP NP			90	5	90		
			a	Diaformin 1000	AF	MP NP			90	5	90		
			a	Formet 1000	RW	MP NP			90	5	90		
			a	Glucobete 1000	ZS	MP NP			90	5	90		
			a	Metformin AN	EA	MP NP			90	5	90		
			a	Metformin GH	HQ	MP NP			90	5	90		
			a	Metformin Sandoz	SZ	MP NP			90	5	90		
Methadone	Injection containing methadone hydrochloride 10 mg in 1 mL	Injection		Physeptone	AS	MP NP	C10745 C10747 C10751 C11696	P10745 P10747 P10751	5	0	5		
						MP	C10745 C10747	P11696	120	0	5		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 1 L bottle, 1 mL	Oral	a	Aspen Methadone Syrup	AS	MP NP	NP C10751 C11696 C14178		840	2	100 0		PB(100)
			a	Biodone Forte	MW	MP NP	C14178		840	2	100 0		PB(100)
	Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 200 mL bottle, 1 mL	Oral		Aspen Methadone Syrup	AS	MP NP	C4902 C4941	P4941	200	0	200		
						MP NP	C4902 C4941	P4902	200	2	200		
			a	Aspen Methadone Syrup	AS	MP NP	C14178		840	2	200		C(100)
			a	Biodone Forte	MW	MP NP	C14178		840	2	200		C(100)
	Tablet containing methadone hydrochloride 10 mg	Oral		Physeptone	AS	MP NP	C10745 C10747 C10751 C11696	P10745 P10747 P10751	20	0	20		
						MP NP	C10745 C10747 C10751 C11696	P11696	120	0	20		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Methenamine	Tablet containing methenamine hippurate 1 g	Oral	a	Hiprex	IL	MP NP			100	5	100		
			a	Uramet	AS	MP NP			100	5	100		
Methotrexate	Injection 5 mg in 2 mL vial	Injection		DBL Methotrexate	PF	MP			5	0	5		
						MP			See Note 2	See Note 2	5		C(100)
						MP		P6276	See Note 2	See Note 2	5		C(100)
	Injection 7.5 mg in 0.15 mL pre-filled syringe	Injection		Trexject	LM	MP	C7488 C7518		4	5	1		
	Injection 10 mg in 0.2 mL pre-filled syringe	Injection		Trexject	LM	MP	C7488 C7518		4	5	1		
	Injection 15 mg in 0.3 mL pre-filled syringe	Injection		Trexject	LM	MP	C7488 C7518		4	5	1		
	Injection 20 mg in 0.4 mL pre-filled syringe	Injection		Trexject	LM	MP	C7488 C7518		4	5	1		
	Injection 25 mg in 0.5 mL pre-filled syringe	Injection		Trexject	LM	MP	C7488 C7518		4	5	1		
	Injection 50 mg in 2 mL vial	Injection		DBL Methotrexate	PF	MP			5	5	5		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						MP			See Note 2	See Note 2	5		C(100)
						MP		P6276	See Note 2	See Note 2	5		C(100)
	Solution concentrate for I.V. infusion 500 mg in 20 mL vial	Injection		DBL Methotrexate	PF	MP			See Note 3	See Note 3	1		PB(100)
						MP		P6276	See Note 3	See Note 3	1		PB(100)
	Solution concentrate for I.V. infusion 1000 mg in 10 mL vial	Injection		DBL Methotrexate	PF	MP			See Note 3	See Note 3	1		PB(100)
						MP		P6276	See Note 3	See Note 3	1		PB(100)
				Methotrexate Accord	OD	MP			See Note 3	See Note 3	1		PB(100)
						MP		P6276	See Note 3	See Note 3	1		PB(100)
				Pfizer Australia Pty Ltd	PF	MP			See Note 3	See Note 3	1		PB(100)
						MP		P6276	See Note 3	See Note 3	1		PB(100)
	Solution concentrate for I.V. infusion 5000 mg in 50 mL vial	Injection		Methotrexate Ebewe	SZ	MP			See Note 3	See Note 3	1		PB(100)
						MP		P6276	See Note 3	See Note 3	1		PB(100)

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Methoxsalen	Tablet 2.5 mg	Oral	a	Chexate	OX	MP			30	5	30		
			a	Methoblastin	PF	MP			30	5	30		
	Tablet 10 mg	Oral		Methoblastin	PF	MP			15	3	15		
			a	Chexate	OX	MP	C5648		50	2	50		
			a	Methoblastin	PF	MP		P5648	50	2	50		
	Solution for blood fraction 20 microgram per mL, 10 mL	Extracorporeal circulation		Uvadex	TQ	MP	C10971 C10985 C10988 C10989 C12531 C12546 C12567 C12579	P10988 P10989	1	5	12		D(100)
						MP	C10971 C10985 C10988 C10989 C12531 C12546 C12567 C12579	P12531 P12567	2	0	12		D(100)
						MP	C10971 C10985 C10988 C10989 C12531 C12546 C12567 C12579	P10971 P10985	2	6	12		D(100)
						MP	C10971 C10985 C10988 C10989 C12531 C12546 C12567 C12579	P12546 P12579	12	1	12		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Methoxyflurane	Liquid for inhalation 999 mg per g, 3 mL (with inhaler)	Inhalation by mouth	Penthrox	DV	See Note 4	See Note 4	See Note 4	See Note 4	See Note 4	1	1	D(MP)
Methoxy polyethylene glycol-epoetin beta	Injection 30 micrograms in 0.3 mL pre-filled syringe	Injection	Mircera	RO	MP	C6294 C9688		2	5	1		D(100)
	Injection 50 micrograms in 0.3 mL pre-filled syringe	Injection	Mircera	RO	MP	C6294 C9688		2	5	1		D(100)
	Injection 75 micrograms in 0.3 mL pre-filled syringe	Injection	Mircera	RO	MP	C6294 C9688		2	5	1		D(100)
	Injection 100 micrograms in 0.3 mL pre-filled syringe	Injection	Mircera	RO	MP	C6294 C9688		2	5	1		D(100)
	Injection 120 micrograms in 0.3 mL pre-filled syringe	Injection	Mircera	RO	MP	C6294 C9688		2	5	1		D(100)
	Injection 200 micrograms in 0.3 mL pre-filled syringe	Injection	Mircera	RO	MP	C6294 C9688		2	5	1		D(100)
	Injection 360 micrograms in 0.6 mL pre-filled syringe	Injection	Mircera	RO	MP	C6294 C9688		2	5	1		D(100)
	Tablet 250 mg (as sesquihydrate)	Oral	Aldomet	AS	MP NP	C13887		100	5	100		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Methylnaltrexone	Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL	Injection		Relistor	LM	MP NP	C6180		7	0	1		
						MP NP	C6180		7	0	7		
Methylphenidate	Capsule containing methylphenidate hydrochloride 10 mg (modified release)	Oral	a	Ritalin LA	NV	MP NP	C13922		30	5	30		
			a	Rubifen LA		MP NP	C13922		30	5	30		
	Capsule containing methylphenidate hydrochloride 20 mg (modified release)	Oral	a	Ritalin LA	NV	MP NP	C13922		30	5	30		
			a	Rubifen LA		MP NP	C13922		30	5	30		
	Capsule containing methylphenidate hydrochloride 30 mg (modified release)	Oral	a	Ritalin LA	NV	MP NP	C13922		30	5	30		
			a	Rubifen LA		MP NP	C13922		30	5	30		
	Capsule containing methylphenidate hydrochloride 40 mg	Oral	a	Ritalin LA	NV	MP NP	C13922		30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	(modified release)												
			a	Rubifen LA	AE	MP NP	C13922		30	5	30		
	Capsule containing methylphenidate hydrochloride 60 mg (modified release)	Oral	a	Ritalin LA	NV	MP NP	C13922		30	5	30		
			a	Rubifen LA	AE	MP NP	C13922		30	5	30		
	Tablet containing methylphenidate hydrochloride 10 mg	Oral	a	Artige	NM	MP NP	C6226		100	5	100		
			a	Ritalin 10	NV	MP NP	C6226		100	5	100		
	Tablet containing methylphenidate hydrochloride 18 mg (extended release)	Oral	a	Concerta	JC	MP NP	C10717		30	5	30		
			a	METHYLPHENIDATE-TEVA XR	TB	MP NP	C10717		30	5	30		
			a	Methylphenidate XR ARX	XT	MP NP	C10717		30	5	30		
	Tablet containing methylphenidate hydrochloride 27 mg (extended release)	Oral	a	Concerta	JC	MP NP	C10717		30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Methylprednisolone	Tablet containing methylphenidate hydrochloride 36 mg (extended release)	Oral	a	METHYLPHENIDATE-TEVA XR	TB	MP NP	C10717		30	5	30		
			a	Methylphenidate XR ARX	XT	MP NP	C10717		30	5	30		
			a	Concerta	JC	MP NP	C10717		30	5	30		
			a	METHYLPHENIDATE-TEVA XR	TB	MP NP	C10717		30	5	30		
			a	Methylphenidate XR ARX	XT	MP NP	C10717		30	5	30		
			a	Concerta	JC	MP NP	C10717		30	5	30		
	Tablet containing methylphenidate hydrochloride 54 mg (extended release)	Oral	a	METHYLPHENIDATE-TEVA XR	TB	MP NP	C10717		30	5	30		
			a	Methylphenidate XR ARX	XT	MP NP	C10717		30	5	30		
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Supriad Cream	LG	MP	C4957 C6218	P4957	1	0	1		

Ready-prepared pharmaceutical benefits **Schedule 1**
Ready-prepared pharmaceutical benefits for prescription and supply **Part 1**

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP	C6231 C6232 C6246 C6263						
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Supriad Cream	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
			a	Supriad Cream	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Supriad Cream	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Supriad Cream	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	Supriad Cream	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
	Injection containing methylprednisolone acetate 40 mg in 1 mL	Injection	a	Depo-Medrol	PF	MP NP	C6273		5	0	5		
						PDP	C6209		5	0	5		
			a	Depo-Nisolone	FZ	MP NP	C6273		5	0	5		
						PDP	C6209		5	0	5		
	Lotion containing methylprednisolone aceponate 1 mg per g, 20 g	Application		Advantan	LO	MP NP	C6218 C6231 C6232 C6246 C6263 C6302	P6302	1	0	1		
						MP NP	C6218 C6231 C6232 C6246 C6263 C6302	P6232	2	5	1		
						MP NP	C6218 C6231 C6232 C6246 C6263 C6302	P6246	3	5	1		
						MP NP	C6218 C6231 C6232 C6246	P6218 P6263	4	5	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
							C6263 C6302						
						MP NP	C6218 C6231 C6232 C6246 C6263 C6302	P6231	5	5	1		
	Fatty ointment containing methylprednisolone aceponate 1 mg per g, 15 g	Application	a	Advantan (Fatty)	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Supriad Fatty Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Tanilone (Fatty)	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Advantan (Fatty)	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Supriad Fatty Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Tanilone (Fatty)	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Advantan (Fatty)	LO	MP NP	C4957 C6218 C6231 C6232	P6246	4	5	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Supriad Fatty Ointment	LG	MP NP	C6246 C6263 C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
			a	Tanilone (Fatty)	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
			a	Advantan (Fatty)	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Supriad Fatty Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Tanilone (Fatty)	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Advantan (Fatty)	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Supriad Fatty Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Tanilone (Fatty)	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Advantan (Fatty)	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	Supriad Fatty Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	Tanilone (Fatty)	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
	Ointment containing methylprednisolone aceponate 1 mg per g, 15 g	Application	a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Supriad Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Supriad Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
			a	Supriad Ointment	LG	MP	C4957 C6218	P6246	4	5	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP	C6231 C6232 C6246 C6263						
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Supriad Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Supriad Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Advantan	LO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	Supriad Ointment	LG	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
	Powder for injection 40 mg (as sodium succinate)	Injection		Methylpred	AL	MP NP			5	0	5		
	Powder for injection 40 mg (as sodium succinate) with diluent	Injection		Solu-Medrol	PF	MP NP			5	0	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Metoclopramide	Powder for injection 40 mg (as sodium succinate) (S19A)	Injection		Solu-Medrone	LM	MP NP			5	0	1		
	Powder for injection 1 g (as sodium succinate)	Injection	a	Methylpred	AL	MP NP			1	0	1		
			a	Solu-Medrol	PF	MP NP			1	0	1		
	Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL	Injection		Maxolon	IL	MP NP MW PDP			10	0	10		
						MP NP		P6084	40 CN6084	2 CN6084	10		
	Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate)	Oral	a	APO-Metoclopramide	TX	MP NP MW PDP			25	0	25		
			a	EMEXLON	RW	MP NP MW PDP			25	0	25		
			a	Maxolon	IL	MP NP MW PDP			25	0	25		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Metoprolol	Tablet containing metoprolol tartrate 50 mg	Oral	a	Pramin	AF	MP NP MW PDP			25	0	25		
			a	APO-Metoclopramide	TX	MP NP		P11683	100	5	25		
			a	EMEXLON	RW	MP NP		P11683	100	5	25		
			a	Maxolon	IL	MP NP		P11683	100	5	25		
			a	Pramin	AF	MP NP		P11683	100	5	25		
			a	APO-Metoprolol	TX	MP NP			100	5	100		
			a	Betaloc	AP	MP NP			100	5	100		
			a	Metoprolol Sandoz	SZ	MP NP			100	5	100		
			a	Metrol 50	RW	MP NP			100	5	100		
			a	Minax 50	AF	MP NP			100	5	100		
				Mistrom	ZS	MP NP			100	5	100		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	NOUMED METOPROLOL	VO	MP NP			100	5	100		
			a	APO-Metoprolol	TX	MP NP		P14238	200	5	100		
			a	Betaloc	AP	MP NP		P14238	200	5	100		
			a	Metoprolol Sandoz	SZ	MP NP		P14238	200	5	100		
			a	Metrol 50	RW	MP NP		P14238	200	5	100		
			a	Minax 50	AF	MP NP		P14238	200	5	100		
				Mistrom	ZS	MP NP		P14238	200	5	100		
			a	NOUMED METOPROLOL	VO	MP NP		P14238	200	5	100		
	Tablet containing metoprolol tartrate 100 mg	Oral	a	APO-Metoprolol	TX	MP NP			60	5	60		
			a	Betaloc	AP	MP NP			60	5	60		
			a	Metoprolol Sandoz	SZ	MP NP			60	5	60		
			a	Metrol 100	RW	MP NP			60	5	60		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Metoprolol succinate	Tablet 23.75 mg (controlled release)	Oral	a	Minax 100	AF	MP NP			60	5	60		
				Mistrom	ZS	MP NP			60	5	60		
			a	NOUMED METOPROLOL	VO	MP NP			60	5	60		
			a	APO-Metoprolol	TX	MP NP		P14238	120	5	60		
			a	Betaloc	AP	MP NP		P14238	120	5	60		
			a	Metoprolol Sandoz	SZ	MP NP		P14238	120	5	60		
			a	Metrol 100	RW	MP NP		P14238	120	5	60		
			a	Minax 100	AF	MP NP		P14238	120	5	60		
				Mistrom	ZS	MP NP		P14238	120	5	60		
			a	NOUMED METOPROLOL	VO	MP NP		P14238	120	5	60		
			a	Metrol-XL 23.75	RW	MP NP	C5324		15	0	15		
			a	Minax XL	AF	MP NP	C5324		15	0	15		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 47.5 mg (controlled release)	Oral	a	Topreloc-XL	CR	MP NP	C5324		15	0	15		
			a	Metrol-XL 47.5	RW	MP NP	C5324 C14251	P5324	30	5	30		
			a	Minax XL	AF	MP NP	C5324 C14251	P5324	30	5	30		
			a	Topreloc-XL	CR	MP NP	C5324 C14251	P5324	30	5	30		
			a	Toprol-XL 47.5	AP	MP NP	C5324 C14251	P5324	30	5	30		
			a	Metrol-XL 47.5	RW	MP NP	C5324 C14251	P14251	60	5	30		
			a	Minax XL	AF	MP NP	C5324 C14251	P14251	60	5	30		
			a	Topreloc-XL	CR	MP NP	C5324 C14251	P14251	60	5	30		
	Tablet 95 mg (controlled release)	Oral	a	Toprol-XL 47.5	AP	MP NP	C5324 C14251	P14251	60	5	30		
			a	Metrol-XL 95	RW	MP NP	C5324 C14251	P5324	30	5	30		
			a	Minax XL	AF	MP NP	C5324 C14251	P5324	30	5	30		
			a	Topreloc-XL	CR	MP NP	C5324 C14251	P5324	30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 190 mg (controlled release)	Oral	a	Toprol-XL 95	AP	MP NP	C5324 C14251	P5324	30	5	30		
			a	Metrol-XL 95	RW	MP NP	C5324 C14251	P14251	60	5	30		
			a	Minax XL	AF	MP NP	C5324 C14251	P14251	60	5	30		
			a	Topreloc-XL	CR	MP NP	C5324 C14251	P14251	60	5	30		
			a	Toprol-XL 95	AP	MP NP	C5324 C14251	P14251	60	5	30		
			a	Metrol-XL 190	RW	MP NP	C5324 C14251	P5324	30	5	30		
			a	Minax XL	AF	MP NP	C5324 C14251	P5324	30	5	30		
			a	Topreloc-XL	CR	MP NP	C5324 C14251	P5324	30	5	30		
			a	Toprol-XL 190	AP	MP NP	C5324 C14251	P5324	30	5	30		
			a	Metrol-XL 190	RW	MP NP	C5324 C14251	P14251	60	5	30		
			a	Minax XL	AF	MP NP	C5324 C14251	P14251	60	5	30		
			a	Topreloc-XL	CR	MP NP	C5324 C14251	P14251	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Metronidazole	Suppositories 500 mg, 10	Rectal	a	Toprol-XL 190	AP	MP NP	C5324 C14251	P14251	60	5	30		
				Flagyl	SW	MP NP PDP			1	0	1		
		Oral		Flagyl S	SW	MP NP PDP			1	0	1		
	Tablet 200 mg	Oral		Metrogyl 200	AF	PDP			21	0	21		
						MP NP			21	1	21		
		Oral	a	Flagyl	SW	PDP	C5701		21	0	21		
			a	Metrogyl 400	AF	PDP	C5701		21	0	21		
			a	Flagyl	SW	MP NP	C5702		21	1	21		
			a	Metrogyl 400	AF	MP NP	C5702		21	1	21		
Mianserin	Tablet containing mianserin hydrochloride 10 mg	Oral		Lumin 10	AF	MP NP	C6278		50	5	50		
	Tablet containing mianserin	Oral		Lumin 20	AF	MP NP	C6278		50	5	50		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Miconazole	hydrochloride 20 mg												
	Cream containing miconazole nitrate 20 mg per g, 30 g	Application		Daktarin	JT	MP NP	C6434		1	2	1		
	Cream containing miconazole nitrate 20 mg per g, 70 g	Application		Daktarin	JT	MP NP	C6434		1	1	1		
	Powder containing miconazole nitrate 20 mg per g, 30 g	Application		Daktarin	JT	MP NP	C6434		1	2	1		
	Tincture 20 mg per mL, 30 mL	Application		Daktarin Tincture	JT	MP NP	C6434		1	2	1		
Midazolam	Injection 5 mg (as hydrochloride) in 1 mL	Injection		Pfizer Australia Pty Ltd	PF	See Note 4	See Note 4	See Note 4	See Note 4	See Note 4	10	10	D(MP) D(NP)
Midostaurin	Capsule 25 mg	Oral		Rydapt	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	56		D(100)
						MP	See Note 3	See Note 3	See Note 3	See Note 3	112		D(100)
Mifepristone and misoprostol	Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms	Oral		MS-2 Step	XH	MP NP MW	C14202		1	0	1		
Milk powder -- synthetic	Low calcium oral powder 400 g	Oral		Locasol	SB	MP	C6208		8	5	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	(Locasol)					NP							
Milk protein and fat formula with vitamins and minerals -- carbohydrate free	Oral powder 225 g (Carbohydrate Free Mixture)	Oral		Carbohydrate Free Mixture	SB	MP NP	C6658		24	5	1		
Minocycline	Tablet 50 mg (as hydrochloride)	Oral	a	Akamin 50	AF	MP NP	C5995		60	5	60		
			a	Minomycin-50	AS	MP NP	C5995		60	5	60		
Minoxidil	Tablet 10 mg	Oral		Loniten	PF	MP NP	C5177		100	5	100		
	Tablet 10 mg (s19A)	Oral		Minoxidil 10 mg (Roma Pharmaceuticals)	OJ	MP NP	C5177		100	5	60		
Mirtazapine	Tablet 15 mg	Oral	a	APO-Mirtazapine	TX	MP NP	C5650		30	5	30		
			a	APX-Mirtazapine	TY	MP NP	C5650		30	5	30		
			a	Axit 15	AF	MP NP	C5650		30	5	30		
			a	Blooms The Chemist Mirtazapine	BG	MP NP	C5650		30	5	30		
			a	MIRTANZA	RF	MP NP	C5650		30	5	30		
			a	Mirtazapine Sandoz	SZ	MP	C5650		30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
	Tablet 15 mg (orally disintegrating)	Oral	a	MIRTANZA ODT	RF	MP NP	C5650		30	5	30		
			a	Mirtazapine AN ODT	EA	MP NP	C5650		30	5	30		
	Tablet 30 mg	Oral	a	APO-Mirtazapine	TX	MP NP	C5650		30	5	30		
			a	APX-Mirtazapine	TY	MP NP	C5650		30	5	30		
			a	Avanza	AL	MP NP	C5650		30	5	30		
			a	Axit 30	AF	MP NP	C5650		30	5	30		
			a	Blooms The Chemist Mirtazapine	BG	MP NP	C5650		30	5	30		
			a	MIRTANZA	RF	MP NP	C5650		30	5	30		
			a	Mirtazapine Sandoz	SZ	MP NP	C5650		30	5	30		
			a	Mirtazon	RW	MP NP	C5650		30	5	30		
			a	NOUMED MIRTAZAPINE	VO	MP NP	C5650		30	5	30		
	Tablet 30 mg (orally	Oral	a	MIRTANZA ODT	RF	MP	C5650		30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Mirtazapine	Tablet 45 mg	Oral	a	Mirtazapine AN ODT	EA	MP NP	C5650		30	5	30		
			a	APO-Mirtazapine	TX	MP NP	C5650		30	5	30		
			a	APX-Mirtazapine	TY	MP NP	C5650		30	5	30		
			a	Axit 45	AF	MP NP	C5650		30	5	30		
			a	Blooms The Chemist Mirtazapine	BG	MP NP	C5650		30	5	30		
			a	MIRTANZA	RF	MP NP	C5650		30	5	30		
			a	Mirtazapine Sandoz	SZ	MP NP	C5650		30	5	30		
			a	Mirtazon	RW	MP NP	C5650		30	5	30		
	Tablet 45 mg (orally disintegrating)	Oral	a	NOUMED MIRTAZAPINE	VO	MP NP	C5650		30	5	30		
			a	MIRTANZA ODT	RF	MP NP	C5650		30	5	30		
			a	Mirtazapine AN ODT	EA	MP NP	C5650		30	5	30		
Mitozantrone	Injection 20 mg (as	Injection		Mitozantrone Ebewe	SZ	MP			See	See	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Moclobemide	hydrochloride) in 10 mL	Injection		Onkotrone	BX	MP			Note 3	Note 3			
									See Note 3	See Note 3	1		D(100)
	Injection 25 mg (as hydrochloride) in 12.5 mL	Injection		Onkotrone	BX	MP			See Note 3	See Note 3	1		D(100)
	Tablet 150 mg	Oral	a	Amira 150	AF	MP NP	C5650		60	5	60		
			a	APO-Moclobemide	TX	MP NP	C5650		60	5	60		
			a	Aurorix	GO	MP NP	C5650		60	5	60		
			a	Clobemix	XT	MP NP	C5650		60	5	60		
			a	Moclobemide AN	EA	MP NP	C5650		60	5	60		
			a	Moclobemide Sandoz	SZ	MP NP	C5650		60	5	60		
	Tablet 300 mg		a	Amira 300	AF	MP NP	C5650		60	5	60		
			a	APO-Moclobemide	TX	MP NP	C5650		60	5	60		
			a	Aurorix 300 mg	GO	MP NP	C5650		60	5	60		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Modafinil	Tablet 100 mg	Oral	a	Clobemix	XT	MP NP	C5650		60	5	60		
			a	Moclobemide AN	EA	MP NP	C5650		60	5	60		
			a	Moclobemide Sandoz	SZ	MP NP	C5650		60	5	60		
			a	APO-Modafinil	TX	MP	C10935 C10968 C10970		120	5	60		
			a	Modafin	RW	MP	C10935 C10968 C10970		120	5	60		
			a	Modafinil GH	GQ	MP	C10935 C10968 C10970		120	5	60		
			a	Modafinil Mylan	AF	MP	C10935 C10968 C10970		120	5	60		
			a	Modafinil Sandoz	SZ	MP	C10935 C10968 C10970		120	5	60		
			a	Modavigil	TB	MP	C10935 C10968 C10970		120	5	60		
Molnupiravir	Capsule 200 mg	Oral		Lagevrio	MK	MP NP	C13748 C13759 C13765 C13824		40	0	40		
Mometasone	Cream containing mometasone furoate 1 mg per g, 15 g	Application	a	Elocon Alcohol Free	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Momasone Alcohol Free	AS	MP	C4957 C6218	P4957	1	0	1		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP	C6231 C6232 C6246 C6263						
	a			Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
	a			Elocon Alcohol Free	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
	a			Momasone Alcohol Free	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
	a			Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
	a			Elocon Alcohol Free	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
	a			Momasone Alcohol Free	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
	a			Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
	a			Elocon Alcohol Free	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Momasone Alcohol Free	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Elocon Alcohol Free	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Momasone Alcohol Free	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Elocon Alcohol Free	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	Momasone Alcohol Free	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Lotion containing mometasone furoate 1 mg per g, 30 mL	Application	a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Zatamil	EO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Zatamil	EO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	3	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	3	5	1		
			a	Zatamil	EO	MP	C4957 C6218	P6246	3	5	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP	C6231 C6232 C6246 C6263						
			a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218 P6263	4	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218 P6263	4	5	1		
			a	Zatamil	EO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218 P6263	4	5	1		
			a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	5	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	5	5	1		
			a	Zatamil	EO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	5	5	1		
	Ointment containing mometasone furoate 1 mg per g, 15 g	Application	a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Momasone	AS	MP NP	C4957 C6218 C6231 C6232	P4957	1	0	1		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Novasone	AF	MP NP	C6246 C6263 C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Zatamil	EO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P4957	1	0	1		
			a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Momasone	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Zatamil	EO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6232	2	5	1		
			a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
			a	Momasone	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
			a	Zatamil	EO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6246	4	5	1		
			a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Momasone	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Zatamil	EO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6218	6	5	1		
			a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Momasone	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232	P6263	8	5	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Montelukast	Tablet, chewable, 4 mg (as sodium)	Oral	a	Zatamil	EO	MP NP	C6246 C6263 C4957 C6218 C6231 C6232 C6246 C6263	P6263	8	5	1		
			a	Elocon	AL	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	Momasone	AS	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	Novasone	AF	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	Zatamil	EO	MP NP	C4957 C6218 C6231 C6232 C6246 C6263	P6231	10	5	1		
			a	MONTELAIR 4	RF	MP NP	C6666		28	5	28		
			a	Montelukast APOTEX	GX	MP NP	C6666		28	5	28		
			a	Montelukast Lupin	HQ	MP NP	C6666		28	5	28		
			a	Montelukast Mylan	AF	MP NP	C6666		28	5	28		
			a	Montelukast Sandoz 4	SZ	MP	C6666		28	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Morphine	Tablet, chewable, 5 mg (as sodium)	Oral	a	MONTELAIR 5	RF	MP NP	C6674 C7781		28	5	28		
			a	Montelukast APOTEX	GX	MP NP	C6674 C7781		28	5	28		
			a	Montelukast Lupin	HQ	MP NP	C6674 C7781		28	5	28		
			a	Montelukast Mylan	AF	MP NP	C6674 C7781		28	5	28		
			a	Montelukast Sandoz 5	SZ	MP NP	C6674 C7781		28	5	28		
	Capsule containing morphine sulfate pentahydrate 10 mg (containing sustained release pellets)	Oral		Kapanol	YN	MP NP	C9248 C10748 C10752 C10755 C11753	P9248 P10748 P10752 P10755	28	0	28		
						MP NP	C9248 C10748 C10752 C10755 C11753	P11753	56	0	28		
	Capsule containing morphine sulfate pentahydrate 20 mg (containing sustained release pellets)	Oral		Kapanol	YN	MP NP	C9248 C10748 C10752 C10755 C11753	P9248 P10748 P10752 P10755	28	0	28		
						MP NP	C9248 C10748 C10752 C10755 C11753	P11753	56	0	28		
	Capsule containing morphine sulfate	Oral		MS Mono	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	14	0	14		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	pentahydrate 30 mg (controlled release)				MP NP		C10748 C10752 C10755 C11753	P11753	28	0	14		
	Capsule containing morphine sulfate pentahydrate 50 mg (containing sustained release pellets)	Oral		Kapanol	YN	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
	Capsule containing morphine sulfate pentahydrate 60 mg (controlled release)	Oral		MS Mono	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	14	0	14		
	Capsule containing morphine sulfate pentahydrate 90 mg (controlled release)	Oral		MS Mono	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	14	0	14		
	Capsule containing morphine sulfate pentahydrate 100 mg (containing sustained release pellets)	Oral		Kapanol	YN	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
	Capsule containing morphine sulfate pentahydrate 120 mg (controlled release)	Oral		MS Mono	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	14	0	14		
	Injection containing	Injection		Morphine Juno	JU	PDP	C10839		5	0	5		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	morphine hydrochloride trihydrate 10 mg in 1 mL				MP		C10762 C10764	P10762 P10764	5	0	5		
					NP		C10765 C11697	P10765					
					MW		C10762 C10764 C10765		5	0	5		
					MP		C10762 C10764	P11697	10	1	5		
					NP		C10765 C11697						
	Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL	Injection		Morphine Juno	JU	PDP	C10839		5	0	5		
					MP		C10762 C10764	P10762 P10764	5	0	5		
					NP		C10765 C11697	P10765					
					MP		C10762 C10764	P11697	10	1	5		
					NP		C10765 C11697						
	Injection containing morphine hydrochloride trihydrate 50 mg in 5 mL	Injection		Morphine Juno	JU	MP	C10762 C10764	P10762 P10764	5	0	5		
					NP		C10765 C11697	P10765					
					MP		C10762 C10764	P11697	10	1	5		
					NP		C10765 C11697						
	Injection containing morphine hydrochloride trihydrate 100 mg in 5 mL	Injection		Morphine Juno	JU	MP	C10762 C10764	P10762 P10764	5	0	5		
					NP		C10765 C11697	P10765					
					MP		C10762 C10764	P11697	10	1	5		
					NP		C10765 C11697						
	Injection containing morphine sulfate pentahydrate 10 mg in 1 mL	Injection		MORPHINE SULFATE 10 mg/1 mL MEDSURGE	DZ	MP	C10762 C10764	P10762 P10764	5	0	5		
					NP		C10765 C11697	P10765					

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						MW	C10762 C10764 C10765		5	0	5		
						PDP	C10839		5	0	5		
						MP NP	C10762 C10764 C10765 C11697	P11697	10	1	5		
	Injection containing morphine sulfate pentahydrate 15 mg in 1 mL	Injection		MORPHINE SULFATE 15 mg/1 mL MEDSURGE	DZ	MP NP	C10762 C10764 C10765 C11697	P10762 P10764 P10765	5	0	5		
						MW	C10762 C10764 C10765		5	0	5		
						PDP	C10839		5	0	5		
						MP NP	C10762 C10764 C10765 C11697	P11697	10	1	5		
	Injection containing morphine sulfate pentahydrate 30 mg in 1 mL	Injection		MORPHINE SULFATE 30 mg/1 mL MEDSURGE	DZ	MP NP	C10762 C10764 C10765 C11697	P10762 P10764 P10765	5	0	5		
						PDP	C10839		5	0	5		
						MP NP	C10762 C10764 C10765 C11697	P11697	10	1	5		
	Oral solution containing morphine hydrochloride	Oral		Ordine 2	MF	MP NP	C10764 C10770 C10777		200	0	200		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	trihydrate 2 mg per mL, 1 mL												
						PDP	C10859		200	0	200		
	Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 1 mL	Oral		Ordine 5	MF	MP NP	C10764 C10770 C10777 C11697	P10764 P10770 P10777	200	0	200		
						PDP	C10859		200	0	200		
						MP NP	C10764 C10770 C10777 C11697	P11697	400	1	200		
	Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL	Oral		Ordine 10	MF	MP NP	C10764 C10770 C10777 C11697	P10764 P10770 P10777	200	0	200		
						PDP	C10859		200	0	200		
						MP NP	C10764 C10770 C10777 C11697	P11697	400	1	200		
	Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 20 mg per sachet	Oral		MS Contin Suspension 20 mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 30 mg per sachet	Oral		MS Contin Suspension 30 mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 60 mg per sachet	Oral		MS Contin Suspension 60 mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 100 mg per sachet	Oral		MS Contin Suspension 100 mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 200 mg per sachet	Oral		MS Contin Suspension 200 mg	MF	MP NP	C10756 C10814 C10836 C10858 C11753	P10756 P10814 P10836 P10858	28	0	28		
						MP NP	C10756 C10814 C10836 C10858 C11753	P11753	56	0	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing morphine sulfate pentahydrate 5 mg (controlled release)	Oral		MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet containing morphine sulfate pentahydrate 10 mg	Oral		Sevredol	MF	MP NP	C6168 C10775 C10837 C10891	P10775 P10837 P10891	20	0	20		
						MP NP	C6168 C10775 C10837 C10891	P6168	20	2	20		
	Tablet containing morphine sulfate pentahydrate 10 mg (controlled release)	Oral	a	MORPHINE MR APOTEX	TX	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	Morphine MR Mylan	AF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	MORPHINE MR APOTEX	TX	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	Morphine MR Mylan	AF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet containing morphine sulfate pentahydrate 15 mg (controlled release)	Oral		MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing morphine sulfate pentahydrate 20 mg	Oral		Sevredol	MF	MP NP	C6168 C10775 C10837 C10891	P10775 P10837 P10891	20	0	20		
						MP NP	C6168 C10775 C10837 C10891	P6168	20	2	20		
	Tablet containing morphine sulfate pentahydrate 30 mg (controlled release)	Oral	a	MORPHINE MR APOTEX	TX	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	Morphine MR Mylan	AF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	MORPHINE MR APOTEX	TX	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	Morphine MR Mylan	AF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet containing morphine sulfate pentahydrate 60 mg (controlled release)	Oral	a	MORPHINE MR APOTEX	TX	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	Morphine MR Mylan	AF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	MORPHINE MR APOTEX	TX	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing morphine sulfate pentahydrate 100 mg (controlled release)	Oral	a	Morphine MR Mylan	AF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	MORPHINE MR APOTEX	TX	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	Morphine MR Mylan	AF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	MORPHINE MR APOTEX	TX	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	Morphine MR Mylan	AF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	MS Contin	MF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet containing morphine sulfate pentahydrate 200 mg (controlled release)	Oral		MS Contin	MF	MP NP	C10756 C10814 C10836 C10858 C11753	P10756 P10814 P10836 P10858	28	0	28		
						MP NP	C10756 C10814 C10836 C10858 C11753	P11753	56	0	28		
Moxonidine	Tablet 200 micrograms	Oral	a	APO-Moxonidine	TX	MP NP	C4944 C14289	P4944	30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Moxonidine GH	GQ	MP NP	C4944 C14289	P4944	30	5	30		
			a	Moxonidine GX	SZ	MP NP	C4944 C14289	P4944	30	5	30		
			a	Moxonidine Viatris	AL	MP NP	C4944 C14289	P4944	30	5	30		
			a	Moxotens	RF	MP NP	C4944 C14289	P4944	30	5	30		
			a	Physiotens	GO	MP NP	C4944 C14289	P4944	30	5	30		
			a	APO-Moxonidine	TX	MP NP	C4944 C14289	P14289	60	5	30		
			a	Moxonidine GH	GQ	MP NP	C4944 C14289	P14289	60	5	30		
			a	Moxonidine GX	SZ	MP NP	C4944 C14289	P14289	60	5	30		
			a	Moxonidine Viatris	AL	MP NP	C4944 C14289	P14289	60	5	30		
			a	Moxotens	RF	MP NP	C4944 C14289	P14289	60	5	30		
			a	Physiotens	GO	MP NP	C4944 C14289	P14289	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 400 micrograms	Oral	a	APO-Moxonidine	TX	MP NP	C4944 C14289	P4944	30	5	30		
			a	Moxonidine GH	GQ	MP NP	C4944 C14289	P4944	30	5	30		
			a	Moxonidine GX	SZ	MP NP	C4944 C14289	P4944	30	5	30		
			a	Moxonidine MYL	AF	MP NP	C4944 C14289	P4944	30	5	30		
			a	Moxonidine Viatris	AL	MP NP	C4944 C14289	P4944	30	5	30		
			a	Moxotens	RF	MP NP	C4944 C14289	P4944	30	5	30		
			a	Physiotens	GO	MP NP	C4944 C14289	P4944	30	5	30		
			a	APO-Moxonidine	TX	MP NP	C4944 C14289	P14289	60	5	30		
			a	Moxonidine GH	GQ	MP NP	C4944 C14289	P14289	60	5	30		
			a	Moxonidine GX	SZ	MP NP	C4944 C14289	P14289	60	5	30		
			a	Moxonidine MYL	AF	MP NP	C4944 C14289	P14289	60	5	30		
			a	Moxonidine Viatris	AL	MP NP	C4944 C14289	P14289	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Moxotens	RF	MP NP	C4944 C14289	P14289	60	5	30		
			a	Physiotens	GO	MP NP	C4944 C14289	P14289	60	5	30		
Mupirocin	Nasal ointment 20 mg (as calcium) per g, 3 g	Nasal		Bactroban	GK	MP NP	C6647		1	0	1		
	Nasal ointment 20 mg (as calcium) per g, 5 g	Nasal		Mupirocin Nasal (Medsurge)	DZ	MP NP	C6647		1	0	1		
Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish 1331 strain	Single dose pack containing powder for irrigation 30 mg, 4 vials	Intravesical		VesiCulture	LM	MP	C5540		3	1	1		
						MP	C5597		3	1	1		C(100)
Mycobacterium bovis (Bacillus Calmette and Guerin), Tice strain	Vial containing powder for intravesical administration approximately 5 x 10 ⁸ CFU	Intravesical		OncoTICE	MK	MP	C5540		3	1	3		
						MP	C5597		3	1	3		C(100)
Mycophenolic acid	Capsule containing mycophenolate mofetil 250 mg	Oral	a	Ceptolate	AF	MP			300	5	50		
			a	APO-Mycophenolate	TX	MP			300	5	100		
			a	CellCept	RO	MP			300	5	100		
			a	Mycophenolate Sandoz	SZ	MP			300	5	100		

Ready-prepared pharmaceutical benefits **Schedule 1**
Ready-prepared pharmaceutical benefits for prescription and supply **Part 1**

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Pharmacor Mycophenolate 250	CR	MP			300	5	100		
			a	Ceptolate	AF	MP		P5600 P5653 P9689 P9690	600 CN5600 CN5653 CN9689 CN9690	5 CN5600 CN5653 CN9689 CN9690	50		C(100)
			a	APO-Mycophenolate	TX	MP		P5600 P5653 P9689 P9690	600 CN5600 CN5653 CN9689 CN9690	5 CN5600 CN5653 CN9689 CN9690	100		C(100)
			a	CellCept	RO	MP		P5600 P5653 P9689 P9690	600 CN5600 CN5653 CN9689 CN9690	5 CN5600 CN5653 CN9689 CN9690	100		C(100)
			a	Mycophenolate Sandoz	SZ	MP		P5600 P5653 P9689 P9690	600 CN5600 CN5653 CN9689 CN9690	5 CN5600 CN5653 CN9689 CN9690	100		C(100)
			a	Pharmacor Mycophenolate 250	CR	MP		P5600 P5653 P9689 P9690	600 CN5600 CN5653 CN9689 CN9690	5 CN5600 CN5653 CN9689 CN9690	100		C(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL	Oral	a	CellCept	RO	MP			1	5	1		
			a	Pharmacor Mycophenolate	CR	MP			1	5	1		
			a	CellCept	RO	MP		P5554 P5795 P9691 P9693	2 CN5554 CN5795 CN9691 CN9693	5 CN5554 CN5795 CN9691 CN9693	1		C(100)
			a	Pharmacor Mycophenolate	CR	MP		P5554 P5795 P9691 P9693	2 CN5554 CN5795 CN9691 CN9693	5 CN5554 CN5795 CN9691 CN9693	1		C(100)
	Tablet (enteric coated) containing mycophenolate sodium equivalent to 180 mg mycophenolic acid	Oral		Myfortic	NV	MP			120	5	120		
						MP		P4084 P4095 P9692 P9809	240 CN4084 CN4095 CN9692 CN9809	5 CN4084 CN4095 CN9692 CN9809	120		C(100)
	Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid	Oral		Myfortic	NV	MP			120	5	120		
						MP		P4084 P4095 P9692 P9809	240 CN4084 CN4095 CN9692	5 CN4084 CN4095 CN9692	120		C(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing mycophenolate mofetil 500 mg	Oral	a	CellCept	RO	MP			CN9809 150	CN9809 5	50		
			a	Ceptolate	AF	MP			150	5	50		
			a	MycoCept	RF	MP			150	5	50		
			a	Mycophenolate APOTEX	GX	MP			150	5	50		
			a	Mycophenolate GH	GQ	MP			150	5	50		
			a	Mycophenolate Sandoz	SZ	MP			150	5	50		
			a	Noumed Mycophenolate	VO	MP			150	5	50		
			a	Pharmacor Mycophenolate 500	CR	MP			150	5	50		
			a	CellCept	RO	MP		P5554 P5795 P9691 P9693	300 CN5554 CN5795 CN9691 CN9693	5 CN5554 CN5795 CN9691 CN9693	50		C(100)
			a	Ceptolate	AF	MP		P5554 P5795 P9691 P9693	300 CN5554 CN5795 CN9691 CN9693	5 CN5554 CN5795 CN9691 CN9693	50		C(100)
			a	MycoCept	RF	MP		P5554 P5795 P9691 P9693	300 CN5554	5 CN5554	50		C(100)

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Mycophenolate APOTEX	GX	MP		P5554 P5795 P9691 P9693	CN5795 CN9691 CN9693 300 CN5554 CN5795 CN9691 CN9693	CN5795 CN9691 CN9693 5 CN5554 CN5795 CN9691 CN9693	50		C(100)
			a	Mycophenolate GH	GQ	MP		P5554 P5795 P9691 P9693	300 CN5554 CN5795 CN9691 CN9693	5 CN5554 CN5795 CN9691 CN9693	50		C(100)
			a	Mycophenolate Sandoz	SZ	MP		P5554 P5795 P9691 P9693	300 CN5554 CN5795 CN9691 CN9693	5 CN5554 CN5795 CN9691 CN9693	50		C(100)
			a	Nourmed Mycophenolate	VO	MP		P5554 P5795 P9691 P9693	300 CN5554 CN5795 CN9691 CN9693	5 CN5554 CN5795 CN9691 CN9693	50		C(100)
			a	Pharmacor Mycophenolate 500	CR	MP		P5554 P5795 P9691 P9693	300 CN5554 CN5795 CN9691 CN9693	5 CN5554 CN5795 CN9691 CN9693	50		C(100)

Ready-prepared pharmaceutical benefits **Schedule 1**
Ready-prepared pharmaceutical benefits for prescription and supply **Part 1**

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Nafarelin	Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses	Nasal		Synarel	PF	MP	C6517 C6552		1	5	1		
						MP	C5046		2	0	1		C(100)
Naloxone	Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule	Injection	a	Naloxone Hydrochloride (DBL)	PF	MP NP PDP			5	0	5		
			a	Naloxone Juno	JU	MP NP PDP			5	0	5		
			a	NALOXONE SXP	XN	MP NP PDP			5	0	5		
				NARCAN	FF	See Note 4	See Note 4	See Note 4	See Note 4	See Note 4	10	10	C(MP) C(NP)
	Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe	Injection		Prenoxad	FF	PDP MP NP			1	0	1		
	Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2	Nasal		Nyxoid	MF	PDP MP NP			1	0	1		
	Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL	Nasal		Nyxoid (UK)	QY	PDP MP			1	0	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Naltrexone	single dose unit, 2 (s19A)					NP							
	Tablet containing naltrexone hydrochloride 50 mg	Oral	a	ARX-NALTREXONE	XT	MP NP	C13967		30	1	30		
			a	Naltrexone GH	GQ	MP NP	C13967		30	1	30		
Naproxen	Oral suspension 125 mg per 5 mL, 474 mL	Oral		Phebra Naproxen Suspension	FF	MP NP	C4124 C4159 C6150		1	3	1		
	Tablet 250 mg	Oral		Naprosyn	IX	PDP	C6256 C6282		100	0	50		
						MP NP	C6149 C6214 C6283		100	3	50		
	Tablet containing naproxen sodium 550 mg	Oral	a	Anaprox 550	IX	PDP	C6368 C6387		50	0	50		
			a	Crysanal	IY	PDP	C6368 C6387		50	0	50		
			a	Anaprox 550	IX	MP NP	C6196 C6463 C6471		50	3	50		
			a	Crysanal	IY	MP NP	C6196 C6463 C6471		50	3	50		
	Tablet 750 mg (sustained release)	Oral	a	Naprosyn SR750	IX	PDP	C6256 C6282		28	0	28		
			a	Proxen SR 750	IY	PDP	C6256 C6282		28	0	28		
			a	Naprosyn SR750	IX	MP NP	C6149 C6214 C6283		28	3	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 1 g (sustained release)	Oral	a	Proxen SR 750	IY	MP NP	C6149 C6214 C6283		28	3	28		
			a	Naprosyn SR1000	IX	PDP	C6256 C6282		28	0	28		
			a	Proxen SR 1000	IY	PDP	C6256 C6282		28	0	28		
			a	Naprosyn SR1000	IX	MP NP	C6149 C6214 C6283		28	3	28		
			a	Proxen SR 1000	IY	MP NP	C6149 C6214 C6283		28	3	28		
Naratriptan	Tablet 2.5 mg (as hydrochloride)	Oral		Naramig	AS	MP NP	C4562 C5849 C5850 C5859 C5860 C5887		4	5	2		
Natalizumab	Solution concentrate for I.V. infusion 300 mg in 15 mL	Injection		Tysabri	BD	MP	C13625 C13718		1	5	1		D(100)
Nebivolol	Tablet 1.25 mg (as hydrochloride)	Oral	a	APO-Nebivolol	TX	MP NP	C5324 C14251	P5324	56	5	28		
			a	Nebilet	FK	MP NP	C5324 C14251	P5324	56	5	28		
			a	Nebivolol Lupin	GQ	MP NP	C5324 C14251	P5324	56	5	28		
			a	Nebivolol Sandoz	SZ	MP NP	C5324 C14251	P5324	56	5	28		
			a	Nepiten	AF	MP NP	C5324 C14251	P5324	56	5	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	APO-Nebivolol	TX	MP NP	C5324 C14251	P14251	112	5	28		
			a	Nebilet	FK	MP NP	C5324 C14251	P14251	112	5	28		
			a	Nebivolol Lupin	GQ	MP NP	C5324 C14251	P14251	112	5	28		
			a	Nebivolol Sandoz	SZ	MP NP	C5324 C14251	P14251	112	5	28		
			a	Nepiten	AF	MP NP	C5324 C14251	P14251	112	5	28		
	Tablet 5 mg (as hydrochloride)	Oral	a	APO-Nebivolol	TX	MP NP	C5324 C14251	P5324	28	5	28		
			a	Nebilet	FK	MP NP	C5324 C14251	P5324	28	5	28		
			a	Nebivolol Lupin	GQ	MP NP	C5324 C14251	P5324	28	5	28		
			a	Nebivolol Sandoz	SZ	MP NP	C5324 C14251	P5324	28	5	28		
			a	Nepiten	AF	MP NP	C5324 C14251	P5324	28	5	28		
			a	APO-Nebivolol	TX	MP NP	C5324 C14251	P14251	56	5	28		
			a	Nebilet	FK	MP NP	C5324 C14251	P14251	56	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Nebivolol Lupin	GQ	MP NP	C5324 C14251	P14251	56	5	28		
			a	Nebivolol Sandoz	SZ	MP NP	C5324 C14251	P14251	56	5	28		
			a	Nepiten	AF	MP NP	C5324 C14251	P14251	56	5	28		
	Tablet 10 mg (as hydrochloride)	Oral	a	APO-Nebivolol	TX	MP NP	C5324 C14251	P5324	28	5	28		
			a	Nebilet	FK	MP NP	C5324 C14251	P5324	28	5	28		
			a	Nebivolol Lupin	GQ	MP NP	C5324 C14251	P5324	28	5	28		
			a	Nebivolol Sandoz	SZ	MP NP	C5324 C14251	P5324	28	5	28		
			a	Nepiten	AF	MP NP	C5324 C14251	P5324	28	5	28		
			a	APO-Nebivolol	TX	MP NP	C5324 C14251	P14251	56	5	28		
			a	Nebilet	FK	MP NP	C5324 C14251	P14251	56	5	28		
			a	Nebivolol Lupin	GQ	MP NP	C5324 C14251	P14251	56	5	28		
			a	Nebivolol Sandoz	SZ	MP NP	C5324 C14251	P14251	56	5	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Nepiten	AF	MP NP	C5324 C14251	P14251	56	5	28		
Netupitant with Palonosetron	Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride)	Oral		Akynzeo	JZ	MP NP	C14443		1	5	1		
Nevirapine	Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL	Oral		Viramune	BY	MP NP	C4454 C4512		10	5	1		D(100)
	Tablet 200 mg	Oral		Nevirapine Alphapharm	AF	MP NP	C4454 C4512		120	5	60		D(100)
	Tablet 400 mg (extended release)	Oral		Viramune XR	BY	MP NP	C4454 C4526		60	5	30		D(100)
Nicorandil	Tablets 10 mg, 60	Oral	a	APO-Nicorandil	TX	MP NP			1	5	1		
			a	Ikorel	SW	MP NP			1	5	1		
			a	Ikotab	AF	MP NP			1	5	1		
			a	APO-Nicorandil	TX	MP NP		P14238	2	5	1		
			a	Ikorel	SW	MP NP		P14238	2	5	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Nicotine	Tablets 20 mg, 60	Oral	a	Ikotab	AF	MP NP		P14238	2	5	1		
			a	APO-Nicorandil	TX	MP NP			1	5	1		
			a	Ikorel	SW	MP NP			1	5	1		
			a	Ikotab	AF	MP NP			1	5	1		
			a	APO-Nicorandil	TX	MP NP		P14238	2	5	1		
			a	Ikorel	SW	MP NP		P14238	2	5	1		
			a	Ikotab	AF	MP NP		P14238	2	5	1		
	Transdermal patch 17.5 mg	Transdermal		Nicotinell Step 3	ON	MP NP	C14040		28	2	28		
	Transdermal patch 35 mg	Transdermal		Nicotinell Step 2	ON	MP NP	C14040		28	2	28		
	Transdermal patch 39.4 mg	Transdermal		nicorette 16hr Invisipatch	JT	MP NP	C14040		28	2	28		
	Transdermal patch 52.5 mg	Transdermal		Nicotinell Step 1	ON	MP NP	C5140 C14040		28	2	28		
	Transdermal patch 114 mg	Transdermal		Nicabate P	GJ	MP NP	C14040		28	2	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Nifedipine	Tablet 30 mg (controlled release)	Oral	a	Addos XR 30	RW	MP NP			30	5	30		
			a	APO-Nifedipine XR	TX	MP NP			30	5	30		
			a	Addos XR 30	RW	MP NP		P14238	60	5	30		
			a	APO-Nifedipine XR	TX	MP NP		P14238	60	5	30		
	Tablet 60 mg (controlled release)	Oral	a	Addos XR 60	RW	MP NP			30	5	30		
			a	APO-Nifedipine XR	TX	MP NP			30	5	30		
			a	Addos XR 60	RW	MP NP		P14238	60	5	30		
			a	APO-Nifedipine XR	TX	MP NP		P14238	60	5	30		
Nilotinib	Capsule 150 mg (as hydrochloride monohydrate)	Oral		Tasigna	NV	MP	C12557 C12572		120	5	120		
	Capsule 200 mg (as hydrochloride monohydrate)	Oral		Tasigna	NV	MP	C12522 C12529 C12549 C12563 C12569		120	5	120		
Nintedanib	Capsule 100 mg	Oral		Ofev	BY	MP	C13378 C13380 C13381 C13401		60	5	60		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Niraparib	Capsule 150 mg	Oral		Ofev	BY	MP	C13412 C13378 C13380 C13381 C13401 C13412		60	5	60		
	Capsule 100 mg (as tosilate monohydrate)	Oral		Zejula	GK	MP	C13202 C13204 C13264 C13273	P13202	56	2	56		
						MP	C13202 C13204 C13264 C13273	P13264	56	5	56		
						MP	C13202 C13204 C13264 C13273	P13273	84	2	84		
Nirmatrelvir and ritonavir	Pack containing 4 tablets nirmatrelvir 150 mg and 2 tablets ritonavir 100 mg, 5	Oral		Paxlovid	HD	MP NP	C13202 C13204 C13264 C13273 C13748 C13759 C13821 C14187	P13204	84	5	84		
						MP NP			1	0	1		
Nitrazepam	Tablet 5 mg	Oral	a	Alodorm	AF	MP NP PDP			25		25		
			a	Mogadon	IL	MP NP PDP			25		25		
			a	Alodorm	AF	MP NP		P6175	50 CN6175	3 CN6175	25		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Nitrofurantoin	Capsule 50 mg	Oral	a	Mogadon	IL	MP NP		P6175	50 CN6175	3 CN6175	25		
			a	Alodorm	AF	MP NP		P5661 P5771 P5941 P5950	50 CN5661 CN5771 CN5941 CN5950	5 CN5661 CN5771 CN5941 CN5950	25		
			a	Mogadon	IL	MP NP		P5661 P5771 P5941 P5950	50 CN5661 CN5771 CN5941 CN5950	5 CN5661 CN5771 CN5941 CN5950	25		
			a	APO-Nitrofurantoin	TX	MP NP MW			30	1	30		
			a	ARX-Nitrofurantoin	XT	MP NP MW			30	1	30		
			a	Nitrofurantoin BNM	BZ	MP NP MW			30	1	30		
	Capsule 100 mg	Oral	a	APO-Nitrofurantoin	TX	MP NP			30	1	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Nivolumab	Injection concentrate for I.V. infusion 40 mg in 4 mL	Injection	a	ARX-Nitrofurantoin	XT	MP NP MW			30	1	30		
			a	Nitrofurantoin BNM	BZ	MP NP MW			30	1	30		
				Opdivo	BQ	MP	C9216 C9252 C9298 C9299 C9312 C9321 C10119 C10120 C10155 C11468 C11477 C11985 C13433 C13445 C13839 C13852 C13853 C13863 C13888 C13900 C14001		See Note 3	See Note 3	1		D(100)
				Opdivo	BQ	MP	C9216 C9252 C9298 C9299 C9312 C9321 C10119 C10120 C10155 C11468 C11477 C11985 C13433 C13445 C13839 C13852 C13853 C13863 C13888 C13900 C14001		See Note 3	See Note 3	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Nizatidine	Capsule 150 mg	Oral	a	Nizac	RF	MP NP			60	5	60		
			a	Tacidine	AF	MP NP			60	5	60		
			a	Tazac	RW	MP NP			60	5	60		
	Capsule 300 mg	Oral	a	Nizac	RF	MP NP			30	5	30		
			a	Tacidine	AF	MP NP			30	5	30		
			a	Tazac	RW	MP NP			30	5	30		
Norethisterone	Tablet 5 mg	Oral		Primolut N	BN	MP NP			30	2	30		
	Tablets 350 micrograms, 28	Oral		Noriday 28 Day	PF	MP NP			4	2	4		
Norethisterone with ethinylestradiol	Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets	Oral		Norimin-1 28 Day	FZ	MP NP			4	2	4		
	Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets	Oral		Norimin 28 Day	FZ	MP NP			4	2	4		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Norfloxacin	Tablet 400 mg	Oral	a	APO-Norfloxacin	TX	MP NP	C5744 C5806		14	1	14		
			a	Nufloxib	AF	MP NP	C5744 C5806		14	1	14		
			a	Roxin	RW	MP NP	C5744 C5806		14	1	14		
Nortriptyline	Tablet 10 mg (as hydrochloride)	Oral	a	Allegron	RW	MP NP	C6235 C6300		50	2	50		
			a	NortriTABS 10 mg	GH	MP NP	C6235 C6300		50	2	50		
	Tablet 25 mg (as hydrochloride)	Oral	a	Allegron	RW	MP NP	C6235 C6300		50	2	50		
			a	NortriTABS 25 mg	GH	MP NP	C6235 C6300		50	2	50		
Nusinersen	Solution for injection 12 mg in 5 mL	Injection		Spinraza	BD	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
Nystatin	Capsule 500,000 units	Oral		Nilstat	AS	MP NP PDP			50	0	50		
	Tablet 500,000 units	Oral		Nilstat	AS	MP NP PDP			50	0	50		
Obeticholic acid	Tablet 5 mg	Oral		Ocaliva	EU	MP	C12084 C12138 C12140		30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Obinutuzumab	Tablet 10 mg	Oral		Ocaliva	EU	MP	C12138 C12140		30	5	30		
					NP								
					MP								
	Solution for I.V. infusion 1000 mg in 40 mL	Injection		Gazyva	RO	MP	C11015 C11755 C11785 C11787 C11815 C14326		See Note 3	See Note 3	1		D(100)
Ocrelizumab	Solution concentrate for I.V. infusion 300 mg in 10 mL	Injection		Ocrevus	RO	MP	C7386 C7699 C9523 C9635		2	0	1		D(100)
Octreotide	Injection 50 micrograms (as acetate) in 1 mL	Injection	a	Octreotide GH	HQ	MP	C6369 C6390 C8165 C9232 C9233 C9289		90	11	5		D(100)
			a	Octreotide (SUN)	RA	MP	C6369 C6390 C8165 C9232 C9233 C9289		90	11	5		D(100)
			a	Sandostatin 0.05	NV	MP	C6369 C6390 C8165 C9232 C9233 C9289		90	11	5		D(100)
	Injection 100 micrograms (as acetate) in 1 mL	Injection	a	Octreotide GH	HQ	MP	C6369 C6390 C8165 C9232 C9233 C9289		90	11	5		D(100)
			a	Octreotide (SUN)	RA	MP	C6369 C6390 C8165 C9232 C9233 C9289		90	11	5		D(100)
			a	Octreotide MaxRx	GQ	MP	C6369 C6390		90	11	5		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Sandostatin 0.1	NV	MP	C8165 C9232 C9233 C9289		90	11	5		D(100)
	Injection 500 micrograms (as acetate) in 1 mL	Injection	a	Octreotide GH	HQ	MP	C6369 C6390 C8165 C9232 C9233 C9289		90	11	5		D(100)
			a	Octreotide (SUN)	RA	MP	C6369 C6390 C8165 C9232 C9233 C9289		90	11	5		D(100)
			a	Octreotide MaxRx	GQ	MP	C6369 C6390 C8165 C9232 C9233 C9289		90	11	5		D(100)
			a	Sandostatin 0.5	NV	MP	C6369 C6390 C8165 C9232 C9233 C9289		90	11	5		D(100)
	Injection (modified release) 10 mg (as acetate), vial and diluent syringe	Injection	a	Octreotide Depot	TB	MP	C5901 C5906 C8161 C8197 C8198 C8208 C9262 C9288 C9313		2	5	1		D(100)
			a	Sandostatin LAR	NV	MP	C5901 C5906 C8161 C8197 C8198 C8208 C9262 C9288 C9313		2	5	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Injection (modified release) 20 mg (as acetate), vial and diluent syringe	Injection	a	Octreotide Depot	TB	MP	C5901 C5906 C8161 C8197 C8198 C8208 C9262 C9288 C9313		2	5	1		D(100)
			a	Sandostatin LAR	NV	MP	C5901 C5906 C8161 C8197 C8198 C8208 C9262 C9288 C9313		2	5	1		D(100)
	Injection (modified release) 30 mg (as acetate), vial and diluent syringe	Injection	a	Octreotide Depot	TB	MP	C5901 C5906 C8161 C8197 C8198 C8208 C9262 C9288 C9313 C10061 C10075 C10077		2	5	1		D(100)
			a	Sandostatin LAR	NV	MP	C5901 C5906 C8161 C8197 C8198 C8208 C9262 C9288 C9313 C10061 C10075 C10077		2	5	1		D(100)
Ofatumumab	Solution for injection 20 mg in 0.4 mL pre-filled pen	Injection		Kesimpta	NV	MP	C10162 C10172	P10172	1	5	1		
						MP	C10162 C10172	P10162	3	0	1		
Ofloxacin	Eye drops 3 mg per	Application to		Ocuflox	VE	AO	C4181		2	0	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Olanzapine	mL, 5 mL	the eye				MP	C4195		2	0	1		
	Powder for injection 210 mg (as pamoate monohydrate) with diluent	Injection		Zyprexa Relprevv	PB	MP NP	C4304		2	5	1		
	Powder for injection 300 mg (as pamoate monohydrate) with diluent	Injection		Zyprexa Relprevv	PB	MP NP	C4304		2	5	1		
	Powder for injection 405 mg (as pamoate monohydrate) with diluent	Injection		Zyprexa Relprevv	PB	MP NP	C4304		1	5	1		
	Tablet 2.5 mg	Oral	a	NOUMED OLANZAPINE	VO	MP NP	C5856 C5869		28	5	28		
			a	Olanzapine APOTEX	GX	MP NP	C5856 C5869		28	5	28		
			a	Olanzapine RBX	RA	MP NP	C5856 C5869		28	5	28		
			a	Olanzapine Sandoz	SZ	MP NP	C5856 C5869		28	5	28		
			a	Ozin 2.5	ZS	MP NP	C5856 C5869		28	5	28		
			a	PRYZEX	RW	MP	C5856 C5869		28	5	28		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
			a	Zypine	AF	MP NP	C5856 C5869		28	5	28		
			a	Zyprexa	PB	MP NP	C5856 C5869		28	5	28		
	Tablet 5 mg	Oral	a	NOUMED OLANZAPINE	VO	MP NP	C5856 C5869		28	5	28		
			a	Olanzapine APOTEX	GX	MP NP	C5856 C5869		28	5	28		
			a	Olanzapine RBX	RA	MP NP	C5856 C5869		28	5	28		
			a	Olanzapine Sandoz	SZ	MP NP	C5856 C5869		28	5	28		
			a	Ozin 5	ZS	MP NP	C5856 C5869		28	5	28		
			a	PRYZEX	RW	MP NP	C5856 C5869		28	5	28		
			a	Zypine	AF	MP NP	C5856 C5869		28	5	28		
			a	Zyprexa	PB	MP NP	C5856 C5869		28	5	28		
	Tablet 5 mg (orally disintegrating)	Oral		APO-Olanzapine ODT	TX	MP NP	C5856 C5869		28	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 7.5 mg	Oral	a	Olanzapine ODT generichealth 5	GQ	MP NP	C5856 C5869		28	5	28		
				Olanzapine Sandoz ODT 5	SZ	MP NP	C5856 C5869		28	5	28		
				PRYZEX ODT	RW	MP NP	C5856 C5869		28	5	28		
				NOUMED OLANZAPINE	VO	MP NP	C5856 C5869		28	5	28		
				Olanzapine APOTEX	GX	MP NP	C5856 C5869		28	5	28		
				Olanzapine RBX	RA	MP NP	C5856 C5869		28	5	28		
				Olanzapine Sandoz	SZ	MP NP	C5856 C5869		28	5	28		
				Ozin 7.5	ZS	MP NP	C5856 C5869		28	5	28		
				PRYZEX	RW	MP NP	C5856 C5869		28	5	28		
				Zypine	AF	MP NP	C5856 C5869		28	5	28		
				Zyprexa	PB	MP NP	C5856 C5869		28	5	28		
				NOUMED OLANZAPINE	VO	MP	C5856 C5869		28	5	28		
	Tablet 10 mg	Oral	a	NOUMED OLANZAPINE	VO	MP	C5856 C5869		28	5	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Olanzapine APOTEX	GX	MP NP	C5856 C5869		28	5	28		
			a	Olanzapine RBX	RA	MP NP	C5856 C5869		28	5	28		
			a	Olanzapine Sandoz	SZ	MP NP	C5856 C5869		28	5	28		
			a	Ozin 10	ZS	MP NP	C5856 C5869		28	5	28		
			a	PRYZEX	RW	MP NP	C5856 C5869		28	5	28		
			a	Zypine	AF	MP NP	C5856 C5869		28	5	28		
			a	Zyprexa	PB	MP NP	C5856 C5869		28	5	28		
	Tablet 10 mg (orally disintegrating)	Oral		APO-Olanzapine ODT	TX	MP NP	C5856 C5869		28	5	28		
				Olanzapine ODT generichealth 10	GQ	MP NP	C5856 C5869		28	5	28		
				Olanzapine Sandoz ODT 10	SZ	MP NP	C5856 C5869		28	5	28		
				PRYZEX ODT	RW	MP NP	C5856 C5869		28	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 15 mg (orally disintegrating)	Oral	APO-Olanzapine ODT	TX	MP NP	C5856 C5869		28	5	28		
			Olanzapine Sandoz ODT 15	SZ	MP NP	C5856 C5869		28	5	28		
			PRYZEX ODT	RW	MP NP	C5856 C5869		28	5	28		
	Tablet 20 mg (orally disintegrating)	Oral	APO-Olanzapine ODT	TX	MP NP	C5856 C5869		28	5	28		
			Olanzapine Sandoz ODT 20	SZ	MP NP	C5856 C5869		28	5	28		
			PRYZEX ODT	RW	MP NP	C5856 C5869		28	5	28		
	Wafer 5 mg	Oral	Zypine ODT	AF	MP NP	C5856 C5869		28	5	28		
			Zyprexa Zydys	PB	MP NP	C5856 C5869		28	5	28		
	Wafer 10 mg	Oral	Zypine ODT	AF	MP NP	C5856 C5869		28	5	28		
			Zyprexa Zydys	PB	MP NP	C5856 C5869		28	5	28		
	Wafer 15 mg	Oral	Zypine ODT	AF	MP NP	C5856 C5869		28	5	28		
			Zyprexa Zydys	PB	MP NP	C5856 C5869		28	5	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Olaparib	Wafer 20 mg	Oral		Zypine ODT	AF	MP NP	C5856 C5869		28	5	28		
				Zyprexa Zydys	PB	MP NP	C5856 C5869		28	5	28		
	Tablet 100 mg	Oral		Lynparza	AP	MP	C10913 C10937 C10958 C12590 C12598 C13226	P10958 P12590 P13226	112	2	56		
						MP	C10913 C10937 C10958 C12590 C12598 C13226	P10913 P10937 P12598	112	5	56		
	Tablet 150 mg	Oral		Lynparza	AP	MP	C10913 C10937 C10958 C12590 C12598 C13226	P10958 P12590 P13226	112	2	56		
						MP	C10913 C10937 C10958 C12590 C12598 C13226	P10913 P10937 P12598	112	5	56		
Olmesartan	Tablet containing olmesartan medoxomil 20 mg	Oral	a	APO-Olmesartan	TX	MP NP			30	5	30		
			a	APX-Olmesartan	TY	MP NP			30	5	30		
			a	OLMERTAN	RW	MP NP			30	5	30		
			a	Olmesartan - MYL	AF	MP NP			30	5	30		

Ready-prepared pharmaceutical benefits **Schedule 1**
Ready-prepared pharmaceutical benefits for prescription and supply **Part 1**

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Olmesartan Sandoz	SZ	MP NP			30	5	30		
			a	Olmetec	AL	MP NP			30	5	30		
			a	Olsetan	MQ	MP NP			30	5	30		
			a	Pharmacor Olmesartan 20	CR	MP NP			30	5	30		
			a	APO-Olmesartan	TX	MP NP		P14238	60	5	30		
			a	APX-Olmesartan	TY	MP NP		P14238	60	5	30		
			a	OLMERTAN	RW	MP NP		P14238	60	5	30		
			a	Olmesartan - MYL	AF	MP NP		P14238	60	5	30		
			a	Olmesartan Sandoz	SZ	MP NP		P14238	60	5	30		
			a	Olmetec	AL	MP NP		P14238	60	5	30		
			a	Olsetan	MQ	MP NP		P14238	60	5	30		
			a	Pharmacor Olmesartan 20	CR	MP NP		P14238	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing olmesartan medoxomil 40 mg	Oral	a	APO-Olmesartan	TX	MP NP			30	5	30		
			a	APX-Olmesartan	TY	MP NP			30	5	30		
			a	OLMERTAN	RW	MP NP			30	5	30		
			a	Olmesartan - MYL	AF	MP NP			30	5	30		
			a	Olmesartan Sandoz	SZ	MP NP			30	5	30		
			a	Olmetec	AL	MP NP			30	5	30		
			a	Olsetan	MQ	MP NP			30	5	30		
			a	Pharmacor Olmesartan 40	CR	MP NP			30	5	30		
			a	APO-Olmesartan	TX	MP NP		P14238	60	5	30		
			a	APX-Olmesartan	TY	MP NP		P14238	60	5	30		
			a	OLMERTAN	RW	MP NP		P14238	60	5	30		
			a	Olmesartan - MYL	AF	MP NP		P14238	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)	Oral	a	Olmesartan Sandoz	SZ	MP NP		P14238	60	5	30		
			a	Olmetec	AL	MP NP		P14238	60	5	30		
			a	Olsetan	MQ	MP NP		P14238	60	5	30		
			a	Pharmacor Olmesartan 40	CR	MP NP		P14238	60	5	30		
			a	OLMEKAR	RW	MP NP	C4373 C14257	P4373	30	5	30		
			a	Olmesartan/Amlodipine - MY L 20/5	AF	MP NP	C4373 C14257	P4373	30	5	30		
			a	Olmesartan/Amlodipine 20/5 APOTEX	TX	MP NP	C4373 C14257	P4373	30	5	30		
			a	Pharmacor Olmesartan Amlodipine 20/5	CR	MP NP	C4373 C14257	P4373	30	5	30		
			a	Sevikar 20/5	AL	MP NP	C4373 C14257	P4373	30	5	30		
			a	OLMEKAR	RW	MP NP	C4373 C14257	P14257	60	5	30		
			a	Olmesartan/Amlodipine - MY L 20/5	AF	MP NP	C4373 C14257	P14257	60	5	30		
			a	Olmesartan/Amlodipine 20/5 APOTEX	TX	MP NP	C4373 C14257	P14257	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)	Oral	a	Pharmacor Olmesartan Amlodipine 20/5	CR	MP NP	C4373 C14257	P14257	60	5	30		
			a	Sevikar 20/5	AL	MP NP	C4373 C14257	P14257	60	5	30		
			a	OLMEKAR	RW	MP NP	C4373		30	5	30		
			a	Olmesartan/Amlodipine - MY L 40/5	AF	MP NP	C4373		30	5	30		
			a	Olmesartan/Amlodipine 40/5 APOTEX	TX	MP NP	C4373		30	5	30		
			a	Pharmacor Olmesartan Amlodipine 40/5	CR	MP NP	C4373		30	5	30		
			a	Sevikar 40/5	AL	MP NP	C4373		30	5	30		
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)	Oral	a	OLMEKAR	RW	MP NP	C4373		30	5	30		
			a	Olmesartan/Amlodipine - MY L 40/10	AF	MP NP	C4373		30	5	30		
			a	Olmesartan/Amlodipine 40/10 APOTEX	TX	MP NP	C4373		30	5	30		
			a	Pharmacor Olmesartan Amlodipine 40/10	CR	MP NP	C4373		30	5	30		
			a	Sevikar 40/10	AL	MP NP	C4373		30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Olmesartan with amlodipine and hydrochlorothiazide	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg	Oral	a	APO-Olmesartan/Amlodipine/ HCTZ 20/5/12.5	TX	MP NP	C4311 C14272	P4311	30	5	30		
			a	Olamlo HCT 20/5/12.5	AL	MP NP	C4311 C14272	P4311	30	5	30		
			a	Olmekar HCT 20/5/12.5	RF	MP NP	C4311 C14272	P4311	30	5	30		
			a	Sevikar HCT 20/5/12.5	AF	MP NP	C4311 C14272	P4311	30	5	30		
			a	APO-Olmesartan/Amlodipine/ HCTZ 20/5/12.5	TX	MP NP	C4311 C14272	P14272	60	5	30		
			a	Olamlo HCT 20/5/12.5	AL	MP NP	C4311 C14272	P14272	60	5	30		
			a	Olmekar HCT 20/5/12.5	RF	MP NP	C4311 C14272	P14272	60	5	30		
			a	Sevikar HCT 20/5/12.5	AF	MP NP	C4311 C14272	P14272	60	5	30		
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg	Oral	a	APO-Olmesartan/Amlodipine/ HCTZ 40/5/12.5 tablet	TX	MP NP	C4311 C14272	P4311	30	5	30		
			a	Olamlo HCT 40/5/12.5	AL	MP NP	C4311 C14272	P4311	30	5	30		
			a	Olmekar HCT 40/5/12.5	RF	MP NP	C4311 C14272	P4311	30	5	30		
			a	Sevikar HCT 40/5/12.5	AF	MP NP	C4311 C14272	P4311	30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg	Oral	a	APO-Olmesartan/Amlodipine/ HCTZ 40/5/12.5 tablet	TX	MP NP	C4311 C14272	P14272	60	5	30		
			a	Olamlo HCT 40/5/12.5	AL	MP NP	C4311 C14272	P14272	60	5	30		
			a	Olmekar HCT 40/5/12.5	RF	MP NP	C4311 C14272	P14272	60	5	30		
			a	Sevikar HCT 40/5/12.5	AF	MP NP	C4311 C14272	P14272	60	5	30		
			a	APO-Olmesartan/Amlodipine/ HCTZ 40/5/25 tablet	TX	MP NP	C4311 C14272	P4311	30	5	30		
			a	Olamlo HCT 40/5/25	AL	MP NP	C4311 C14272	P4311	30	5	30		
			a	Olmekar HCT 40/5/25	RF	MP NP	C4311 C14272	P4311	30	5	30		
			a	Sevikar HCT 40/5/25	AF	MP NP	C4311 C14272	P4311	30	5	30		
			a	APO-Olmesartan/Amlodipine/ HCTZ 40/5/25 tablet	TX	MP NP	C4311 C14272	P14272	60	5	30		
			a	Olamlo HCT 40/5/25	AL	MP NP	C4311 C14272	P14272	60	5	30		
			a	Olmekar HCT 40/5/25	RF	MP NP	C4311 C14272	P14272	60	5	30		
			a	Sevikar HCT 40/5/25	AF	MP NP	C4311 C14272	P14272	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg	Oral	a	APO-Olmesartan/Amlodipine/ HCTZ 40/10/12.5	TX	MP NP	C4311 C14272	P4311	30	5	30		
			a	Olamlo HCT 40/10/12.5	AL	MP NP	C4311 C14272	P4311	30	5	30		
			a	Olmekar HCT 40/10/12.5	RF	MP NP	C4311 C14272	P4311	30	5	30		
			a	Sevikar HCT 40/10/12.5	AF	MP NP	C4311 C14272	P4311	30	5	30		
			a	APO-Olmesartan/Amlodipine/ HCTZ 40/10/12.5	TX	MP NP	C4311 C14272	P14272	60	5	30		
			a	Olamlo HCT 40/10/12.5	AL	MP NP	C4311 C14272	P14272	60	5	30		
			a	Olmekar HCT 40/10/12.5	RF	MP NP	C4311 C14272	P14272	60	5	30		
			a	Sevikar HCT 40/10/12.5	AF	MP NP	C4311 C14272	P14272	60	5	30		
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg	Oral	a	APO-Olmesartan/Amlodipine/ HCTZ 40/10/25	TX	MP NP	C4311		30	5	30		
			a	Olamlo HCT 40/10/25	AL	MP NP	C4311		30	5	30		
			a	Olmekar HCT 40/10/25	RF	MP NP	C4311		30	5	30		
			a	Sevikar HCT 40/10/25	AF	MP NP	C4311		30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg	Oral	a	APO-Olmesartan/HCTZ 20/12.5	TX	MP NP	C4374 C14255	P4374	30	5	30		
			a	APX-Olmesartan/HCTZ	TY	MP NP	C4374 C14255	P4374	30	5	30		
			a	OLMERTAN COMBI 20/12.5	RW	MP NP	C4374 C14255	P4374	30	5	30		
			a	Olmesartan HCT - MYL 20/12.5	AF	MP NP	C4374 C14255	P4374	30	5	30		
			a	Olmesartan/HCT Sandoz	SZ	MP NP	C4374 C14255	P4374	30	5	30		
			a	Olmetec Plus	AL	MP NP	C4374 C14255	P4374	30	5	30		
			a	Pharmacor Olmesartan HCTZ 20/12.5	CR	MP NP	C4374 C14255	P4374	30	5	30		
			a	APO-Olmesartan/HCTZ 20/12.5	TX	MP NP	C4374 C14255	P14255	60	5	30		
			a	APX-Olmesartan/HCTZ	TY	MP NP	C4374 C14255	P14255	60	5	30		
			a	OLMERTAN COMBI 20/12.5	RW	MP NP	C4374 C14255	P14255	60	5	30		
			a	Olmesartan HCT - MYL 20/12.5	AF	MP NP	C4374 C14255	P14255	60	5	30		
			a	Olmesartan/HCT Sandoz	SZ	MP NP	C4374 C14255	P14255	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg	Oral	a	Olmotec Plus	AL	MP NP	C4374 C14255	P14255	60	5	30		
			a	Pharmacor Olmesartan HCTZ 20/12.5	CR	MP NP	C4374 C14255	P14255	60	5	30		
			a	APO-Olmesartan/HCTZ 40/12.5	TX	MP NP	C4374 C14255	P4374	30	5	30		
			a	APX-Olmesartan/HCTZ	TY	MP NP	C4374 C14255	P4374	30	5	30		
			a	OLMERTAN COMBI 40/12.5	RW	MP NP	C4374 C14255	P4374	30	5	30		
			a	Olmesartan HCT - MYL 40/12.5	AF	MP NP	C4374 C14255	P4374	30	5	30		
			a	Olmesartan/HCT Sandoz	SZ	MP NP	C4374 C14255	P4374	30	5	30		
			a	Olmotec Plus	AL	MP NP	C4374 C14255	P4374	30	5	30		
			a	Pharmacor Olmesartan HCTZ 40/12.5	CR	MP NP	C4374 C14255	P4374	30	5	30		
			a	APO-Olmesartan/HCTZ 40/12.5	TX	MP NP	C4374 C14255	P14255	60	5	30		
			a	APX-Olmesartan/HCTZ	TY	MP NP	C4374 C14255	P14255	60	5	30		
			a	OLMERTAN COMBI 40/12.5	RW	MP NP	C4374 C14255	P14255	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg	Oral	a	Olmesartan HCT - MYL 40/12.5	AF	MP NP	C4374 C14255	P14255	60	5	30		
			a	Olmesartan/HCT Sandoz	SZ	MP NP	C4374 C14255	P14255	60	5	30		
			a	Olmetec Plus	AL	MP NP	C4374 C14255	P14255	60	5	30		
			a	Pharmacor Olmesartan HCTZ 40/12.5	CR	MP NP	C4374 C14255	P14255	60	5	30		
			a	APO-Olmesartan/HCTZ 40/25	TX	MP NP	C4374 C14255	P4374	30	5	30		
			a	APX-Olmesartan/HCTZ	TY	MP NP	C4374 C14255	P4374	30	5	30		
			a	OLMERTAN COMBI 40/25	RW	MP NP	C4374 C14255	P4374	30	5	30		
			a	Olmesartan HCT - MYL 40/25	AF	MP NP	C4374 C14255	P4374	30	5	30		
			a	Olmesartan/HCT Sandoz	SZ	MP NP	C4374 C14255	P4374	30	5	30		
			a	Olmetec Plus	AL	MP NP	C4374 C14255	P4374	30	5	30		
			a	Pharmacor Olmesartan HCTZ 40/25	CR	MP NP	C4374 C14255	P4374	30	5	30		
			a	APO-Olmesartan/HCTZ 40/25	TX	MP NP	C4374 C14255	P14255	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Olsalazine	Capsule containing olsalazine sodium 250 mg	Oral	a	APX-Olmesartan/HCTZ	TY	MP NP	C4374 C14255	P14255	60	5	30		
			a	OLMERTAN COMBI 40/25	RW	MP NP	C4374 C14255	P14255	60	5	30		
			a	Olmesartan HCT - MYL 40/25	AF	MP NP	C4374 C14255	P14255	60	5	30		
			a	Olmesartan/HCT Sandoz	SZ	MP NP	C4374 C14255	P14255	60	5	30		
			a	Olmetec Plus	AL	MP NP	C4374 C14255	P14255	60	5	30		
			a	Pharmacor Olmesartan HCTZ 40/25	CR	MP NP	C4374 C14255	P14255	60	5	30		
	Tablet containing olsalazine sodium 500 mg	Oral		Dipentum	IX	MP NP	C4824		100	5	100		
Omalizumab	Injection 75 mg in 0.5 mL single dose pre-filled syringe	Injection		Xolair	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Injection 150 mg in 1 mL single dose pre-filled syringe	Injection		Xolair	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Omeprazole	Capsule 20 mg	Oral	APO-Omeprazole	TX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			Maxor	AF	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			Omeprazole Sandoz	HX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			Pemzo	RW	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			Pharmacor Omeprazole 20	CR	MP	C8774 C8775 C8776 C8780	P8774 P8775	30	1	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
					NP	C8866 C11310 C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			Probitor	SZ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			APO-Omeprazole	TX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			Maxor	AF	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			Omeprazole Sandoz	HX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
					NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			Pemzo	RW	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			Pharmacor Omeprazole 20	CR	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			Probitor	SZ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			APO-Omeprazole	TX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			Maxor	AF	MP	C8774 C8775 C8776 C8780	P11310	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
				Omeprazole Sandoz	HX	MP	C8866 C11310 C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
				Pemzo	RW	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
				Pharmacor Omeprazole 20	CR	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
				Probitor	SZ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
	Tablet 10 mg (as magnesium)	Oral		Losec Tablets	PB	MP NP	C5444 C5512 C5529		30	5	30		
	Tablet 20 mg	Oral		APO-Omeprazole	TX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
				Maxor EC Tabs	AF	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
					NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			Ozmep	RW	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			APO-Omeprazole	TX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			Maxor EC Tabs	AF	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
					NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			Ozmep	RW	MP	C8774 C8775 C8776 C8780	P8776 P8780 P8866	30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP	C8866 C11310						
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
				APO-Omeprazole	TX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
				Maxor EC Tabs	AF	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
				Ozmep	RW	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
	Tablet 20 mg (as magnesium)	Oral		Acimax Tablets	FJ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
				Losec Tablets	PB	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
				Omepral	FQ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
				Omeprazole Sandoz	SZ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
				Acimax Tablets	FJ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
				Losec Tablets	PB	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
				Omepral	FQ	MP	C8774 C8775 C8776 C8780	P8776 P8780 P8866	30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			Omeprazole Sandoz	NP	MP	C8866 C11310	P8776 P8780 P8866	30	5	30		
						C8774 C8775 C8776 C8780 C8866						
				SZ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						C8774 C8775 C8776 C8780 C8866						
			Acimax Tablets	FJ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
						C8774 C8775 C8776 C8780 C8866 C11310						
			Losec Tablets	PB	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
						C8774 C8775 C8776 C8780 C8866 C11310						
			Omepral	FQ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
						C8774 C8775 C8776 C8780 C8866 C11310						
						C8774 C8775 C8776 C8780 C8866 C11310						
Onasemnogene abeparvovec	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5	Injection	Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	mL and 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL												
	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 1 vial	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See	See	1		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL								Note 3	Note 3			
	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 8 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 1 vial solution for I.V. infusion 20 trillion vector genomes	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	per mL, 8.3 mL												
	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	mL and 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL												
	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3	Injection		Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	mL											
	Pack containing 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection	Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection	Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection	Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection	Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 8 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL	Injection	Zolgensma	NV	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Pack containing 9 vials solution for I.V. infusion	Injection	Zolgensma	NV	MP	See Note 3	See Note 3	See	See	1		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	20 trillion vector genomes per mL, 8.3 mL								Note 3	Note 3			
Ondansetron	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL	Oral		Zofran syrup 50 mL	AS	MP NP	C4102 C5721	P5721	1	0	1		
						MP	C5778		1	0	1		C(100)
						MP NP	C4102 C5721	P4102	1	1	1		
	Tablet (orally disintegrating) 4 mg	Oral		APO-Ondansetron ODT	TX	MP NP	C5618 C10498	P5618	4	0	4		
						MP	C5743		4	0	4		C(100)
				APX-Ondansetron ODT	TY	MP NP	C5618 C10498	P5618	4	0	4		
						MP	C5743		4	0	4		C(100)
				Ondansetron AN ODT	EA	MP NP	C5618 C10498	P5618	4	0	4		
						MP	C5743		4	0	4		C(100)
				Ondansetron Mylan ODT	AF	MP NP	C5618 C10498	P5618	4	0	4		
						MP	C5743		4	0	4		C(100)
				Ondansetron ODT-DRLA	RZ	MP NP	C5618 C10498	P5618	4	0	4		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
				Ondansetron SZ ODT	MP		C5743		4	0	4		C(100)
				Ondansetron SZ ODT	HX	MP NP	C5618 C10498	P5618	4	0	4		
				Zotren ODT	MP		C5743		4	0	4		C(100)
				Zotren ODT	RF	MP NP	C5618 C10498	P5618	4	0	4		
				APO-Ondansetron ODT	MP		C5743		4	0	4		C(100)
				APO-Ondansetron ODT	TX	MP NP	C5618 C10498	P10498	10	1	10		
				APX-Ondansetron ODT	TY	MP NP	C5618 C10498	P10498	10	1	10		
				Ondansetron AN ODT	EA	MP NP	C5618 C10498	P10498	10	1	10		
				Ondansetron Mylan ODT	AF	MP NP	C5618 C10498	P10498	10	1	10		
				Ondansetron ODT-DRLA	RZ	MP NP	C5618 C10498	P10498	10	1	10		
				Ondansetron ODT Lupin	HQ	MP NP	C10498		10	1	10		
				Ondansetron SZ ODT	HX	MP NP	C5618 C10498	P10498	10	1	10		
				Zotren ODT	RF	MP NP	C5618 C10498	P10498	10	1	10		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 4 mg (as hydrochloride dihydrate)	Oral	a	APO-Ondansetron	TX	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	APX-Ondansetron	TY	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Ondansetron AN	EA	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Ondansetron APOTEX	GX	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Ondansetron Mylan Tablets	AF	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Ondansetron SZ	HX	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Ondansetron-DRLA	RZ	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Zofran	AS	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Zotren 4	RF	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	APO-Ondansetron	TX	MP NP	C4118 C10498	P10498	10	1	10		
			a	APX-Ondansetron	TY	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron AN	EA	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron APOTEX	GX	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron Mylan Tablets	AF	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron SZ	HX	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron-DRLA	RZ	MP NP	C4118 C10498	P10498	10	1	10		
			a	Zofran	AS	MP NP	C4118 C10498	P10498	10	1	10		
			a	Zotren 4	RF	MP	C4118 C10498	P10498	10	1	10		

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet (orally disintegrating) 8 mg	Oral	APO-Ondansetron ODT	TX	NP							
					MP	C5618 C10498	P5618	4	0	4		
			APX-Ondansetron ODT	TY	NP	C5743		4	0	4		C(100)
					MP	C5618 C10498	P5618	4	0	4		
			Ondansetron AN ODT	EA	NP	C5743		4	0	4		C(100)
					MP	C5618 C10498	P5618	4	0	4		
			Ondansetron Mylan ODT	AF	NP	C5743		4	0	4		C(100)
					MP	C5618 C10498	P5618	4	0	4		
			Ondansetron ODT-DRLA	RZ	NP	C5743		4	0	4		C(100)
					MP	C5618 C10498	P5618	4	0	4		
			Ondansetron SZ ODT	HX	NP	C5743		4	0	4		C(100)
					MP	C5618 C10498	P5618	4	0	4		
			Zotren ODT	RF	NP	C5743		4	0	4		C(100)
					MP	C5618 C10498	P5618	4	0	4		
					MP	C5743		4	0	4		C(100)

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet 8 mg (as hydrochloride dihydrate)	Oral	a	APO-Ondansetron ODT	TX	MP NP	C5618 C10498	P10498	10	1	10		
				APX-Ondansetron ODT	TY	MP NP	C5618 C10498	P10498	10	1	10		
				Ondansetron AN ODT	EA	MP NP	C5618 C10498	P10498	10	1	10		
				Ondansetron Mylan ODT	AF	MP NP	C5618 C10498	P10498	10	1	10		
				Ondansetron ODT-DRLA	RZ	MP NP	C5618 C10498	P10498	10	1	10		
				Ondansetron ODT Lupin	HQ	MP NP	C10498		10	1	10		
				Ondansetron SZ ODT	HX	MP NP	C5618 C10498	P10498	10	1	10		
				Zotren ODT	RF	MP NP	C5618 C10498	P10498	10	1	10		
				APO-Ondansetron	TX	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	APX-Ondansetron	TY	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)

Ready-prepared pharmaceutical benefits **Schedule 1**
Ready-prepared pharmaceutical benefits for prescription and supply **Part 1**

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Ondansetron AN	EA	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Ondansetron APOTEX	GX	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Ondansetron Mylan Tablets	AF	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Ondansetron SZ	HX	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Ondansetron-DRLA	RZ	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Zofran	AS	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	Zotren 8	RF	MP NP	C4118 C10498	P4118	4	0	4		
						MP	C5778		4	0	4		C(100)
			a	APO-Ondansetron	TX	MP	C4118 C10498	P10498	10	1	10		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	APX-Ondansetron	TY	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron AN	EA	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron APOTEX	GX	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron Mylan Tablets	AF	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron SZ	HX	MP NP	C4118 C10498	P10498	10	1	10		
			a	Ondansetron-DRLA	RZ	MP NP	C4118 C10498	P10498	10	1	10		
			a	Zofran	AS	MP NP	C4118 C10498	P10498	10	1	10		
			a	Zotren 8	RF	MP NP	C4118 C10498	P10498	10	1	10		
	Wafer 4 mg	Oral		Zofran Zydys	AS	MP NP	C10498		10	1	10		
	Wafer 8 mg	Oral		Zofran Zydys	AS	MP NP	C5618 C10498	P5618	4	0	4		
						MP	C5743		4	0	4		C(100)
						MP NP	C5618 C10498	P10498	10	1	10		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Opicapone	Capsule 50 mg	Oral		Ongentys	XY	MP NP	C5133		30	5	30		
Osimertinib	Tablet 40 mg	Oral		Tagrisso	AP	MP	C11181 C11183		30	5	30		
	Tablet 80 mg	Oral		Tagrisso	AP	MP	C11178 C11181 C11183 C11185		30	5	30		
Oxaliplatin	Solution concentrate for I.V. infusion 100 mg in 20 mL	Injection		DBL Oxaliplatin Concentrate	PF	MP			See Note 3	See Note 3	1		D(100)
				Oxaliplatin Accord	OC	MP			See Note 3	See Note 3	1		D(100)
				Oxaliplatin SUN	RA	MP			See Note 3	See Note 3	1		D(100)
	Solution concentrate for I.V. infusion 200 mg in 40 mL	Injection		Oxaliplatin SUN	RA	MP			See Note 3	See Note 3	1		D(100)
Oxazepam	Tablet 15 mg	Oral	a	Alepam 15	AF	MP NP PDP			25	0	25		
			a	Serepax	AS	MP NP PDP			25	0	25		
			a	Alepam 15	AF	MP NP		P6176	50 CN6176	3 CN6176	25		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Serepax	AS	MP NP		P6176	50 CN6176	3 CN6176	25		
			a	Alepam 15	AF	MP NP		P6217 P6230 P6262	50 CN6217 CN6230 CN6262	5 CN6217 CN6230 CN6262	25		
			a	Serepax	AS	MP NP		P6217 P6230 P6262	50 CN6217 CN6230 CN6262	5 CN6217 CN6230 CN6262	25		
	Tablet 30 mg	Oral	a	Alepam 30	AF	MP NP PDP			25	0	25		
			a	APO-Oxazepam	TX	MP NP PDP			25	0	25		
			a	Murelax	RW	MP NP PDP			25	0	25		
			a	Serepax	AS	MP NP PDP			25	0	25		
			a	Alepam 30	AF	MP NP		P6176	50 CN6176	3 CN6176	25		
			a	APO-Oxazepam	TX	MP		P6176	50	3	25		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Oxcarbazepine	Oral suspension 60 mg per mL, 250 mL Tablet 150 mg	Oral	a	Murelax	RW	MP NP	C5183	P6176	50 CN6176	3 CN6176	25		
			a	Serepax	AS	MP NP		P6176	50 CN6176	3 CN6176	25		
			a	Ale pam 30	AF	MP NP		P6217 P6230 P6262	50 CN6217 CN6230 CN6262	5 CN6217 CN6230 CN6262	25		
			a	APO-Oxazepam	TX	MP NP		P6217 P6230 P6262	50 CN6217 CN6230 CN6262	5 CN6217 CN6230 CN6262	25		
			a	Murelax	RW	MP NP		P6217 P6230 P6262	50 CN6217 CN6230 CN6262	5 CN6217 CN6230 CN6262	25		
			a	Serepax	AS	MP NP		P6217 P6230 P6262	50 CN6217 CN6230 CN6262	5 CN6217 CN6230 CN6262	25		
Oxcarbazepine	Oral suspension 60 mg per mL, 250 mL	Oral		Trileptal	NV	MP NP	C5183		2	5	1		
	Tablet 150 mg	Oral		Trileptal	NV	MP NP	C5183		100	5	100		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Oxprenolol	Tablet 300 mg	Oral	Trileptal	NV	MP NP	C5183		100	5	100		
	Tablet 600 mg	Oral	Trileptal	NV	MP NP	C5183		100	5	100		
	Tablet containing oxprenolol hydrochloride 40 mg	Oral	Corbeton 40	AF	MP NP			100	5	100		
Oxybutynin	Transdermal patches 36 mg, 8	Transdermal	Oxytrol	TT	MP NP	C6243		1	5	1		
Oxycodone	Tablet containing oxybutynin hydrochloride 5 mg	Oral	Ditropan	SW	MP NP	C6241		100	5	100		
	Capsule containing oxycodone hydrochloride 5 mg	Oral	OxyNorm	MF	PDP	C10766 C10768	P10766	10	0	10		
					MP NP	C10764 C10766 C10771 C10772	P10766	10	0	10		
					PDP	C10766 C10768	P10768	20	0	20		
					MP NP	C10764 C10766 C10771 C10772	P10764 P10771 P10772	20	0	20		
	Capsule containing oxycodone hydrochloride 10 mg	Oral	OxyNorm	MF	MP NP	C10764 C10766 C10771 C10772	P10766	10	0	20		
					PDP	C10766 C10768	P10766	10	0	20		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						MP NP	C10764 C10766 C10771 C10772	P10764 P10771 P10772	20	0	20		
						PDP	C10766 C10768	P10768	20	0	20		
	Capsule containing oxycodone hydrochloride 20 mg	Oral		OxyNorm	MF	MP NP	C10764 C10771 C10772		20	0	20		
	Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL	Oral		OxyNorm Liquid 1mg/mL	MF	PDP	C10768		250	0	250		
						MP NP	C10764 C10771 C10772		250	0	250		
	Suppository 30 mg (as pectinate)	Rectal		Proladone	FF	MP NP	C10764 C10890 C10910		12	0	12		
						PDP	C10860		12	0	12		
	Tablet containing oxycodone hydrochloride 5 mg	Oral	a	ENDONE	AF	MP NP	C10764 C10766 C10771 C10772	P10766	10	0	10		
						PDP	C10766 C10768	P10766	10	0	10		
			a	Oxycodone Viatrix	MQ	MP NP	C10764 C10766 C10771 C10772	P10766	10	0	10		
						PDP	C10766 C10768	P10766	10	0	10		
			a	ENDONE	AF	MP NP	C10764 C10766 C10771 C10772	P10764 P10771 P10772	20	0	20		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing oxycodone hydrochloride 10 mg (controlled release)	Oral	a	Mayne Pharma Oxycodone IR	YN	MP NP	C10766 C10768 C10764 C10771 C10772	P10768	20	0	20		
			a	Oxycodone Mylan	AL	MP NP	C10764 C10771 C10772		20	0	20		
			a	Oxycodone Viatriis	MQ	MP NP	C10764 C10766 C10771 C10772	P10764 P10771 P10772	20	0	20		
			a	Oxyndone	TX	MP NP	C10766 C10768 C10764 C10771 C10772	P10768	20	0	20		
			a	Oxycodone Sandoz	SZ	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	Oxycodone Sandoz	SZ	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
				OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
				OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
				OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
				OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	hydrochloride 15 mg (controlled release)				MP NP		C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet containing oxycodone hydrochloride 20 mg (controlled release)	Oral	a	Oxycodone Sandoz	SZ	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	Oxycodone Sandoz	SZ	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet containing oxycodone hydrochloride 30 mg (controlled release)	Oral		OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
					MP NP		C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet containing oxycodone hydrochloride 40 mg (controlled release)	Oral	a	Oxycodone Sandoz	SZ	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	Oxycodone Sandoz	SZ	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet containing oxycodone	Oral	a	Oxycodone Sandoz	SZ	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Oxycodone with naloxone	hydrochloride 80 mg (controlled release)	Oral	a	OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
			a	Oxycodone Sandoz	SZ	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
			a	OxyContin	MF	MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet (controlled release) containing oxycodone hydrochloride 2.5 mg with naloxone hydrochloride 1.25 mg			Targin 2.5/1.25 mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet (controlled release) containing oxycodone hydrochloride 5 mg with naloxone hydrochloride 2.5 mg			Targin 5/2.5mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg			Targin 10/5mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet (controlled release) containing oxycodone			Targin 15/7.5mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	hydrochloride 15 mg with naloxone hydrochloride 7.5 mg					MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg	Oral		Targin 20/10mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet (controlled release) containing oxycodone hydrochloride 30 mg with naloxone hydrochloride 15 mg	Oral		Targin 30/15 mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg	Oral		Targin 40/20mg	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Tablet (controlled release) containing oxycodone hydrochloride 60 mg with naloxone	Oral		Targin 60/30	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Ozanimod	hydrochloride 30 mg												
	Tablet (controlled release) containing oxycodone hydrochloride 80 mg with naloxone hydrochloride 40 mg	Oral		Targin 80/40	MF	MP NP	C10748 C10752 C10755 C11753	P10748 P10752 P10755	28	0	28		
						MP NP	C10748 C10752 C10755 C11753	P11753	56	0	28		
	Capsule 920 micrograms	Oral		Zeposia	CJ	MP	C10162 C10172 C13946 C13993 C13995 C14002 C14003 C14004 C14005	P13995 P14003 P14004 P14005	28	3	28		
						MP	C10162 C10172 C13946 C13993 C13995 C14002 C14003 C14004 C14005	P10162 P10172 P13946 P13993 P14002	28	5	28		
Paclitaxel	Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms	Oral		Zeposia	CJ	MP	C10162 C10172 C14017		1	0	1		
	Solution concentrate for I.V. infusion 300 mg in 50 mL	Injection		Paclitaxel Accord	OC	MP			See Note 3	See Note 3	1		D(100)
				Paclitaxel Ebewe	SZ	MP			See Note 3	See Note 3	1		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Paclitaxel, nanoparticle albumin-bound	Powder for I.V. injection containing 100 mg paclitaxel	Injection		Abraxane	TS	MP	C4657 C6106 C6119		See Note 3	See Note 3	1		D(100)
Palbociclib	Tablet 75 mg	Oral		Ibrance	PF	MP	C13055 C13066		21	5	21		
	Tablet 100 mg	Oral		Ibrance	PF	MP	C13055 C13066		21	5	21		
	Tablet 125 mg	Oral		Ibrance	PF	MP	C13055 C13066		21	5	21		
Paliperidone	I.M. injection (modified release) 25 mg (as palmitate) in pre-filled syringe	Injection		Invega Sustenna	JC	MP NP	C4246		1	5	1		
	I.M. injection (modified release) 50 mg (as palmitate) in pre-filled syringe	Injection		Invega Sustenna	JC	MP NP	C4246		1	5	1		
	I.M. injection (modified release) 75 mg (as palmitate) in pre-filled syringe	Injection		Invega Sustenna	JC	MP NP	C4246		1	5	1		
	I.M. injection (modified release) 100 mg (as palmitate) in pre-filled syringe	Injection		Invega Sustenna	JC	MP NP	C4246		1	5	1		
	I.M. injection (modified release) 150 mg (as palmitate) in pre-filled syringe	Injection		Invega Sustenna	JC	MP NP	C4246		1	5	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	I.M. injection (modified release) 175 mg (as palmitate) in pre-filled syringe	Injection	Invega Trinza	JC	MP NP	C13049		1	1	1		
	I.M. injection (modified release) 263 mg (as palmitate) in pre-filled syringe	Injection	Invega Trinza	JC	MP NP	C13049		1	1	1		
	I.M. injection (modified release) 350 mg (as palmitate) in pre-filled syringe	Injection	Invega Trinza	JC	MP NP	C13049		1	1	1		
	I.M. injection (modified release) 525 mg (as palmitate) in pre-filled syringe	Injection	Invega Trinza	JC	MP NP	C13049		1	1	1		
	I.M. injection (modified release) 700 mg (as palmitate) in pre-filled syringe	Injection	Invega Hafyera	JC	MP NP	C13082		1	0	1		
	I.M. injection (modified release) 1000 mg (as palmitate) in pre-filled syringe	Injection	Invega Hafyera	JC	MP NP	C13082		1	0	1		
	Tablet 3 mg (prolonged release)	Oral	Invega	JC	MP NP	C4246		28	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Palonosetron	Tablet 6 mg (prolonged release)	Oral		Invega	JC	MP NP	C4246		28	5	28		
	Tablet 9 mg (prolonged release)	Oral		Invega	JC	MP NP	C4246		28	5	28		
	Injection 250 micrograms (as hydrochloride) in 5 mL	Injection	a	Aloxi	JZ	MP NP	C5686		1	0	1		
						MP	C5805		1	0	1		C(100)
			a	Palonosetron Dr.Reddy's	RZ	MP NP	C5686		1	0	1		
Pamidronic acid	Concentrated injection containing pamidronate disodium 15 mg in 5 mL	Injection		Pamisol	PF	MP NP	C4877		4	0	1		
						MP	C4433 C9234		4	2	1		C(100)
						MP NP	C4877		2	0	1		
	Concentrated injection containing pamidronate disodium 30 mg in 10 mL	Injection		Pamisol	PF	MP NP	C4877		2	2	1		C(100)
						MP	C4433 C9234		2	2	1		
	Concentrated injection containing pamidronate disodium 60 mg in 10 mL	Injection		Pamisol	PF	MP NP	C4877		1	0	1		
						MP	C4433 C9234		1	2	1		C(100)
	Concentrated injection containing pamidronate disodium 90 mg in 10	Injection		Pamisol	PF	MP	C4433 C5218 C5291 C9234 C9315 C9335		1	11	1		PB(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Pancreatic extract	mL												
	Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity	Oral		Creon 10,000	GO	MP NP			500	10	100		
						MP NP		P14238	1000	10	100		
	Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity	Oral		Creon 25,000	GO	MP NP			200	10	100		
						MP NP		P14238	400	10	100		
	Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity	Oral		Creon 35,000	GO	MP NP			200	10	100		
						MP NP		P14238	400	10	100		
	Granules (enteric coated) providing not	Oral		Creon Micro	GO	MP NP			3	10	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	less than 5,000 BP units of lipase activity per 100 mg, 20 g												
Pancrelipase	Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity	Oral		Panzytrat 25000	TM	MP NP		P14238	6	10	1		
						MP NP			200	10	100		
						MP		P5779	200	21	100		
	Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity (s19A)	Oral		Panzytrat 25 000 (Allergan)	DZ	MP NP			200	10	100		
Panitumumab	Solution concentrate for I.V. infusion 100 mg in 5 mL	Injection		Vectibix	AN	MP		P5779	200	21	100		
						MP	C5452 C5526 C12035 C12066		See Note 3	See Note 3	1		D(100)
						MP	C5452 C5526 C12035 C12066		See Note 3	See Note 3	1		D(100)
Pantoprazole	Sachet containing granules 40 mg (as sodium	Oral		Somac	NQ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	sesquihydrate)												
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
						MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
						MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	a	APO-Pantoprazole	TX	MP NP	C5444 C5512 C5529		30	5	30		
			a	NOUMED PANTOPRAZOLE	VO	MP NP	C5444 C5512 C5529		30	5	30		
			a	Ozpan	RA	MP NP	C5444 C5512 C5529		30	5	30		
			a	Panthron	ZS	MP NP	C5444 C5512 C5529		30	5	30		
			a	Pantoprazole APOTEX	TY	MP NP	C5444 C5512 C5529		30	5	30		
			a	Pantoprazole generichealth	HQ	MP NP	C5444 C5512 C5529		30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Pantoprazole Sandoz	SZ	MP NP	C5444 C5512 C5529		30	5	30		
			a	Salpraz	AF	MP NP	C5444 C5512 C5529		30	5	30		
			a	Somac	NQ	MP NP	C5444 C5512 C5529		30	5	30		
			a	Sozol	RW	MP NP	C5444 C5512 C5529		30	5	30		
	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	a	APO-Pantoprazole	TX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			a	I-Pantoprazole	CR	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			a	NOUMED PANTOPRAZOLE	VO	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780	P8774 P8775	30	1	30		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Ozpan	RA	MP	C8866 C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			a	Panthron	ZS	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			a	Pantoprazole AN	EA	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
			a	Pantoprazole APOTEX	TY	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Pantoprazole generic	health	HQ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30	
							NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30	
			a	Pantoprazole Sandoz		SZ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30	
							NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30	
			a	Salpraz		AF	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30	
							NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30	
			a	Somac		NQ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8774 P8775	30	1	30	
							NP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30	
			a	Sozol		RW	MP	C8774 C8775 C8776 C8780	P8774 P8775	30	1	30	

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP	C8866 C11310						
			a	APO-Pantoprazole	TX	MP	C8774 C8775 C8776 C8780 C8866	P8774 P8775	30	1	30		
						NP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
			a	I-Pantoprazole	CR	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			a	NOUMED PANTOPRAZOLE	VO	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			a	Ozpan	RA	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			a	Panthron	ZS	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			a	Pantoprazole AN	EA	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			a	Pantoprazole APOTEX	TY	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			a	Pantoprazole generichealth	HQ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780	P8776 P8780 P8866	30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Pantoprazole Sandoz	SZ	MP	C8866 C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			a	Salpraz	AF	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			a	Somac	NQ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		
			a	Sozol	RW	MP	C8774 C8775 C8776 C8780 C8866 C11310	P8776 P8780 P8866	30	5	30		
						NP	C8774 C8775 C8776 C8780 C8866	P8776 P8780 P8866	30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	APO-Pantoprazole	TX	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	I-Pantoprazole	CR	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	NOUMED PANTOPRAZOLE	VO	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	Ozpan	RA	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	Panthron	ZS	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	Pantoprazole AN	EA	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	Pantoprazole APOTEX	TY	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	Pantoprazole generichealth	HQ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	Pantoprazole Sandoz	SZ	MP	C8774 C8775 C8776 C8780	P11310	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Paracetamol	Oral liquid 120 mg per 5 mL, 100 mL	Oral	a	Salpraz	AF	MP	C8866 C11310 C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	Somac	NQ	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
			a	Sozol	RW	MP	C8774 C8775 C8776 C8780 C8866 C11310	P11310	60	5	30		
	Oral liquid 240 mg per 5 mL, 200 mL	Oral		Panamax	SW	PDP	C5846		1	0	1		
						MP NP	C5835		1	2	1		
	Oral liquid 240 mg per 5 mL, 200 mL	Oral		Panamax 240 Elixir	SW	PDP	C5846		1	0	1		
						MP NP	C5835		1	2	1		
	Suppository 500 mg	Rectal		Panadol	GJ	MP NP	C6167		100	3	10		
	Tablet 500 mg	Oral	a	APO-Paracetamol	TX	PDP	C5846 C5885	P5846	100	0	100		
			a	Febridol	EA	PDP	C5846 C5885	P5846	100	0	100		
			a	Panamax	SW	PDP	C5846 C5885	P5846	100	0	100		
			a	Paracetamol (Sandoz)	SZ	PDP	C5846 C5885	P5846	100	0	100		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Paracetamol Sandoz Pharma	QS	PDP	C5846 C5885	P5846	100	0	100		
			a	Paralgin	OW	PDP	C5846 C5885	P5846	100	0	100		
			a	Parapane	AF	PDP	C5846 C5885	P5846	100	0	100		
			a	PHARMACY CARE PARACETAMOL	SI	PDP	C5846 C5885	P5846	100	0	100		
			a	Wagner Health Paracetamol	BG	PDP	C5846 C5885	P5846	100	0	100		
			a	APO-Paracetamol	TX	MP NP	C5835 C5865	P5835	100	1	100		
			a	Febridol	EA	MP NP	C5835 C5865	P5835	100	1	100		
			a	Panamax	SW	MP NP	C5835 C5865	P5835	100	1	100		
			a	Paracetamol (Sandoz)	SZ	MP NP	C5835 C5865	P5835	100	1	100		
			a	Paracetamol Sandoz Pharma	QS	MP NP	C5835 C5865	P5835	100	1	100		
			a	Paralgin	OW	MP NP	C5835 C5865	P5835	100	1	100		
			a	Parapane	AF	MP NP	C5835 C5865	P5835	100	1	100		
			a	PHARMACY CARE PARACETAMOL	SI	MP NP	C5835 C5865	P5835	100	1	100		
			a	Wagner Health Paracetamol	BG	MP	C5835 C5865	P5835	100	1	100		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
			a	APO-Paracetamol	TX	PDP	C5846 C5885	P5885	300	0	100		
			a	Febridol	EA	PDP	C5846 C5885	P5885	300	0	100		
			a	Panamax	SW	PDP	C5846 C5885	P5885	300	0	100		
			a	Paracetamol (Sandoz)	SZ	PDP	C5846 C5885	P5885	300	0	100		
			a	Paracetamol Sandoz Pharma	QS	PDP	C5846 C5885	P5885	300	0	100		
			a	Paralgin	OW	PDP	C5846 C5885	P5885	300	0	100		
			a	Parapane	AF	PDP	C5846 C5885	P5885	300	0	100		
			a	PHARMACY CARE PARACETAMOL	SI	PDP	C5846 C5885	P5885	300	0	100		
			a	Wagner Health Paracetamol	BG	PDP	C5846 C5885	P5885	300	0	100		
			a	APO-Paracetamol	TX	MP NP	C5835 C5865	P5865	300	4	100		
			a	Febridol	EA	MP NP	C5835 C5865	P5865	300	4	100		
			a	Panamax	SW	MP NP	C5835 C5865	P5865	300	4	100		
			a	Paracetamol (Sandoz)	SZ	MP NP	C5835 C5865	P5865	300	4	100		
			a	Paracetamol Sandoz Pharma	QS	MP NP	C5835 C5865	P5865	300	4	100		
			a	Paralgin	OW	MP	C5835 C5865	P5865	300	4	100		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
			a	Parapane	AF	MP NP	C5835 C5865	P5865	300	4	100		
			a	PHARMACY CARE PARACETAMOL	SI	MP NP	C5835 C5865	P5865	300	4	100		
			a	Wagner Health Paracetamol	BG	MP NP	C5835 C5865	P5865	300	4	100		
	Tablet 665 mg (modified release)	Oral	a	APOHEALTH Osteo Relief Paracetamol 665 mg	TX	MP NP	C6225 C6280	P6225	192	3	96		
			a	Osteomol 665 Paracetamol	CR	MP NP	C6225 C6280	P6225	192	3	96		
						MP NP	C6225 C6280	P6225	192	3	192		
			a	Parapane OSTEO	AF	MP NP	C6225 C6280	P6225	192	3	96		
			a	APOHEALTH Osteo Relief Paracetamol 665 mg	TX	MP NP	C6225 C6280	P6280	192	5	96		
			a	Osteomol 665 Paracetamol	CR	MP NP	C6225 C6280	P6280	192	5	96		
						MP NP	C6225 C6280	P6280	192	5	192		
			a	Parapane OSTEO	AF	MP NP	C6225 C6280	P6280	192	5	96		
Paraffin	Eye drops containing	Application to		Cationorm	CS	MP	C6172		1	5	1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Paraffin with retinol palmitate	liquid paraffin, glycerol, tyloxapol, poloxamer-188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free)	the eye				NP AO							
	Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g	Application to the eye		Poly Visc	IQ	MP NP AO		P5713	2	5	1		
	Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g	Application to the eye		Poly Visc	IQ	MP NP AO			1	5	1		
				Refresh Night Time	VE	MP NP AO			1	5	1		
				Poly Visc	IQ	MP		P4894	1	11	1		
				Refresh Night Time	VE	MP		P4894	1	11	1		
	Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and	Application to the eye		VitA-POS	AE	AO MP NP			2	5	1		
						MP		P4072	2	11	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Paroxetine	retinol palmitate, 5 g	Oral											
	Tablet 20 mg (as hydrochloride)		a	APO-Paroxetine	TX	MP NP	C4755 C6277 C6636		30	5	30		
			a	APX-Paroxetine	TY	MP NP	C4755 C6277 C6636		30	5	30		
			a	Aropax	AS	MP NP	C4755 C6277 C6636		30	5	30		
			a	Blooms The Chemist Paroxetine	BG	MP NP	C4755 C6277 C6636		30	5	30		
			a	Extine 20	RW	MP NP	C4755 C6277 C6636		30	5	30		
			a	Noumed Paroxetine	VO	MP NP	C4755 C6277 C6636		30	5	30		
			a	Paroxetine AN	EA	MP NP	C4755 C6277 C6636		30	5	30		
			a	Paroxetine GH	GQ	MP NP	C4755 C6277 C6636		30	5	30		
			a	Paroxetine Sandoz	SZ	MP NP	C4755 C6277 C6636		30	5	30		
			a	Paxtine	AF	MP NP	C4755 C6277 C6636		30	5	30		
Pasireotide	Injection (modified release) 20 mg (as embonate), vial and	Injection		Signifor LAR	RJ	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	diluent syringe											
	Injection (modified release) 40 mg (as embonate), vial and diluent syringe	Injection	Signifor LAR	RJ	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Injection (modified release) 60 mg (as embonate), vial and diluent syringe	Injection	Signifor LAR	RJ	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
Patiromer	Powder for oral suspension 8.4 g	Oral	Veltassa	CS	MP	C14327 C14342		30	5	30		
					NP	C14327		30	5	30		
	Powder for oral suspension 16.8 g	Oral	Veltassa	CS	MP	C14327 C14342		30	5	30		
					NP	C14327		30	5	30		
Pazopanib	Tablet 200 mg (as hydrochloride)	Oral	Votrient	NV	MP	C7458 C7459 C9247 C11937 C11939 C11974	P7459 P11939	30	5	30		
					MP	C7458 C7459 C9247 C11937 C11939 C11974	P9247 P11974	90	2	90		
					MP	C7458 C7459 C9247 C11937 C11939 C11974	P7458 P11937	90	5	90		
	Tablet 400 mg (as hydrochloride)	Oral	Votrient	NV	MP	C7458 C7459 C9247 C11937 C11939 C11974	P7459 P11939	30	5	30		

Ready-prepared pharmaceutical benefits **Schedule 1**
Ready-prepared pharmaceutical benefits for prescription and supply **Part 1**

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						MP	C7458 C7459 C9247 C11937 C11939 C11974	P9247 P11974	60	2	60		
						MP	C7458 C7459 C9247 C11937 C11939 C11974	P7458 P11937	60	5	60		
Pegcetacoplan	Solution for subcutaneous infusion 1,080 mg in 20 mL	Injection		Empaveli	ZO	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
Pegfilgrastim	Injection 6 mg in 0.6 mL single use pre-filled syringe	Injection	a	Pelgraz	OC	MP	C7822 C7843 C9235 C9303		1	11	1		D(100)
			a	Ristempa	JO	MP	C7822 C7843 C9235 C9303		1	11	1		D(100)
			a	Ziextenzo	SZ	MP	C7822 C7843 C9235 C9303		1	11	1		D(100)
Peginterferon alfa-2a	Injection 135 micrograms in 0.5 mL single use pre-filled syringe	Injection		Pegasys	XO	MP NP			4	5	4		
						MP NP		P5004 P9603	8 CN5004 CN9603	5 CN5004 CN9603	4		C(100)
	Injection 180 micrograms in 0.5 mL single use pre-filled	Injection		Pegasys	XO	MP NP			4	5	4		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	syringe				MP NP		P5004 P9603	8 CN5004 CN9603	5 CN5004 CN9603	4		C(100)
Peginterferon beta-1a	Single use injection pen containing 125 micrograms in 0.5 mL	Injection	Plegridy	BD	MP	C6860 C7695	P7695	2	4	2		
					MP	C6860 C7695	P6860	2	5	2		
	Pack containing single use injection pens containing 63 micrograms in 0.5 mL and 94 micrograms in 0.5 mL	Injection	Plegridy	BD	MP	C7695		1	0	1		
Pegvisomant	Injection set containing powder for injection 10 mg, 30 and diluent, 30	Injection	Somavert	PF	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Injection set containing powder for injection 15 mg, 30 and diluent, 30	Injection	Somavert	PF	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Injection set containing powder for injection 20 mg, 1 and diluent, 1	Injection	Somavert	PF	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
	Injection set containing powder for injection 20 mg, 30 and diluent, 30	Injection	Somavert	PF	MP	See Note 3	See Note 3	See Note 3	See Note 3	1		D(100)
Pembrolizumab	Solution concentrate	Injection	Keytruda	MK	MP	C10676 C10687		See	See	1		D(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	for I.V. infusion 100 mg in 4 mL						C10688 C10689 C10695 C10696 C10701 C10705 C13431 C13432 C13436 C13437 C13726 C13727 C13728 C13730 C13731 C13732 C13735 C13736 C13738 C13739 C13741 C13948 C13949 C13986 C14027 C14028 C14044 C14324 C14403 C14404 C14405		Note 3	Note 3			
Pemetrexed	Powder for I.V. infusion 100 mg (as disodium)	Injection		Pemetrexed Accord	OD	MP			See Note 3	See Note 3	1		D(100)
				Pemetrexed-AFT	AE	MP			See Note 3	See Note 3	1		D(100)
				Pemetrexed SUN	RA	MP			See Note 3	See Note 3	1		D(100)
	Powder for I.V. infusion 500 mg (as disodium)	Injection		Pemetrexed Accord	OD	MP			See Note 3	See Note 3	1		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Penicillamine	Powder for I.V. infusion 1 g (as disodium)	Injection	Pemetrexed-AFT	AE	MP			See Note 3	See Note 3	1		D(100)
			Pemetrexed APOTEX	TX	MP			See Note 3	See Note 3	1		D(100)
			Pemetrexed SUN	RA	MP			See Note 3	See Note 3	1		D(100)
			Pemetrexed Accord	OD	MP			See Note 3	See Note 3	1		D(100)
			Pemetrexed SUN	RA	MP			See Note 3	See Note 3	1		D(100)
			Pemetrexed Ever Pharma	IT	MP			See Note 3	See Note 3	1		D(100)
			Pemetrexed Ever Pharma	IT	MP			See Note 3	See Note 3	1		D(100)
			Pemetrexed Ever Pharma	IT	MP			See Note 3	See Note 3	1		D(100)
	Tablet 125 mg	Oral	D-Penamine	AL	MP NP			100	1	100		
					MP NP		P14238	200	1	100		
	Tablet 250 mg	Oral	D-Penamine	AL	MP			100	1	100		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Perampanel	Tablet 2 mg (as hemisesquihydrate)	Oral	Fycompa		EI	MP	C4656 C7815	P14238	200	1	100		
	Tablet 4 mg (as hemisesquihydrate)	Oral	Fycompa		EI	MP	C4658 C7789	P7789	28	2	28		
	Tablet 6 mg (as hemisesquihydrate)	Oral	Fycompa		EI	MP	C4658 C7789	P7789	28	2	28		
	Tablet 8 mg (as hemisesquihydrate)	Oral	Fycompa		EI	MP	C4658 C7789	P4658	28	5	28		
Perfluorohexyloctane	Eye drops, 3 mL	Application to the eye	Novatears		AE	AO	C6172		1	5	1		
Perhexiline	Tablet containing perhexiline maleate	Oral		Pexsig	AS	MP	C5592		100	5	100		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Periciazine	100 mg											
	Tablet 2.5 mg	Oral	Neulactil	IX	MP NP			100	5	100		
	Tablet 10 mg	Oral	Neulactil	IX	MP NP			100	5	100		
Perindopril	Tablet containing perindopril erbumine 2 mg	Oral	APO-Perindopril	TX	MP NP			30	5	30		
			Blooms the Chemist Perindopril	IB	MP NP			30	5	30		
			BTC Perindopril	JB	MP NP			30	5	30		
			Idaprex 2	SZ	MP NP			30	5	30		
			Indosyl Mono 2	RW	MP NP			30	5	30		
			Perindo	AF	MP NP			30	5	30		
			PERISYL	AL	MP NP			30	5	30		
			APO-Perindopril	TX	MP NP		P14238	60	5	30		
			Blooms the Chemist Perindopril	IB	MP NP		P14238	60	5	30		
			BTC Perindopril	JB	MP		P14238	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
				Idaprex 2	SZ	MP NP		P14238	60	5	30		
				Indosyl Mono 2	RW	MP NP		P14238	60	5	30		
				Perindo	AF	MP NP		P14238	60	5	30		
				PERISYL	AL	MP NP		P14238	60	5	30		
	Tablet containing perindopril arginine 2.5 mg	Oral		APO-Perindopril Arginine	TX	MP NP			30	5	30		
				APX-Perindopril Arginine	XT	MP NP			30	5	30		
				Coversyl 2.5mg	SE	MP NP			30	5	30		
				PREXUM 2.5	RX	MP NP			30	5	30		
				APO-Perindopril Arginine	TX	MP NP		P14238	60	5	30		
				APX-Perindopril Arginine	XT	MP NP		P14238	60	5	30		
				Coversyl 2.5mg	SE	MP NP		P14238	60	5	30		
				PREXUM 2.5	RX	MP		P14238	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing perindopril erbumine 4 mg	Oral		APO-Perindopril	TX	MP NP			30	5	30		
				Blooms the Chemist Perindopril	IB	MP NP			30	5	30		
				BTC Perindopril	JB	MP NP			30	5	30		
				Idaprex 4	SZ	MP NP			30	5	30		
				Indosyl Mono 4	RW	MP NP			30	5	30		
				Perindo	AF	MP NP			30	5	30		
				Perindopril generichealth	GQ	MP NP			30	5	30		
				PERISYL	AL	MP NP			30	5	30		
				APO-Perindopril	TX	MP NP		P14238	60	5	30		
				Blooms the Chemist Perindopril	IB	MP NP		P14238	60	5	30		
				BTC Perindopril	JB	MP NP		P14238	60	5	30		
				Idaprex 4	SZ	MP		P14238	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
				Indosyl Mono 4	RW	MP NP		P14238	60	5	30		
				Perindo	AF	MP NP		P14238	60	5	30		
				Perindopril generichealth	GQ	MP NP		P14238	60	5	30		
				PERISYL	AL	MP NP		P14238	60	5	30		
	Tablet containing perindopril arginine 5 mg	Oral		APO-Perindopril Arginine	TX	MP NP			30	5	30		
				APX-Perindopril Arginine	XT	MP NP			30	5	30		
				Coversyl 5mg	SE	MP NP			30	5	30		
				PREXUM 5	RX	MP NP			30	5	30		
				APO-Perindopril Arginine	TX	MP NP		P14238	60	5	30		
				APX-Perindopril Arginine	XT	MP NP		P14238	60	5	30		
				Coversyl 5mg	SE	MP NP		P14238	60	5	30		
				PREXUM 5	RX	MP		P14238	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
					NP							
	Tablet containing perindopril erbumine 8 mg	Oral	APO-Perindopril	TX	MP NP			30	5	30		
			Blooms the Chemist Perindopril	IB	MP NP			30	5	30		
			BTC Perindopril	JB	MP NP			30	5	30		
			Idaprex 8	SZ	MP NP			30	5	30		
			Indosyl Mono 8	RW	MP NP			30	5	30		
			Perindo	AF	MP NP			30	5	30		
			Perindopril generichealth	GQ	MP NP			30	5	30		
			PERISYL	AL	MP NP			30	5	30		
			APO-Perindopril	TX	MP NP		P14238	60	5	30		
			Blooms the Chemist Perindopril	IB	MP NP		P14238	60	5	30		
			BTC Perindopril	JB	MP NP		P14238	60	5	30		
			Idaprex 8	SZ	MP		P14238	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
				Indosyl Mono 8	RW	MP NP		P14238	60	5	30		
				Perindo	AF	MP NP		P14238	60	5	30		
				Perindopril generichealth	GQ	MP NP		P14238	60	5	30		
				PERISYL	AL	MP NP		P14238	60	5	30		
	Tablet containing perindopril arginine 10 mg	Oral		APO-Perindopril Arginine	TX	MP NP			30	5	30		
				APX-Perindopril Arginine	XT	MP NP			30	5	30		
				Coversyl 10mg	SE	MP NP			30	5	30		
				PREXUM 10	RX	MP NP			30	5	30		
				APO-Perindopril Arginine	TX	MP NP		P14238	60	5	30		
				APX-Perindopril Arginine	XT	MP NP		P14238	60	5	30		
				Coversyl 10mg	SE	MP NP		P14238	60	5	30		
				PREXUM 10	RX	MP		P14238	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Perindopril with amlodipine	Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate)	Oral	a	APO-Perindopril Arginine/Amlodipine 5/5	TX	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	APX-Perindopril Arginine/Amlodipine 5/5	XT	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	Coveram 5/5	SE	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	Reaptan 5/5	RX	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	APO-Perindopril Arginine/Amlodipine 5/5	TX	MP NP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	APX-Perindopril Arginine/Amlodipine 5/5	XT	MP NP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	Coveram 5/5	SE	MP NP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	Reaptan 5/5	RX	MP NP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
	Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate)	Oral	a	APO-Perindopril Arginine/Amlodipine 5/10	TX	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	APX-Perindopril Arginine/Amlodipine 5/10	XT	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	Coveram 5/10	SE	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	Reaptan 5/10	RX	MP	C4398 C4418	P4398 P4418	30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate)	Oral	Oral	a	APO-Perindopril Arginine/Amlodipine 5/10	TX	MP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	APX-Perindopril Arginine/Amlodipine 5/10	XT	MP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	Coveram 5/10	SE	MP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	Reaptan 5/10	RX	MP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	APO-Perindopril Arginine/Amlodipine 10/5	TX	MP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	APX-Perindopril Arginine/Amlodipine 10/5	XT	MP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	Coveram 10/5	SE	MP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	Reaptan 10/5	RX	MP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	APO-Perindopril Arginine/Amlodipine 10/5	TX	MP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	APX-Perindopril Arginine/Amlodipine 10/5	XT	MP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	Coveram 10/5	SE	MP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	Reaptan 10/5	RX	MP	C4398 C4418	P14245 P14246	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Perindopril with indapamide	Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate)	Oral	a	APO-Perindopril Arginine/Amlodipine 10/10	TX	MP NP	C14245 C14246 C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	APX-Perindopril Arginine/Amlodipine 10/10	XT	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	Coveram 10/10	SE	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	Reaptan 10/10	RX	MP NP	C4398 C4418 C14245 C14246	P4398 P4418	30	5	30		
			a	APO-Perindopril Arginine/Amlodipine 10/10	TX	MP NP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	APX-Perindopril Arginine/Amlodipine 10/10	XT	MP NP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	Coveram 10/10	SE	MP NP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
			a	Reaptan 10/10	RX	MP NP	C4398 C4418 C14245 C14246	P14245 P14246	60	5	30		
	Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg	Oral	a	Coversyl Plus LD 2.5mg/0.625mg	SE	MP NP			30	5	30		
			a	PREXUM Combi LD 2.5/0.625	RX	MP NP			30	5	30		
			a	Coversyl Plus LD 2.5mg/0.625mg	SE	MP NP		P14238	60	5	30		
			a	PREXUM Combi LD	RX	MP		P14238	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	Oral		2.5/0.625		NP							
			APO-Perindopril/Indapamide	TX	MP NP	C4375 C14267	P4375	30	5	30		
			GenRx Perindopril/Indapamide 4/1.25	GX	MP NP	C4375 C14267	P4375	30	5	30		
			Idaprex Combi 4/1.25	SZ	MP NP	C4375 C14267	P4375	30	5	30		
			Indosyl Combi 4/1.25	RW	MP NP	C4375 C14267	P4375	30	5	30		
			Perindo Combi 4/1.25	AF	MP NP	C4375 C14267	P4375	30	5	30		
			PERISYL COMBI 4/1.25	AL	MP NP	C4375 C14267	P4375	30	5	30		
			APO-Perindopril/Indapamide	TX	MP NP	C4375 C14267	P14267	60	5	30		
			GenRx Perindopril/Indapamide 4/1.25	GX	MP NP	C4375 C14267	P14267	60	5	30		
			Idaprex Combi 4/1.25	SZ	MP NP	C4375 C14267	P14267	60	5	30		
			Indosyl Combi 4/1.25	RW	MP NP	C4375 C14267	P14267	60	5	30		
			Perindo Combi 4/1.25	AF	MP NP	C4375 C14267	P14267	60	5	30		
			PERISYL COMBI 4/1.25	AL	MP	C4375 C14267	P14267	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg	Oral	Coversyl Plus 5mg/1.25mg	SE	MP NP	C4375 C14267	P4375	30	5	30		
			Prexum Combi 5/1.25	RX	MP NP	C4375 C14267	P4375	30	5	30		
			Coversyl Plus 5mg/1.25mg	SE	MP NP	C4375 C14267	P14267	60	5	30		
			Prexum Combi 5/1.25	RX	MP NP	C4375 C14267	P14267	60	5	30		
Permethrin	Cream 50 mg per g, 30 g	Application	Lyclear	JT	MP NP			1	1	1		
Pertuzumab	Solution for I.V. infusion 420 mg in 14 mL	Injection	Perjeta	RO	MP	C10414 C13018		See Note 3	See Note 3	1		D(100)
Phenelzine	Tablet 15 mg (as sulfate)	Oral	Nardil	LM	MP	C6236		100	1	100		
	Tablet 15 mg (as sulfate) s19A	Oral	Nardil (Canada)	DZ	MP	C6236		120	1	60		
Phenobarbital	Injection 200 mg (as sodium) in 1 mL	Injection	Phenobarbitone Injection (Aspen Pharmacare Australia Pty Ltd)	AS	MP NP	C6295		5	0	5		
	Tablet 30 mg	Oral	Phenobarb	RW	MP NP	C6295		200	4	200		
Phenoxybenzamine	Capsule containing	Oral	Dibenyline	GH	MP	C6145 C6178		100	5	100		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Phenoxymethylpenicillin	phenoxybenzamine hydrochloride 10 mg					NP							
	Capsules containing phenoxybenzamine hydrochloride 10 mg, 30	Oral		Amdipharm Mercury (Australia) Pty Limited	GH	MP NP	C6145 C6178		3	5	1		
	Capsule 250 mg phenoxymethylpenicillin (as potassium)	Oral		Cilicaine VK	AF	MP NP PDP			50	0	50		
				LPV	IL	MP NP PDP			50	0	50		
				Cilicaine VK	AF	MP NP		P5697	50	5	50		
				LPV	IL	MP NP		P5697	50	5	50		
	Capsule 500 mg phenoxymethylpenicillin (as potassium)	Oral		Cilicaine VK	AF	MP NP PDP			50	0	50		
				LPV	IL	MP NP PDP			50	0	50		
	Oral suspension 150 mg (as benzathine) per 5 mL, 100 mL	Oral		Cilicaine V	AF	PDP MP NP			2 2	0 1	1 1		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Phenylalanine with carbohydrate	Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL	Oral		Phenoxymethylpenicillin-AFT	AE	PDP			2	0	1		
						MP NP			2	1	1		
	Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL	Oral		Phenoxymethylpenicillin-AFT	AE	PDP			2	0	1		
						MP NP			2	1	1		
	Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL (s19A)	Oral		Penopen	QY	PDP			2	0	1		
						MP NP			2	1	1		
	Tablet 250 mg phenoxymethylpenicillin (as potassium)	Oral		Aspecillin VK	AF	MP NP PDP		P5697	50	0	25		
						MP NP			50	5	25		
	Tablet 500 mg phenoxymethylpenicillin (as potassium)	Oral		Aspecillin VK	AF	MP NP PDP			50	0	25		
	Sachets of oral powder 4 g containing 50 mg phenylalanine, 30 (Phenylalanine 50)	Oral		Phenylalanine 50	VF	MP NP	C5533		4	5	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Phenytoin	Capsule containing phenytoin sodium 30 mg	Oral		Dilantin Sodium	UJ	MP NP			200	2	200		
	Capsule containing phenytoin sodium 100 mg	Oral		Dilantin Sodium	UJ	MP NP			200	2	200		
	Oral suspension 30 mg per 5 mL, 500 mL	Oral		Dilantin	UJ	MP NP			1	3	1		
	Tablet 50 mg	Oral		Dilantin Infatabs	UJ	MP NP			200	2	200		
Phytomenadione	Injection 10 mg in 1 mL	Injection/oral		Konakion MM	PB	See Note 4	See Note 4	See Note 4	See Note 4	See Note 4	5	5	D(MP)
Pilocarpine	Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL	Application to the eye		Isopto Carpine	NV	MP AO			1	5	1		
	Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL	Application to the eye		Isopto Carpine	NV	MP AO			1	5	1		
	Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL	Application to the eye		Isopto Carpine	NV	MP AO			1	5	1		
Pimecrolimus	Cream 10 mg per g, 15	Application		Elidel	GO	MP	C5472 C5482		1	1	1		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Pioglitazone	g Tablet 15 mg (as hydrochloride)	Oral	a	Acpio 15	RF	MP NP	C4363 C4364 C4388		28	5	28		
			a	Actaze	RW	MP NP	C4363 C4364 C4388		28	5	28		
			a	Actos	EW	MP NP	C4363 C4364 C4388		28	5	28		
			a	APOTEX-Pioglitazone	TX	MP NP	C4363 C4364 C4388		28	5	28		
			a	Vexazone	AF	MP NP	C4363 C4364 C4388		28	5	28		
	Tablet 30 mg (as hydrochloride)	Oral	a	Acpio 30	RF	MP NP	C4363 C4364 C4388		28	5	28		
			a	Actaze	RW	MP NP	C4363 C4364 C4388		28	5	28		
			a	Actos	EW	MP NP	C4363 C4364 C4388		28	5	28		
			a	APOTEX-Pioglitazone	TX	MP NP	C4363 C4364 C4388		28	5	28		
			a	NOUMED PIOGLITAZONE	VO	MP NP	C4363 C4364 C4388		28	5	28		
			a	Pioglitazone Sandoz	SZ	MP NP	C4363 C4364 C4388		28	5	28		
			a	Vexazone	AF	MP	C4363 C4364		28	5	28		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Pirfenidone	Tablet 45 mg (as hydrochloride)	Oral	a	Acpio 45	RF	MP	C4388		28	5	28		
						NP	C4363 C4364						
			a	Actaze	RW	MP	C4388		28	5	28		
						NP	C4363 C4364						
			a	Actos	EW	MP	C4388		28	5	28		
						NP	C4363 C4364						
			a	APOTEX-Pioglitazone	TX	MP	C4388		28	5	28		
						NP	C4363 C4364						
Pirfenidone	Tablet 267 mg	Oral	a	NOUMED PIOGLITAZONE	VO	MP	C4388		28	5	28		
						NP	C4363 C4364						
			a	Pioglitazone Sandoz	SZ	MP	C4388		28	5	28		
						NP	C4363 C4364						
			a	Vexazone	AF	MP	C4388		28	5	28		
						NP	C4363 C4364						
				Pirfenidone Sandoz	SZ	MP	C13378 C13380		270	5	90		
							C13381						
Piroxicam	Tablet 801mg	Oral		Pirfenidone Sandoz	SZ	MP	C13380		90	5	90		
	Capsule 10 mg	Oral		APO-Piroxicam	TX	PDP	C6214		50	0	50		
						MP	C6214		50	3	50		
						NP							
	Capsule 20 mg	Oral		APO-Piroxicam	TX	PDP	C6214		25	0	25		
						MP	C6214		25	3	25		

Schedule 1 Ready-prepared pharmaceutical benefits
Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						NP							
	Dispersible tablet 20 mg	Oral		Feldene-D	PF	PDP	C6214		25	0	25		
						MP NP	C6214		25	3	25		
Pizotifen	Tablet 500 micrograms (as malate)	Oral		Sandomigran 0.5	AE	MP NP			100	2	100		
Plerixafor	Injection 24 mg in 1.2 mL	Injection	a	Mozobil	GZ	MP	C4549 C9329		1	1	1		D(100)
			a	Plerixafor ARX	XT	MP	C4549 C9329		1	1	1		D(100)
Polyethylene glycol 400 with propylene glycol	Eye drops 4 mg-3 mg per mL, single dose units 0.8 mL, 30	Application to the eye		Systane	AQ	AO MP NP	C6172		2	5	1		
	Eye drops 4 mg-3 mg per mL, 15 mL	Application to the eye	a	Optix	PP	AO	C6120		1	5	1		
						MP	C6073 C6098	P6073	1	5	1		
						NP	C6073		1	5	1		
			a	Systane	AQ	AO	C6120		1	5	1		
						MP	C6073 C6098	P6073	1	5	1		
						NP	C6073		1	5	1		
			a	Optix	PP	MP	C6073 C6098	P6098	1	11	1		
			a	Systane	AQ	MP	C6073 C6098	P6098	1	11	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Poly-L-lactic acid	Powder for injection 150 mg	Injection	Sculptra	GA	MP	C5087 C5122	P5122	2	0	1		
					MP	C5087 C5122	P5087	2	4	1		
Pomalidomide	Capsule 3 mg	Oral	Pomalidomide Sandoz	SZ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Pomalyst	CJ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Pomolide	JU	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
	Capsule 4 mg	Oral	Pomalidomide Sandoz	SZ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Pomalyst	CJ	MP	See Note 3	See Note 3	See Note 3	See Note 3	14		D(100)
					MP	See Note 3	See Note 3	See Note 3	See Note 3	21		D(100)
			Pomolide	JU	MP	See Note 3	See Note 3	See	See	14		D(100)

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Ponatinib	Tablet 15 mg (as hydrochloride)	Oral		Iclusig	TK	MP	C5572 C5589 C9465 C9614 C13006 C13022 C13025 C13030	P5572 P5589 P9465 P9614	60	2	60		
						MP	C5572 C5589 C9465 C9614 C13006 C13022 C13025 C13030	P13006 P13022 P13025 P13030	60	5	60		
	Tablet 45 mg (as hydrochloride)	Oral		Iclusig	TK	MP	C5572 C5589 C9465 C9614 C13006 C13022 C13025 C13030	P5572 P5589 P9465 P9614	30	2	30		
						MP	C5572 C5589 C9465 C9614 C13006 C13022 C13025 C13030	P13006 P13022 P13025 P13030	30	5	30		
Posaconazole	Tablet (modified release) 100 mg	Oral	a	Pharmacor Posaconazole	CR	MP NP	C5169 C5395 C5396		24	0	24		
			a	Posaconazole ARX	XT	MP NP	C5169 C5395 C5396		24	0	24		
			a	POSACONAZOLE DR.REDDY'S	RZ	MP NP	C5169 C5395 C5396		24	0	24		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Potassium chloride	Tablet 600 mg (sustained release)	Oral	a	Posaconazole Juno	JU	MP NP	C5169 C5395 C5396		24	0	24		
			a	Posaconazole Sandoz	SZ	MP NP	C5169 C5395 C5396		24	0	24		
				Span-K	AS	MP NP			200	1	200		
						MP NP		P14238	400	1	200		
Potassium chloride with potassium bicarbonate	Tablet, effervescent, 14 mmol potassium and 8 mmol chloride	Oral		Chlorvescent	AS	MP NP			60	1	60		
						MP NP		P14238	120	1	60		
Pralatrexate	Solution for I.V. infusion 20 mg in 1 mL	Injection		Folotyn	MF	MP	C7526 C7558		See Note 3	See Note 3	1		D(100)
Pramipexole	Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms	Oral	a	APO-Pramipexole	TX	MP NP	C5363		30	0	30		
			a	Sifrol	BY	MP NP	C5363 C5411	P5363	30	0	30		
			a	Simipex 0.125	RW	MP NP	C5363 C5411	P5363	30	0	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms	Oral	a	Simpral	AF	MP NP	C5363		30	0	30		
			a	Sifrol	BY	MP NP	C5363 C5411	P5411	30	2	30		
			a	Simipex 0.125	RW	MP NP	C5363 C5411	P5411	30	2	30		
			a	Sifrol	BY	MP NP	C5363 C5411	P5411	100	2	100		
			a	Simipex 0.25	RW	MP NP	C5363 C5411	P5411	100	2	100		
			a	APO-Pramipexole	TX	MP NP	C5363		100	5	100		
			a	Sifrol	BY	MP NP	C5363 C5411	P5363	100	5	100		
			a	Simipex 0.25	RW	MP NP	C5363 C5411	P5363	100	5	100		
			a	Simpral	AF	MP NP	C5363		100	5	100		
	Tablet (extended release) containing pramipexole	Oral	a	APO-Pramipexole ER	TX	MP NP	C5131		30	5	30		
			a	Sifrol ER	BY	MP	C5131		30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	dihydrochloride monohydrate 375 micrograms		a	SIMIPEX XR	RW	MP NP	C5131		30	5	30		
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms	Oral	a	APO-Pramipexole ER	TX	MP NP	C5131		30	5	30		
			a	Sifrol ER	BY	MP NP	C5131		30	5	30		
			a	SIMIPEX XR	RW	MP NP	C5131		30	5	30		
	Tablet containing pramipexole dihydrochloride monohydrate 1 mg	Oral	a	APO-Pramipexole	TX	MP NP	C5363		100	5	100		
			a	Sifrol	BY	MP NP	C5363		100	5	100		
			a	Simipex 1	RW	MP NP	C5363		100	5	100		
			a	Simpral	AF	MP NP	C5363		100	5	100		
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg	Oral	a	APO-Pramipexole ER	TX	MP NP	C5131		30	5	30		
			a	Sifrol ER	BY	MP NP	C5131		30	5	30		
			a	SIMIPEX XR	RW	MP NP	C5131		30	5	30		
	Tablet (extended	Oral	a	APO-Pramipexole ER	TX	MP	C5131		30	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	release) containing pramipexole dihydrochloride monohydrate 2.25 mg		a	Sifrol ER	BY	MP NP	C5131		30	5	30		
			a	SIMIPEX XR	RW	MP NP	C5131		30	5	30		
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg	Oral	a	APO-Pramipexole ER	TX	MP NP	C5131		30	5	30		
			a	Sifrol ER	BY	MP NP	C5131		30	5	30		
			a	SIMIPEX XR	RW	MP NP	C5131		30	5	30		
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg	Oral	a	APO-Pramipexole ER	TX	MP NP	C5131		30	5	30		
			a	Sifrol ER	BY	MP NP	C5131		30	5	30		
			a	SIMIPEX XR	RW	MP NP	C5131		30	5	30		
	Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg	Oral	a	APO-Pramipexole ER	TX	MP NP	C5131		30	5	30		
			a	Sifrol ER	BY	MP NP	C5131		30	5	30		
			a	SIMIPEX XR	RW	MP NP	C5131		30	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Pravastatin	Tablet containing pravastatin sodium 10 mg	Oral	a	APO-Pravastatin	TX	MP NP			30	5	30		
			a	APX-Pravastatin	TY	MP NP			30	5	30		
			a	Cholstat 10	AF	MP NP			30	5	30		
			a	Lipostat 10	RF	MP NP			30	5	30		
			a	Pravachol	RW	MP NP			30	5	30		
			a	Pravastatin Sandoz	SZ	MP NP			30	5	30		
			a	APO-Pravastatin	TX	MP NP		P14238	60	5	30		
			a	APX-Pravastatin	TY	MP NP		P14238	60	5	30		
			a	Cholstat 10	AF	MP NP		P14238	60	5	30		
			a	Lipostat 10	RF	MP NP		P14238	60	5	30		
			a	Pravachol	RW	MP NP		P14238	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing pravastatin sodium 20 mg	Oral	a	Pravastatin Sandoz	SZ	MP NP		P14238	60	5	30		
			a	APO-Pravastatin	TX	MP NP			30	5	30		
			a	APX-Pravastatin	TY	MP NP			30	5	30		
			a	Cholstat 20	AF	MP NP			30	5	30		
			a	Lipostat 20	RF	MP NP			30	5	30		
			a	Pravachol	RW	MP NP			30	5	30		
			a	Pravastatin Sandoz	SZ	MP NP			30	5	30		
			a	APO-Pravastatin	TX	MP NP		P14238	60	5	30		
			a	APX-Pravastatin	TY	MP NP		P14238	60	5	30		
			a	Cholstat 20	AF	MP NP		P14238	60	5	30		
			a	Lipostat 20	RF	MP NP		P14238	60	5	30		
			a	Pravachol	RW	MP NP		P14238	60	5	30		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing pravastatin sodium 40 mg	Oral	a	Pravastatin Sandoz	SZ	MP NP		P14238	60	5	30		
			a	APO-Pravastatin	TX	MP NP			30	5	30		
			a	APX-Pravastatin	TY	MP NP			30	5	30		
			a	Cholstat 40	AF	MP NP			30	5	30		
			a	Lipostat 40	RF	MP NP			30	5	30		
			a	Pravachol	RW	MP NP			30	5	30		
			a	Pravastatin Sandoz	SZ	MP NP			30	5	30		
			a	APO-Pravastatin	TX	MP NP		P14238	60	5	30		
			a	APX-Pravastatin	TY	MP NP		P14238	60	5	30		
			a	Cholstat 40	AF	MP NP		P14238	60	5	30		
			a	Lipostat 40	RF	MP NP		P14238	60	5	30		
			a	Pravachol	RW	MP NP		P14238	60	5	30		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing pravastatin sodium 80 mg	Oral	a	Pravastatin Sandoz	SZ	MP NP		P14238	60	5	30		
			a	APO-Pravastatin	TX	MP NP			30	5	30		
			a	APX-Pravastatin	TY	MP NP			30	5	30		
			a	Lipostat 80	RF	MP NP			30	5	30		
			a	Pravachol	RW	MP NP			30	5	30		
			a	APO-Pravastatin	TX	MP NP		P14238	60	5	30		
			a	APX-Pravastatin	TY	MP NP		P14238	60	5	30		
			a	Lipostat 80	RF	MP NP		P14238	60	5	30		
Praziquantel	Tablet 600 mg	Oral		Biltricide	BN	MP NP	C5659		8	0	8		
Prazosin	Tablet 1 mg (as hydrochloride)	Oral	a	APO-Prazosin	TX	MP NP			100	5	100		
			a	Minipress	PF	MP NP			100	5	100		
			a	APO-Prazosin	TX	MP NP		P14238	200	5	100		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Prednisolone	Tablet 2 mg (as hydrochloride)	Oral	a	Minipress	PF	MP NP		P14238	200	5	100		
			a	APO-Prazosin	TX	MP NP			100	5	100		
			a	Minipress	PF	MP NP			100	5	100		
			a	APO-Prazosin	TX	MP NP		P14238	200	5	100		
	Tablet 5 mg (as hydrochloride)	Oral	a	Minipress	PF	MP NP		P14238	200	5	100		
			a	APO-Prazosin	TX	MP NP			100	5	100		
			a	Minipress	PF	MP NP			100	5	100		
			a	APO-Prazosin	TX	MP NP		P14238	200	5	100		
	Tablet 1 mg	Oral	a	Minipress	PF	MP NP		P14238	200	5	100		
			a	Panafcortelone	AS	MP NP			100	4	100		
			a	Predsolone	LN	MP NP			100	4	100		
				Panafcortelone	AS	MP NP			60	4	60		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Prednisolone with phenylephrine	Tablet 25 mg	Oral		Solone	IL	MP NP			60	4	60		
				Panafcortelone	AS	MP NP			30	4	30		
				Solone	IL	MP NP			30	4	30		
	Suppositories 5 mg (as sodium phosphate), 10	Rectal		Predsol	AS	MP NP	C4872 C4893		3	3	1		
	Enema, retention, 20 mg (as sodium phosphate) in 100 mL	Rectal		Predsol	AS	MP NP			28	3	7		
	Oral solution 5 mg (as sodium phosphate) per mL, 30 mL	Oral	a	PredMix	LN	MP NP			1	5	1		
			a	Redipred	AS	MP NP			1	5	1		
	Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL	Application to the eye		Prednefrin Forte	VE	MP	C6080 C6101 C10095	P10095	1	0	1		
						AO	C6087		1	0	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Prednisone	Tablet 1 mg	Oral	a	Panafcort	MP		C6080 C6101 C10095	P6080 P6101	1	2	1		
					NP		C6080 C6101		1	2	1		
				Predsone	AS	MP NP			100	4	100		
					LN	MP NP			100	4	100		
	Tablet 5 mg	Oral		Panafcort	AS	MP NP			60	4	60		
					IL	MP NP			60	4	60		
				Sone	AS	MP NP			30	4	30		
					IL	MP NP			30	4	30		
Pregabalin	Capsule 25 mg	Oral	a	APO-Pregabalin	TX	MP NP	C4172		56	5	56		
			a	Blooms The Chemist Pregabalin	IB	MP NP	C4172		56	5	56		
			a	Cipla Pregabalin	LR	MP NP	C4172		56	5	56		
			a	LYPRALIN	RW	MP NP	C4172		56	5	56		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Lyrica	UJ	MP NP	C4172		56	5	56		
			a	Lyzalon	AF	MP NP	C4172		56	5	56		
			a	Neuroccord	CR	MP NP	C4172		56	5	56		
			a	NOUMED PREGABALIN	VO	MP NP	C4172		56	5	56		
			a	Prebalin	RF	MP NP	C4172		56	5	56		
			a	Pregabalin Lupin	HQ	MP NP	C4172		56	5	56		
			a	Pregabalin Sandoz	SZ	MP NP	C4172		56	5	56		
			a	PREGABALIN-DRLA	RZ	MP NP	C4172		56	5	56		
	Capsule 75 mg	Oral	a	APO-Pregabalin	TX	MP NP	C4172		56	5	56		
			a	Blooms The Chemist Pregabalin	IB	MP NP	C4172		56	5	56		
			a	Cipla Pregabalin	LR	MP NP	C4172		56	5	56		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	LYPRALIN	RW	MP NP	C4172		56	5	56		
			a	Lyrica	UJ	MP NP	C4172		56	5	56		
			a	Lyzalon	AF	MP NP	C4172		56	5	56		
			a	Neuroccord	CR	MP NP	C4172		56	5	56		
			a	NOUMED PREGABALIN	VO	MP NP	C4172		56	5	56		
			a	Prebalin	RF	MP NP	C4172		56	5	56		
			a	Pregabalin GH	GQ	MP NP	C4172		56	5	56		
			a	Pregabalin Lupin	HQ	MP NP	C4172		56	5	56		
			a	Pregabalin Sandoz	SZ	MP NP	C4172		56	5	56		
			a	PREGABALIN-DRLA	RZ	MP NP	C4172		56	5	56		
	Capsule 150 mg	Oral	a	APO-Pregabalin	TX	MP NP	C4172		56	5	56		
			a	Blooms The Chemist Pregabalin	IB	MP NP	C4172		56	5	56		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Cipla Pregabalin	LR	MP NP	C4172		56	5	56		
			a	LYPRALIN	RW	MP NP	C4172		56	5	56		
			a	Lyrica	UJ	MP NP	C4172		56	5	56		
			a	Lyzalon	AF	MP NP	C4172		56	5	56		
			a	Neuroccord	CR	MP NP	C4172		56	5	56		
			a	NOUMED PREGABALIN	VO	MP NP	C4172		56	5	56		
			a	Prebalin	RF	MP NP	C4172		56	5	56		
			a	Pregabalin GH	GQ	MP NP	C4172		56	5	56		
			a	Pregabalin Lupin	HQ	MP NP	C4172		56	5	56		
			a	Pregabalin Sandoz	SZ	MP NP	C4172		56	5	56		
			a	PREGABALIN-DRLA	RZ	MP NP	C4172		56	5	56		
	Capsule 300 mg	Oral	a	APO-Pregabalin	TX	MP NP	C4172		56	5	56		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
			a	Blooms The Chemist Pregabalin	IB	MP NP	C4172		56	5	56		
			a	Cipla Pregabalin	LR	MP NP	C4172		56	5	56		
			a	LYPRALIN	RW	MP NP	C4172		56	5	56		
			a	Lyrica	UJ	MP NP	C4172		56	5	56		
			a	Lyzalon	AF	MP NP	C4172		56	5	56		
			a	Neuroccord	CR	MP NP	C4172		56	5	56		
			a	NOUMED PREGABALIN	VO	MP NP	C4172		56	5	56		
			a	Prebalin	RF	MP NP	C4172		56	5	56		
			a	Pregabalin Lupin	HQ	MP NP	C4172		56	5	56		
			a	Pregabalin Sandoz	SZ	MP NP	C4172		56	5	56		
			a	PREGABALIN-DRLA	RZ	MP NP	C4172		56	5	56		
Primidone	Tablet 250 mg	Oral		Mysoline	LM	MP NP			200	2	200		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Probenecid	Tablet 500 mg	Oral		Pro-Cid	FF	MP NP			100	5	100		
Procaine benzylpenicillin	Injection 1.5 g in disposable syringe	Injection		Cilicaine	AF	MP NP PDP			5	0	5		
Prochlorperazine	Injection containing prochlorperazine mesilate 12.5 mg in 1 mL	Injection		Stemetil	SW	MP NP PDP			10	0	10		
	Tablet containing prochlorperazine maleate 5 mg	Oral	a	APO-Prochlorperazine	TX	MP NP PDP			25	0	25		
			a	ProCalm	RW	MP NP PDP			25	0	25		
			a	Prochlorperazine GH	GQ	MP NP PDP			25	0	25		
			a	Stemetil	SW	MP NP PDP			25	0	25		
			a	Stemzine	AV	MP NP PDP			25	0	25		
Progesterone	Capsule 200 mg	Vaginal		Utrogestan	HB	MP	C4997		42	0	42		C(100)

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
						MP NP MW	C11835		42	3	42		
	Vaginal gel (prolonged release) 90 mg in single dose pre-filled applicator	Vaginal		Crinone 8%	SG	MP	C5045		30	0	15		PB(100)
	Pessary 100 mg	Vaginal		Oripro	ON	MP	C4997		45	0	15		PB(100)
	Pessary 200 mg	Vaginal		Oripro	ON	MP	C4997		45	0	15		C(100)
						MP NP MW	C11673		45	3	15		
Promethazine	Vaginal tablet 100 mg	Vaginal		Endometrin	FP	MP	C4997		42	0	21		PB(100)
	Injection containing promethazine hydrochloride 50 mg in 2 mL	Injection		DBL Promethazine Hydrochloride	PF	MP NP PDP			10	0	5		
Propantheline	Tablet containing propantheline bromide 15 mg	Oral		Pro-Banthine	RW	MP NP	C6241		200	5	100		
Propranolol	Tablet containing propranolol hydrochloride 10 mg	Oral	a	APO-Propranolol	TX	MP NP			100	5	100		
			a	Deralin 10	AF	MP NP			100	5	100		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing propranolol hydrochloride 40 mg	Oral	a	Inderal	IX	MP NP			100	5	100		
			a	APO-Propranolol	TX	MP NP		P14238	200	5	100		
			a	Deralin 10	AF	MP NP		P14238	200	5	100		
			a	Inderal	IX	MP NP		P14238	200	5	100		
			a	APO-Propranolol	TX	MP NP			100	5	100		
			a	Deralin 40	AF	MP NP			100	5	100		
			a	Inderal	IX	MP NP			100	5	100		
			a	APO-Propranolol	TX	MP NP		P14238	200	5	100		
			a	Deralin 40	AF	MP NP		P14238	200	5	100		
			a	Inderal	IX	MP NP		P14238	200	5	100		
Propylthiouracil	Tablet 50 mg	Oral		PTU	FF	MP NP			200	2	100		
Protein formula with amino acids,	Oral liquid 130 mL, 30 (PKU Easy)	Oral		PKU Easy	OH	MP NP	C5970		5	5	1		

Listed Drug	Form	Manner of Administration	Schedule Equivalent Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
carbohydrates, vitamins and minerals without phenylalanine, and supplemented with docosahexaenoic acid												
Protein formula with carbohydrate, fat, vitamins and minerals	Oral liquid 500 mL, 12 (Nutrini Peptisorb Energy)	Oral	Nutrini Peptisorb Energy	NU	MP NP	C6890		7	5	1		
Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A	Oral liquid 125 mL, 24 (Renastep)	Oral	Renastep	VF	MP NP	C11070		8	5	1		
Protein hydrolysate formula with medium chain triglycerides	Oral powder 400 g (Alfaré)	Oral	Alfaré	NT	MP NP	C6137 C6138 C6148 C6157 C6158 C6166 C6174 C6182 C6193 C6194 C6195 C6204 C6205 C6206		8	5	1		
	Oral powder 450 g (Aptamil Gold+ Pepti-Junior)	Oral	Aptamil Gold+ Pepti-Junior	NU	MP NP	C6137 C6138 C6148 C6157 C6158 C6166 C6174 C6182 C6193 C6194 C6195 C6204 C6205		8	5	1		
Pyrantel	Tablet 125 mg (as	Oral	Anthel 125	AF	MP			6	0	6		

Schedule 1 Ready-prepared pharmaceutical benefits

Part 1 Ready-prepared pharmaceutical benefits for prescription and supply

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
Pyridostigmine	embonate)					NP							
	Tablet 250 mg (as embonate)	Oral		Anthel 250	AF	MP NP			6	0	6		
	Tablet containing pyridostigmine bromide 10 mg	Oral		Mestinon	IL	MP			100	5	50		
	Tablet containing pyridostigmine bromide 60 mg	Oral		Mestinon	IL	MP			150	5	150		
	Tablet containing pyridostigmine bromide 180 mg (modified release)	Oral		Mestinon Timespan	IL	MP			100	5	50		

Listed Drug	Form	Manner of Administration	Schedule Equivalent	Brand	Responsible Person	Authorised Prescriber	Circumstances	Purposes	Maximum Quantity	Number of Repeats	Pack Quantity	Determined Quantity	Section 100/ Prescriber Bag only
	Tablet containing pyridostigmine bromide 180 mg (modified release) s19A	Oral		Pyridostigmine Bromide Extended-Release Tablets (Rising)	DZ	MP			100	5	30		